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Introduction: Mortality due to overdose has been increasing since 2010 in the U.S., with 
an increase in the reported use of heroin and co-use of heroin and prescription opioids.  
Trends and correlates of polydrug use need to be analyzed to propose policies to reduce 
overdose risk.  The overall objective of this study is to characterize high-risk polydrug 
groups among people who use opioids (PWUO) to understand the patterns of co-used 
substances and overdose risk factors.   
Methods: Publicly available data from the 2002-2017 National Survey on Drug Use and 
Health were analyzed to obtain weighted prevalence rates and trends for PWUO groups, 
core substance use among each group, as well as polydrug latent classes.  Trend analyses 
consisted of Rao-Scott Chi-square (χ2) tests and joinpoint regression modeling. 
Multinomial logistic regression was used to determine associations between latent class 
membership and correlates such as sociodemographic factors, past year opioid use 
disorder (OUD) and residential transience.  
Results: Overall prevalence of all individuals who reported the use of either a 
prescription pain reliever (PPR) or heroin in the past month has declined since 2006, 
however, the prevalence of the combination opioid use group has been increasing since 
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2002.  Multiple substance use by the past month combination opioid use group was 
substantially greater than those who exclusively used PPR or heroin in the past month, a 
finding that aligns with past research.  Although it was hypothesized the combination 
opioid class would be characterized as having the highest risk of past year OUD, this was 
not the case; the Class with the highest adjusted odds of having past year OUD had the 
highest probability of reporting the past month use of heroin, marijuana, and other illicit 
substances [aOR (95% CI): 11.03 (6.46, 18.82)]. 
Conclusion:  The increasing prevalence of polydrug use populations among people who 
use opioids, particularly those who have reported heroin use, underscores the need for 
prompt action from local, state, and federal stakeholders to pursue more aggressive action 
to stem the opioid crisis. Policies should conform to a unified public health framework, 
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INTRODUCTION AND STUDY OVERVIEW 
 
Historical Overview of Opioid Use in the United States 
Although pain-relieving substances, such as opioids, have been used by many 
civilizations throughout history, their use was relatively uncommon in the United States 
until the beginning of the American Revolution.1-4  Opioids used in the late 1800s 
consisted predominantly of morphine and opium and were used widely for many 
reasons.5  For instance, mothers used opium tinctures to treat themselves and their 
children, soldiers used morphine to treat diarrhea and painful injuries, and Chinese 
immigrants imported opium to smoke in the U.S.5  Heroin was also administered 
iatrogenically, but because it was developed as a weaker pain reliever, it was not 
prescribed as liberally by medical doctors.3  Physicians also administered morphine to 
patients who suffered pain from conditions that were not well understood, such as 
infectious diseases, asthma, and gastrointestinal diseases.5  By the start of the 20th 
century, opioids were being misused by the thousands.2  The rapid increase of people 
who used opium and heroin was eventually stemmed after the implementation of 
legislative policies (e.g., Harrison Act, 1909 Smoking Opium Exclusion Act) hindering 
the sale and import of these products, as well as discoveries by medical researchers (e.g., 
development of antibiotics and aspirin) which provided better treatment options.3,5 
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After the 1930s, heroin became the dominant opioid used in the U.S., which was 
likely the result of the rising cost of cocaine, as well as the effects of drug policies, like 
the Smoking Opium Exclusion Act.3  Also changing were the populations highest at risk 
of misusing opioids.  Previously, Caucasian and Chinese populations were highest at risk, 
but after the 1950s, the prevalence of heroin use increased among inner-city minorities.5  
By the late 1980s, prescription opioid use began its slow ascent after Portenoy and Foley 
published results from their study that investigated the long-term safety of opioid pain 
relievers (OPR) in chronic non-cancer pain patients, concluding that OPRs may be used 
safely, a connection that was likely to be happenstance.6  However, a major factor in the 
steep use of OPRs came after 1995, when Purdue Pharma debuted a new product, 
OxyContin, and heavily campaigned the medical community for the next six years 
arguing for the importance of addressing pain symptoms among all patients.5 
During the current opioid epidemic, it is estimated that more than 500,000 people 
died from drug overdoses from 2000 to 2015, with the majority involving an opioid.7  
According to the National Center for Health Statistics, the number of overdose deaths 
involving opioids, including prescription opioids and heroin, has nearly quintupled from 
1999 to 2016.8  In the 21st century, the opioid epidemic can be thought of as having three 
waves of high mortality, as shown in Figure 1.1.9  The first wave started in the 1990s and 
primarily involved prescription opioids, while the second wave of opioid mortality 
starting in 2010 involved mostly heroin overdoses.10  The third wave, characterized by a 
doubling of overdose death rates from 2013 to 2014, was related to synthetic opioids, 
including illicitly manufactured fentanyl and fentanyl analogs.10,11  And while mortality 
due to overdose has been increasing steadily since 2010, the most recent data from the 
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Centers for Disease Control and Prevention’s (CDC) online database, the Wide-ranging 
ONline Data for Epidemiologic Research (WONDER), indicated that synthetic opioids 
have now surpassed all other categories of drugs involved in U.S. overdose death, as 
shown in Figure 1.2.12 
 
Figure 1.1 | The Three Waves of the Rise in Opioid Overdose Deaths 
 
Figure 1.2 | Opioids Involved in United States Overdose Deaths, 2000 to 20161 
                                                 
1Among the more than 64,000 drug overdose deaths estimated in 2016, the sharpest increase occurred 
among deaths related to fentanyl and fentanyl analogs (synthetic opioids) with over 20,000 overdose 
deaths. Source: CDC WONDER 
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Based on nationwide data from health insurance claims, the total economic 
burden on the societal costs of prescription opioid use in the U.S. (including workplace, 
health care, and criminal justice costs) was estimated to be $55.7 billion2 per year from 
1999 to 2007.13  The workplace costs considered in this study were derived from loss of 
earnings due to premature death and reduced compensation or lost employment, while 
health care costs primarily reflected treatment costs.  Finally, criminal justice costs 
included the cost of operating correctional facilities and employing police.13  However, 
the opioid epidemic has continued to progress. Based on the most current data from the 
National Vital Statistics System (NVSS) and the 2013 results of the National Survey on 
Drug Use and Health (NSDUH), it is now estimated that the total economic burden was 
$78.5 billion in 2013.  More than one-third of this cost is attributed to increased health 
care and substance abuse treatment costs, while approximately one quarter was borne by 
the public sector in health care, substance abuse treatment, and criminal justice costs.14  
 
Changing Trends of Prescription Opioid Misuse and Heroin Use in the United 
States, 2008 to 2014 
 After the first wave of high opioid-related overdose deaths, there has been a 
noticeable downturn in the reported misuse of prescription opioids with a simultaneous 
increase in the use of heroin.15  In order to examine this relationship more closely, Cicero 
and colleagues collected data on a quarterly basis from January 1, 2008 through 
September 21, 2014 using self-administered surveys among independent cohorts with 
opioid dependence who were entering non-methadone maintenance programs 
                                                 
2 This cost was adjusted for inflation and represents the cost in United States dollars (USD) in 2009 
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nationwide.16  The investigators found that rates of exclusive prescription opioid misuse 
decreased starting in 2010, while concurrent misuse of heroin and prescription opioids in 
the previous month increased by about 10.3% on average from 2008 (23.6%) to 2014 
(41.8%).16  And although the use of heroin-only was low in the study population, the 
prevalence more than doubled during the study period.16  Also, while limited research has 
documented the polydrug use patterns and trends during the first wave of high opioid 
mortality (i.e., from 1999 to 2009), many subsequent studies indicated that multiple 
substance use was occurring prior to 2010.17-20  Furthermore, it has been documented that 
those who co-use OPRs and heroin have a high burden of polydrug use compared to 
those who only use prescription opioids or heroin.21  This finding suggests that polydrug 
classes emerging in 2010 may have substance use characteristics that are affecting their 
increase in prevalence compared to those in Wave I of high opioid mortality in the United 
States. 
 
Defining Polydrug Use 
Because the main purpose of this study is to investigate polydrug use in PWUO, it 
is important to define the term.  In 1975, the National Institute on Drug Abuse released a 
monograph titled “Operational Definitions in Socio-Behavioral Drug Use Research”.22  
While the monograph discussed a multitude of topics, such as the history of drug use, 
functional taxonomy of drugs, and conditions of drug use, it also included a chapter on 
defining “polydrug use”.22  The chapter delineates the three different concepts listed 
below based on contemporaneous literature.22  
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(1) Any use of more than one mood-altering drug by an individual at any time in 
the past (i.e., ever use). 
(2) Any use of more than one mood-altering drug during a delimited recent period 
(i.e., non-overlapping recent use). 
(3) Any use of more than one mood-altering drug within an overlapping time 
frame (i.e., overlapping use). 
 
It should also be noted that a fourth concept could be described, which would include 
polydrug use that (4) does not include the use of opiates.22 
 These concepts were later refined by substance use researchers to reflect 
concurrent versus simultaneous drug use.  Concurrent polydrug use has been defined in 
the literature as using more than one drug in the same period (e.g., in the past year).23  On 
the other hand, simultaneous polydrug use refers to the co-ingestion of different drugs at 
the same intake event.23,24  However, it should be noted that the current study will only be 
able to address concurrent use of more than one substance in PWUO due to the nature of 
the NSDUH methodology. 
 
Rationale and Significance of the Study 
As this third wave of opioid-related mortality progresses, a major priority that 
public health professionals must address are the fundamental causes of opioid-related 
overdose, and to use this information to prevent adverse health outcomes related to 
polydrug use.  While not a new concept in the literature, polydrug use in an adult 
population of people who use opioids (PWUO) has thus far been investigated and defined 
as non-opioid drug use (e.g., benzodiazepines, alcohol drinking, cigarettes, marijuana, 
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and cocaine).25-27  Polydrug use patterns have been explored using a variety of analytic 
strategies, including the assessment of individual drug covariates or other substance use 
disorders among a certain subpopulations,28-30 using bivariate (yes/no) substance 
combinations,27 and composite scores.31,32  More recently, person-centered approaches 
such as latent class analysis (LCA) and latent profile analysis (LPA) have emerged in the 
literature.19,33-37  However, most of the studies that examine patterns of polydrug use 
limited the scope of the types of substances included (e.g., drinking behaviors, injection 
drugs, illicit drugs), with specific foci on different subpopulations, such as adolescents, 
people who inject drugs, chronic pain patients, etc.   
Therefore, this study fills an important gap in the literature by examining the 
prevalence and trends of polydrug use in the U.S. among all PWUO using LCA.  The 
advantage of using LCA over other non-person-centered approaches, is the ability to 
determine the substances that are most probabilistically associated with the co-use of 
opioids.  Knowing the composition of each polydrug latent class will allow us to refine 
policies and interventions to decrease the overall prevalence of overdose risk.  
Additionally, associations between correlates of interest in PWUO will be assessed using 
data that marks the beginning of the changing opioid overdose risk environment (i.e., 
2010 to 2017), which will allow us to characterize the current subpopulations of PWUO.    
The public health significance of examining the prevalence and correlates of 
polydrug use among PWUO includes understanding the latent classes of people who are 
more likely to have adverse health effects and also provide a basis for exploring multiple 
drug interactions from a pharmacological and physiological standpoint.  Finally, the 
results of this study could act as a catalyst for restructuring national surveys such as the 
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NSDUH to update their methodologies to allow the examination of simultaneous 
polydrug use or add additional substance use modules (e.g. fentanyl).. 
Not only will this study utilize multiple NSDUH core substance categories in the 
analysis, it will also build upon prior knowledge related to polydrug use in PWUO by 
examining the longitudinal trends of specific polydrug combinations concurrently used 
by PWUO using joinpoint regression analysis.  In the current literature, trends of 
polydrug use have been tracked using different statistical methods, including specifying 
linear time trends using a year variable in logistic regression models, calculating the 
difference in prevalence and percent change in prevalence for the period endpoints, and 
even using automated machine learning tools to employ iterative rounds of data gathering 
related to polydrug use using social media (e.g., Twitter).18,21,38,39  Limitations of the 
current studies that use the logistic regression method of trend analysis mainly center on 
the reliance of self-reported data, but also include the absence of using person-centered 
measures like latent classes.  Additionally, the use of machine learning tools are hindered 
by selection bias and the background noise of communication on social platforms.  A 
better understanding of the changes in trends of polydrug use will allow public health 
professions to track substances that are being reported by larger numbers of PWUO in 
order to inform proper intervention strategies.  
 
Objective and Specific Aims 
 The overall objective of this study is to characterize high-risk polydrug groups in 
PWUO in the United States to understand the patterns of co-used substances and 
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overdose risk factors.  Therefore, three specific aims and their corresponding subaims are 
proposed to achieve this objective: 
 
Specific Aim 1. To examine the prevalence of polydrug use among PWUO in a 
nationally representative sample in the U.S. over the period 2002-2017 
1.1 To ascertain the prevalence of the all PWUO as well as opioid use groups 
(i.e., heroin only, prescription opioid only, and combination opioids) and 
determine whether the prevalence differ over time. 
1.2 To ascertain the prevalence of all past month substance use in all PWUO 
and opioid use groups and determine whether the prevalence differ over 
time. 
 
Specific Aim 2. To examine the prevalence of discrete latent classes of polydrug use 
in PWUO using data from the United States over the period 2002 to 2017.  
2.1 To identify the latent class variable of polydrug use in PWUO using the 11 
core substance indicators (pain relievers, heroin, alcohol, 
tranquilizers/sedatives, tobacco [cigarettes], other tobacco products, 
marijuana, cocaine, crack, hallucinogens/inhalants, and stimulants). 
 




3. To examine factors related to substance use in the context of polydrug use in 
PWUO from 2010 to 2017. 
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3.1 To determine the prevalence and bivariable associations of the following 
covariates using the latent class variable as an outcome: age, sex, 
race/ethnicity, total household income, education level, employment 
status, marital status, age at prescription pain reliever initiation, opioid use 
disorder, depression, health insurance status, county type, and residential 
transience. 
3.2 To determine the multivariable associations of specific combinations of 
variables using the drug, set, and setting model of substance use behavior 
to predict membership of the polydrug latent class. 
Hypotheses Testing for Aim 3 
For Aim 3, three hypotheses and their related sub-hypotheses will be assessed: 
Hypothesis 1: Polydrug latent classes will differ by sociodemographic characteristics. 
  
Sub-hypothesis 1.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
opioid polydrug Class’ more likely than other Classes to be male, non-Hispanic 
white, unemployed, younger at time of survey, uninsured, and having less 
education and less total household income. 
 
 
Hypothesis 2: Polydrug latent classes will differ by their opioid use history and OUD 
status. 
Sub-hypothesis 2.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
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opioid polydrug Class’ more likely than other Classes to have initiated 




Hypothesis 3: Polydrug latent classes will differ by their environment.  
Sub-hypothesis 3.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
opioid polydrug Class’ more likely than other Classes to reside in a large metro 
and to have moved at least twice in the past year. 
 
Overview of the Present Study 
To tackle these gaps in knowledge, publicly available data from 2002 to 2017 
from the NSDUH was used to examine patterns of polydrug use in PWUO and to 
evaluate the effects of key covariates on high-risk polydrug use in that population. 
NSDUH is the premier surveillance system for monitoring drug use behavior because it is 
a cross-sectional survey administered every year by the Substance Abuse and Mental 
Health Services Administration (SAMHSA), in conjunction with the Research Triangle 
Institute (RTI).  It utilizes a 50-state sampling design with an independent, multistage 
area probability sample for all states and the District of Columbia.40  Its primary purpose 
is to measure the prevalence and correlates of drug use among noninstitutionalized 
civilians in the United States.40  The participants recruited to complete the survey are 
aged 12 years and older, non-institutionalized, and English and Spanish speaking.40  
Given the magnitude of topics covered by the survey, it is dataset to capture information 
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relevant to polydrug use behavior, the covariates of interest, as well as sociodemographic 
characteristics. It was ultimately preferred over other publicly available datasets such as 
the National Comorbidity Survey (NCS) or the National Epidemiologic Survey on 
Alcohol and Related Conditions (NESARC) because of its ability to track reported 
substance use trends every year, without sacrificing data on covariates that were of most 








There are three main goals of this literature review; the first is to summarize 
major themes that appear in opioid and polydrug use literature before and following the 
1990s.  The importance of discussing these studies is to set the historical context to the 
current opioid epidemic, which largely diverge into heroin and OPR studies.  Second, 
recent studies related to populations at higher risk of opioid-related polydrug use will be 
presented to elucidate what is known about the co-use of opioids and other substances.  
Third, studies related to PWUO which evaluate covariates belonging to the drug, set, and 
setting framework will be described.   
 
Opioid Literature from 1970 to 1990 
Although literature on polydrug use has been around since the early 1970s, 
research related to opioids in this context did not begin to burgeon until 2012.41-43  Prior 
to 1990, literature specific to polydrug use consisted of commentaries or editorials about 
drug addiction, treatment strategies, and patterns and distributions of drug use in different 
populations (e.g., adolescents, mothers, nationally representative populations).41-45  And 
while these themes are not exclusively confined to the 1970s, one unique aspect was that 
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only one type of opioid was mentioned – namely, heroin.  Heroin was of significant 
concern during this period, especially because of the “War on Drugs” sociopolitical 
sentiment of drug use in the 1970s.46  Populations most at risk of heroin and other 
polydrug use were predominantly African American, male, and between the ages of 21 to 
25.45 
It was not until the early 1980s that literature on the use of OPRs in humans began 
to surface, many of which focused on evaluating the efficacy of iatrogenically 
administered OPRs, such as morphine and pethidine.47,48  Other early studies focused on 
chronic pain patients because of the risk of their inappropriate or even excessive use of 
multiple pain medications.49-51  In 1979, Maruta et al. conducted a study that sought to 
characterize substance use in nonmalignant pain patients. One such commentary that was 
very influential in establishing the opioid prescribing practices that were common in the 
1990s and 2000s came from two physicians (Porter and Jick) at the Boston University 
Medical Center.  They noted that out of 11,882 patients who received one narcotic 
preparation, only four were documented to have developed an addiction, with no prior 
history of addiction.52  Therefore, they concluded that developing narcotic addiction was 
rare in patients with no prior history, despite the widespread use of narcotic drugs in the 
hospital.52  In 1982, Turner et al. completed a study that suggested that the overuse of 
pain medications in their study population led to many adverse social and physical 
consequences (e.g., higher hypochondriasis and hysteria scores, incurring higher costs per 
month on medication spending).50,51     
Although the overall message from the results of Turner et al. echoed the 
sentiment that existed in the early 1900s regarding the dangers of pain medication use, 
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this was quickly overturned by research conducted by pharmaceutical companies.51  In 
1986, a study was published in Pain by two physicians who sought to weigh in on the 
controversial use of opioid analgesics in non-cancer patients.6  Their retrospective study 
involved reviewing case histories of a total of 38 patients from two separate sources: 
active and former patients who had previously been given non-opioid analgesics at the 
Pain Clinic of Memorial Sloan-Kettering Cancer Center.53  After reviewing all patient 
files, Portenoy and Foley found that 63% of the study population had notably enhanced 
comfort after the use of OPRs, the results of which aligned with other studies during the 
time.6,54-56  Not only did they conclude that pain medication is safe to administer on a 
long-term basis, but they also argued that ‘addiction’ differed from ‘physical 
dependence,’ arguing that ‘addiction’ should be called ‘psychological dependence.’6  
 
Opioid Literature after 1990 
In the final decade of the 21st century, before the onset of the first wave of high 
mortality in the current opioid epidemic, polydrug use in PWUO remained confined to 
patient populations and many studies focused on understanding biological effects of 
opioids and substance detoxification processes.57,58  After 1999, the distributions and 
patterns of opioid use were reassessed, and many studies no longer focused on heroin; 
OPR misuse was now a hot topic in substance research.7,59-61  However, it was eventually 
revealed that a faction of individuals who misused OPRs would eventually begin to use 
heroin, which further complicated previous understanding regarding PWUO, because of 
the presupposition that the demographics of those who use heroin differed greatly from 
those who were prescribed pain medication.62,63  
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Of marked importance around the turn of the 21st century was understanding the 
characteristics of individuals who used prescription opioids.64-66  These included special 
populations such as individuals with chronic infectious diseases (e.g., HIV, hepatitis), 
adolescents and young adults, and people with psychological conditions (e.g., depression, 
anxiety).34,67,68  Based on the literature search conducted, it was evident that researchers 
in this field were starting to move away from non-cancer chronic pain patients as a study 
population and expanding their research goals in other high-risk groups.  Additionally, 
studies investigating the toxicological and pharmacologic effects of polydrug use in 
PWUO were more abundant, including the possible potentiating effects of 
benzodiazepines on opioids.69-72  Most recently, literature related to opioid misuse now 
included a multitude of case reports regarding the role of fentanyl in the massive increase 
of opioid-related overdose deaths in the United States and internationally.73,74 
 
Epidemiology of People Who Use Opioids  
Sociodemographic characteristics  
In the United States, studies in PWUO have ranged from those who only use 
prescription opioids, to those who only use heroin, and finally, a combination of the two. 
This oversimplification may have been due to necessity, since ‘complex’ is an 
understatement for the characterization of affected and at-risk populations in this 
epidemic, partially due to the intertwining opioid use behaviors.75,76  It should also be 
noted that many studies and reports on the current opioid epidemic used mortality records 
or observational data, which may report different and contradicting information regarding 
populations most at risk.  
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Many reports on the distribution and trends on opioid mortality rely heavily on 
surveillance data from sources like the CDC WONDER, which base their analyses and 
characterization on specific opioid categories (i.e., natural, semi-synthetic, fully 
synthetic).  For example, a recent Morbidity and Mortality Weekly Report (MMWR) 
detailed an increase from 2014 to 2015 in natural and semi-synthetic opioid overdose 
deaths, with a significant increase in death in men of all ages, women between 25 and 44 
years of age, and White non-Hispanic populations.7  Methadone overdose deaths differed 
slightly during this period in that both sexes of all ages, especially those over 65 years of 
age experienced increased death rates.7  However, beginning in 2015, deaths involving 
synthetic opioids (excluding methadone) and heroin were highest in men aged 25 to 44.7  
From 2015 to 2016, updated opioid mortality rates were reported in a 2018 MMWR, 
which showed increases among both men and women, as well as those greater than 15 
years of age.77  Additionally, males aged 15 to 24 had the largest rate change in mortality 
rates, indicating that younger populations are now being affected by heroin and 
prescription opioid deaths.77 
Other reports related to opioid use are generated from NSDUH data.  Multiple 
SAMHSA reports predominantly focus on the single use of prescription opioids and 
heroin, with the most recent report providing some statistics on their combined use.78,79  
According to the 2015 SAMHSA report, past month nonmedical use of pain relievers 
from 2002 to 2014 was on the decline for individuals 12 years and older in the most 
recent years.78  In contrast, reported heroin use from 2002 to 2014 was shown to increase 
slowly, and was reported by a higher percentage of young adults (aged 18 to 25), while 
the percentage of adolescents who reported its use remained at a lower, and steady trend 
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from 2012 to 2014.78  In the 2018 NSDUH report, the prevalence of individuals who use 
heroin remained steady in the same age groups from 2015 to 2017.79  Non-medical use of 
prescription pain relievers (PPR) was also discussed, but trend data was not presented.80  
In terms of racial and ethnic distributions of the opioid epidemic, much of the 
research investigating racial differences focus on non-Hispanic Whites, non-Hispanic 
Blacks, and Hispanics, which may be due to low representation of other racial groups or 
the high proportion of non-Hispanic Whites who are affected in this epidemic.  Morbidity 
due to prescription opioid overdose was previously understood as a White, non-Hispanic 
epidemic, driven by a multitude of factors which include (but are not limited to) 
structural racism and physician prescribing practices.15,81,82  Structural racism is generally 
defined as the “totality of ways in which societies foster [racial] discrimination, via 
mutually reinforcing [inequitable] systems…(e.g., in housing, education, employment, 
earnings, benefits, credit, media, health care, criminal justice, etc.) that in turn reinforce 
discriminatory beliefs, values, and distribution of resources”.83  The effects of structural 
racism has been shown to result in the vilification of Black and Brown opioid abuse and 
dependence, especially in the media, which ultimately drove different public responses 
and policy interventions (e.g., criminalization of substance use behaviors in non-White 
populations).84    
However, based on a recent MMWR publication, racial and ethnic changes in 
either ‘any opioid’ or ‘just prescription opioid’ deaths have significantly increased in the 
non-Hispanic White, non-Hispanic Black, and Hispanic populations from 2015 to 2016, 
with non-Hispanic Blacks having the greatest percent rate change in heroin and 
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prescription opioid mortality.77  This indicated a decrease in racial disparities in opioid 
use and mortality.77   
Other significant sociodemographic indicators of substance use morbidity and 
mortality found in the literature are academic attainment and income.  A recent study 
looking at the educational gradients in relation to drug overdose using data from the 
National Vital Statistics Survey (NVSS) and the National Death Index from 2002 to 2011 
showed that individuals with less than high school education consistently had the highest 
death rates from drug overdose (per 100,000 persons) for each time period analyzed (i.e., 
1992-1996, 1997-2001, etc.).85  It has also been shown that those with lower incomes, 
especially those on publicly funded health insurance policies, are more likely to have an 
opioid use disorder (OUD) and to misuse opioids when compared to the general U.S. 
population.86-89   
 
Geographic distribution of opioid-related morbidity and mortality  
Figures 2.1 and 2.2 show the geographic distribution of the number of reported 
heroin and nonmedical use of prescription opioids (NMUPO) among those aged 26 and 
older (i.e., the population with the highest risk of opioid overdose) using NSDUH data 
from 2016 to 2017, respectively.90  Regions of the U.S. with the highest percentage levels 
of reported heroin use included the Midwest (Indiana, Ohio, West Virginia), the 
Northeast (Pennsylvania, Connecticut, New Hampshire, Maine), and the West 




Figure 2.1 | Nonmedical Use of Past Year Heroin among Individuals Aged 26 and older, 
NSDUH 2016 to 201790 
 
 
Figure 2.2 | Nonmedical Use of Past Year Prescription Pain Relievers among Individuals Aged 
26 and Older, NSDUH 2016 to 201790 
 
Figure 2.3 shows the opioid-related mortality rates using data from the 1999 to 
2017 CDC WONDER as analyzed by the Kaiser Family Foundation.§  Opioid deaths 
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were defined using codes from the International Classification of Disease, 10th Revision 
(ICD-10).§  The ICD-10 codes included were opioids (T40.0, T40.1, T40.2, T40.3, T40.4, 
or T40.6); natural and semisynthetic opioids (T40.2); methadone (T40.3); synthetic 
opioids, other than methadone (T40.4); and heroin (T40.1).§  As shown in Figure 2.3, 
states with the highest opioid-related mortality rates included Maine, New Hampshire, 






Figure 2.3 | Opioid-Related Overdose Deaths in the U.S. by State, 1999 to 2017‡§ 
                                                 
‡The National Vital Statistics System multiple cause-of-death mortality files were used to identify 
drug overdose deaths. Drug overdose deaths were classified using the International Classification 
of Disease, Tenth Revision (ICD-10), based on the ICD-10 underlying cause-of-death codes 
X40–44 (unintentional), X60–64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent). 
Among the deaths with drug overdose as the underlying cause, the type of opioid involved is 
indicated by the following ICD-10 multiple cause-of-death codes: opioids (T40.0, T40.1, T40.2, 
T40.3, T40.4, or T40.6); natural and semisynthetic opioids (T40.2); methadone (T40.3); synthetic 
opioids, other than methadone (T40.4); and heroin (T40.1). 
 
Age-adjusted death rates were calculated by applying age-specific death rates to the 2000 U.S. 
standard population age distribution. Death Rates are deaths per 100,000 population (age-
adjusted). 
 
Deaths from illegally-made fentanyl cannot be distinguished from pharmaceutical fentanyl in the 
data source. For this reason, deaths from both legally prescribed and illegally produced fentanyl 




Kaiser Family Foundation analysis of Centers for Disease Control and Prevention (CDC), 
National Center for Health Statistics. Multiple Cause of Death 1999-2017 on CDC WONDER 
Online Database, released 2018. Data are from the Multiple Cause of Death Files, 1999-2017, as 
compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics 
Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10.html on January 10, 2019. 
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Literature on Polydrug use in PWUO 
Current polydrug use literature may be described as wide-ranging and includes a 
variety of populations (e.g., adolescents, young adults; HIV populations; those who use 
illicit substances; PWUO, people who inject drugs; etc.), but may not necessarily include 
opioids.91  However, because the focus of this study centers on PWUO, this section will 
review polydrug use studies primarily in the U.S. where participants have reported using 
either heroin or prescription opioids, with an emphasis on studies that use latent class 
analysis (LCA) to characterize these subpopulations.   
 
Opioid-related polydrug use in adolescents 
In a study by Katherine Keyes and colleagues, polydrug use was explored among 
young adults (aged 18-29) in the United States using data from the National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC).92  The results of 
their study found that 44% of people who currently use ecstasy reported taking at least 
three other classes of substances (i.e., cannabis, cocaine, opiates, tranquilizers), compared 
to only 1.6% in non-ecstasy users.92  Additionally, lifetime psychiatric comorbidities 
among current ecstasy users were much greater compared to non-illicit drug users.92  
The idea that younger populations exhibited opioid-related polydrug use patterns 
was also validated several years later in a multi-site study by Lankenau et al. where the 
study population consisted of young adults (aged 16-25) who were known misusers of a 
prescription drug (e.g., opioids, tranquilizers, stimulants).93  Participants were asked 
questions within a multitude of key concepts including lifetime history of receiving a 
prescription medication, age at initiation of prescription drugs and other illicit drug use, 
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lifetime history of using illicit drugs, and polydrug use with prescription drugs.93  
Substances reported by participants as having been misused in the past 90-days included 
a combination of opioids and tranquilizers, followed by stimulants (e.g., cocaine and 
amphetamines).93 
 
Polydrug use subpopulations among PWUO 
 Nationally representative data has also been used to explore opioid-related 
polydrug groups.  Wu et al. analyzed data from the 2001 and 2002 NESARC to 
determine whether there are subtypes of nonmedical opioid users and whether these 
subtypes may be characterized by distinct socioeconomic factors and other health-related 
variables.19  The target population of the NESARC is adults at least 18 years of age, and 
sampling for the survey involved a multistage cluster design.  A total of 43,093 
respondents were included in the analyses.19  Subtypes were determined using LCA 
techniques, and among this population, four LCA subtypes were identified: opioid-
marijuana users (33%), opioid-other prescription drug users (9%), opioid-marijuana-
hallucinogen users (28%), and opioid-polydrug users (30%).19  Moreover, the prevalence 
of substance use disorders (SUD) by LCA-subtype were largely significant.19  
 A more recent study conducted by Bobashev et al. investigated patterns of 
polydrug use where participants were recruited from a syringe exchange program in 
Cleveland, Ohio.37  The overall purpose of the study was to establish the polydrug use 
patterns while distinguishing concurrent versus simultaneous polydrug use.37  The 
investigators also sought to characterize these subpopulations by their demographics and 
their attitudes regarding the different substances that they reported using.37  They found 
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five polydrug group clusters using cluster analysis: 1) concomitant heroin, alcohol, and 
occasional crack use; 2) daily heroin and crack cocaine use; 3) mostly heroin; 4) daily 
heroin and marijuana use; and 5) part-time drug users.37   Bobashev et al. also found that 
polydrug use was facilitated by high availability and low cost of heroin and cocaine.37  
 Prescription opioid misuse and comorbid substance use were also explored using 
2016 NSDUH data in a study published in early 2019 by Grigsby and Howard.94  The 
authors found that the majority of the participants reported prescription opioid and 
polydrug use** [prevalence rate, PR (95% CI): 0.67% (0.56 – 0.79%)], followed by:  
1) prescription opioid only use; 2) prescription opioid and alcohol use; 3) prescription 
opioid and marijuana use; 4) prescription opioid and cigarette use; and 5) prescription 
opioid and hard drug use.94  Additionally, men, younger individuals, and those who 
reported an annual household income of less than $20,000 per year were more likely to 
report past month prescription opioid misuse with an illicit drug or with polydrug use.94    
 
 Opioid-related polydrug use in people who inject drugs (PWID) 
 Prescription opioid and heroin use has been documented in previous studies as 
precursors to other injection drug use.62,67,95,96  Furthermore, injection drug use (including 
opioids) is thought to increase a person’s risk of contracting bloodborne infections that 
may lead to worse health outcomes.97,98   Using data from a longitudinal cohort study of 
PWID, Roth et al. examined distinct and habitual polydrug drug use (i.e., weekly or more 
frequent use) patterns among PWID living in San Diego, California using LCA to model 
the five substances that were reported to be most in use (i.e., heroin, methamphetamine, 
                                                 
**Grigsby and Howard defined polydrug use as past month misuse of prescription opioids and more than 
one recreational drug in the past month.73  
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prescription drugs, alcohol, and marijuana) by different routes of administration (i.e., 
snorting, swallowing, injecting, and smoking).36   
The LCA analysis conducted by Roth et al. identified two distinct classes of drug 
users: methamphetamine by multiple routes (n = 261; 51%) and heroin by injection (n = 
250; 49%).36  The conditional probabilities of prescription drugs and binge drinking were 
similar in both classes, but Class 1 members had a higher probability of marijuana use 
compared to Class 2 members (48.6% versus 25.4%, respectively).36  In their 
multivariable model, non-Hispanic Blacks [aOR (95% CI): 3.23 (1.53, 6.84)] and 
Hispanics [aOR (95% CI): 1.84 (1.14, 3.01)] were more likely to belong in the primarily 
heroin injecting class, and those who reported ever overdosing on heroin, morphine, 
methadone, or oxycontin were more likely to belong in the primarily heroin injector class 
[aOR (95% CI): 1.89 (1.23, 2.89)].36    
 In a study by Meacham et al., data from a prospective cohort study was used to 
identify substance use patterns among PWID in Tijuana.  Four major criteria were used to 
decide which substance use variables went into the LCA model: type of substance, route 
of administration, co-injection, and frequency of use.33  From the LCA analysis, 
participants were classified into five subgroups33:  
1) Class 1 (polydrug and polyroute, plus cocaine; 5% of the sample)  
2) Class 2 (polydrug and polyroute; 29% of the sample) 
3) Class 3 (stimulant and heroin injection; 4% of the sample)  
4) Class 4 (methamphetamine and heroin injection, 10% of the sample) 




Additionally, the investigators found that the two polydrug and polyroute classes (i.e., 
Classes 1 and 2) were more likely to report HIV risk behaviors (e.g., unprotected sex, 
having two or more sexual partners, drug use before or during sex, etc.) when compared 
to those who predominantly injected heroin (i.e., Class 5).  Furthermore, Class 1 
members were more likely than Class 5 members to report having had an overdose in the 
past six months [OR (p-value): 3.35 (0.01)].33  And while the overall population from 
which the sample is drawn is not comparable to the U.S. population, the study results are 
consistent with the idea that those who have a greater amount of polydrug use behaviors 
are more likely to report needle sharing and overdose risk.99,100 
 
Drug, Set, and Setting Conceptual Framework 
A theoretical framework by Norman Zinberg, a professor in clinical psychiatry at 
Harvard Medical School will be used to guide the selection of correlates and to determine 
the analytical strategy.  The drug, set, and setting model was used in one of his studies 
funded by The Drug Abuse Council (DAC), which sought to provide a description of 
participants who were categorized as controlled, marginal, and compulsive subjects based 
on preset conditions.101  The results of this study helped to pave the foundation of 
understanding opiate addiction.101   
Drug in Zinberg’s model refers to the type of substance used, how it is used (i.e., 
route of administration or whether other substances are combined during use), and the 
legal status of the substance.  Set variables refer to the individual’s unique traits (e.g., 
personality, preparation, intention, etc.) while setting factors may be broadly 
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characterized as environmental components of an individual’s life that influence the use 
or nonuse of substances (e.g., social, physical, and cultural environment).102   
 
Drug Factors: Commonly Co-used Substances in PWUO 
 The purpose of the following subsections is to discuss research that has been 
conducted that explore the associations between opioid use and other substances that are 
surveyed in the NSDUH.   
 
Alcohol 
 As with other medications, the effects of alcohol and opioid have been researched 
since the 1960s.103,104  The dangers of the co-use of these substances involve the 
significant respiratory distress that can occur due to the depressive effects of both 
substances on the central nervous system.105-107  The current extent of alcohol and opioid 
co-use has been documented in a study by McCabe et al. where data from the NESARC 
was analyzed to determine the prevalence of the misuse of four prescription drug classes, 
including prescription opioids.27  Of the 43,093 survey respondents, the unadjusted 
prevalence of past-year NMUPO by past-year drinking status for all participants is shown 
in Table 2.1.27  As shown in Table 2.2, the prevalence of individuals who misuse opioid 
analgesics across all categories of past-year drinking, was highest when compared to 








Table 2.1 | Unadjusted prevalence estimates of past-year NMUPO by past-year drinking 





















2.13 (0.16) 1.08 (0.10) 0.87 (0.09) 0.59 (0.09) 0.14 (0.04) 
Binge drinking 
(no AUDs) 












Benzodiazepines: Tranquilizers and Sedatives  
Benzodiazepines are a type of prescription drug commonly used to aid in 
relieving anxiety symptoms or insomnia and may be classified as either a tranquilizer or a 
sedative.108,109  When individuals take both substances, the effects include increased 
sedation, suppressed breathing, and impaired cognitive function, the interaction of which 
may be additive or synergistic.108,110  Based on data from the IMS Health Vector One ® 
Total Patient Tracker of patients from 2002 to 2014, the annual trend of concomitant 
prescribing of benzodiazepines and opioids rose from 6.8% to 9.6%, which corresponded 
to a relative increase of 41%.111  The investigators also found that approximately half of 
all patients who were included in the study were prescribed both on the same day.111  
The danger of benzodiazepine and opioid co-use was also assessed from a 
prospective observational cohort study in North Carolina.26  The study population 
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consisted of all living North Carolina residents in 2010 (n = 9,560,234).26  Data from the 
controlled substances prescription monitoring program was name-linked to mortality data 
from the North Carolina State Center for Health Statistics.26  The investigators found that 
22.8% of all living residents in 2010 had been prescribed opioid analgesics; of these, 80% 
had also been prescribed benzodiazepines.26  The incidence rate ratios for overdose 
deaths involving opioid analgesics showed a dose-response relationship in all individuals, 
but especially in co-users of benzodiazepines, as shown in Figure 2.4.26  Overall, the 
rates of overdose death of residents who had been co-dispensed benzodiazepines and 
opioids were ten times higher than for opioid only users.26 
 
 
Figure 2.4 | Mortality Incidence Rate Ratios among Opioid Analgesic Users by Benzodiazepine 
Use Status26 
 
Adding to this narrative are the results of a more recent investigation of the 
concurrent use of opioids and benzodiazepines by McClure et al. where specimens of 
patients who had been prescribed at least one type of prescription opioid or 
benzodiazepine, were reanalyzed for co-used substances.25  Nationwide patient samples 
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collected from March 2015 to December 2015 were sent to Quest Diagnostics for co-
testing of opioids and benzodiazepines using a combination of presumptive immunoassay 
screening and confirmatory quantitative mass spectrometry testing.25  Of the 231,228 sets 
of toxicologic test results available from 144,535 patients, 59,557 (25.8%) were positive 
for both substances.25  Concurrent use was then broken down into subtypes based on 
prescription attributes, as shown in Figure 2.5.25  Based on the results of this study, the 
authors concluded that the extent of the co-usage of these substances goes beyond what 
was previously assessed using available prescription databases and monitoring programs 
because non-prescribed medications in the urine samples were detected.25 
 
 







Cigarette smoking and smokeless tobacco 
 It has been shown in the literature that the connection between the co-use of 
cigarettes and opioids is a person’s chronic pain condition, including mental health.112-115  
Furthermore, major results from observational studies looking at the specific association 
between cigarette smoking and opioid use support the idea that smokers were more likely 
to report the use of opioids.116-118  Potential pathways for the continued co-use of 
cigarettes and opioids include pharmacological interaction between the two substances, 
or the mutual reinforcement of pain and tobacco use (i.e., individuals suffering from 
chronic pain conditions smoke cigarettes to alleviate pain).112,114,119  A study by Hooten et 
al. examined the association between depression and pain severity by smoking status as 
well as the association between depression and opioid use of the sample population (N = 
1,241).120  The authors found that status as a current smoker was associated with the use 
of greater morphine dosages after adjusting for depression scores [beta (β) coefficient (p-
value): 26.77 (0.003)]; this means that current smoking status was independently 
associated with a 27 mg/day increase in morphine equivalent dose compared to never 
smokers.120  
 In a more recent study by John et al., data from the National Institute on Drug 
Abuse (NIDA) Clinical Trials Network (CTN) were analyzed to examine the extent of 
opioid misuse among different subgroups of tobacco users.121  The investigators found 
that approximately 14.0% of participants who reported past year tobacco use (n = 882), 
also reported past year opioid misuse, whereas the prevalence of past year opioid misuse 
was 2% among non-tobacco users.121  LCA was used to assess latent subgroups of 
tobacco users, and three classes were enumerated121: 
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1. Class 1 was referred to as the ‘tobacco-minimal drug use group’ and was 
characterized as having a low probability of any past year drug use.121 
2. Class 2 was referred to as the ‘tobacco-cannabis use group’ and was characterized 
by a high probability of past year cannabis use with moderate probability of other 
past year drug use.121  
3. Class 3 was referred to as the ‘tobacco-opioid/polydrug use group’ and was 
characterized by the high probability of opioid misuse, and moderate probability 
of past year cannabis, cocaine, and prescription stimulant and sedative use.121 
 
When comparing the latent drug classes using sociodemographic factors, they found that 
Class 2 was more likely to be younger and have reported past year alcohol use.  
Additionally, Class 3 was more likely to be male, white, less educated, unemployed, 
disabled, and more likely to have reported past year alcohol use.121 
 With smokeless tobacco use, limited studies have been found that would be 
relevant in the context of opioids.  However, in a 2014 article published by Fu et al., data 
from Wave I of the NESARC was analyzed to determine the association between snuff 
and chewing tobacco use and different psychiatric conditions, including OUD.122  The 
investigators found that those who used both chewing tobacco and snuff were almost 
twice as likely [aOR (95% CI): 1.81 (1.09, 3.03)] ever to develop an OUD.122 
 
Crack and Cocaine  
 Although these two substances are treated as separate categories in this study, 
freebase cocaine (or “crack”) is a highly concentrated form of cocaine, that is typically 
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smoked (whereas cocaine is snorted or injected).123  As such, both are derived from coca 
plants indigenous to the Andes Mountains in South America and induce short term 
effects such as extreme happiness and energy, irritability, or paranoia.123  The “high” 
effects of snorting or injecting the substance lasts for approximately 15 to 30 minutes.  
On the other hand, the effects of smoking may last only five to 10 minutes, exacerbating 
the urge to use crack.123 
The biological effects of the co-use of cocaine and opioids (also known as 
“speedballing”) differ from that of alcohol or benzodiazepines with opioids; instead of 
further depressing the CNS and leading to respiratory distress, it has been shown that 
both opioids and cocaine can act as powerful motivators of appetitive behavior.124-126  
Furthermore, many individuals co-use heroin and cocaine to lessen the negative side 
effects of the individual substance.126  Additionally, studies have documented a variety of 
reasons for co-use that are seemingly unrelated to their biological effects, including the 
overall feeling of their co-use as being ‘different’ or ‘better’ than using a single substance 
alone, or as a method to self-medicate for mental health purposes or even reduce their 
intake of other substances (e.g., opioids).127-131  Macro-level factors related to availability 
have also been suggested in various news outlets.  For instance, an analysis of data from 
the Drug Enforcement Administration’s (DEA) System to Retrieve Information from 
Drug Evidence (STRIDE), showed that drug prices for cocaine have generally decreased 
from 1986 to 2012, as a result of organizational changes by drug traffickers.132  
While fewer epidemiologic studies have focused on the co-use of crack or cocaine 
and opioids compared to alcohol or benzodiazepines, existing research has established 
that not only has heroin use increased among cocaine users, but that cocaine use disorder 
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increased the risk of developing heroin and prescription opioid use disorder.18,88  From 
2002 to 2013, the prevalence rate (by 1,000 population) of reported past-year cocaine use 
among past-year heroin users increased by 87.1% when comparing 2002-2004 and 2011-
2013 rates, and 34.0% from 2008-2010 to 2011-2013 using NSDUH data.18  Moreover, 
individuals with cocaine use disorders in the U.S. had a 1.41 times greater prevalence of 
also having prescription opioid use disorders compared to those who did not [prevalence 
rate, PR (95% CI): 14.3 (13.74-14.97)].88  
To explore the relationship between concurrent opioid and cocaine use and its 
effect on mortality, McCall Jones et al. analyzed data from the NVSS to inform public 
health efforts how to curb overdose and to increase treatment strategies.17  Major findings 
of their study revealed a heterogeneous pattern of cocaine-related opioid overdose 
deaths.17  Cocaine-related deaths involving opioids increased from 2000 to 2006, and 
again from 2010 to 2015, as shown in Figure 2.6.17 
 
Figure 2.6 | Heroin or synthetic opioid involved mortality rate trend from 2000 to 2015, National 
Vital Statistics System, United States17 
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Hallucinogens and inhalants 
  Hallucinogens (i.e., psychedelics) are substances that alter an individual’s 
perception, thoughts, and feelings. 133  In other words, they cause hallucinations or 
sensations that appear to be real.133  To date, some commonly used hallucinogens include 
ayahuasca, peyote, mescaline, and psilocybin.133  Inhalants are volatile substances that 
also have a psychoactive (i.e., mind-altering) effect when inhaled, and may be broadly 
categorized into four groups: volatile solvents, aerosols, gases, and nitrites.134  
 To date, the co-use of either hallucinogens or inhalants and opioids have been 
extremely limited, and somewhat mixed.  In a 2011 study by Wu et al., data from the 
2001 to 2002 NESARC was analyzed to determine whether opioid use groups (i.e., 
heroin-other opioid; other opioid only; heroin only; and non-opioid drugs users) differed 
in their patterns of drug use.135  Compared to non-opioid drug users, all other opioid use 
groups reported greater use of both hallucinogens and inhalants and this association was 
significantly different across all opioid use groups.135  Table 2.2 shows the prevalence of 
reported use for hallucinogens and inhalants in this study population.135 
 
Table 2.2 | Reported prevalence of lifetime hallucinogen and inhalant use among opioid 




















Hallucinogens Yes 97.4 46.1 68 19.2 128.5 
(3) 
<0.001 
No 2.6 53.9 32.1 80.8 
Inhalants Yes 46.3 18 24.1 4.4 87.3 
(3) 
<0.001 





 In a more recent study by Pisano et al., the relationship between psychedelic use 
history and OUDs within an illicit opioid user population was analyzed using NSDUH 
data from 2008 to 2013.136  The authors found that psychedelic substance use was 
associated with a 27% reduced risk of past year opioid dependence [weighted RR, RRw 
(95% CI): 0.73 (0.60 – 0.89)] among participants with a history of illicit opioid use.136   
 
Marijuana  
 Another substance that has been recently assessed for its relationship with 
prescription opioid use disorder is marijuana.  Initial literature, including news articles, 
has questioned whether the availability of marijuana may curtail the need for the use of 
prescription opioids.137-142  In a study by Bachhuber et al., a time-series ecologic analysis 
was conducted using state-level death certificate data in the U.S. from 1999 to 2010.140  
The investigators found that the existence of medical cannabis laws (MCL) was 
significantly associated with lower state-level opioid overdose mortality rates.140  Also, in 
a recent study by Vigil et al., data from a preliminary study on a cohort of chronic pain 
patients with a history of habitual opioid use (n = 37) were analyzed to establish whether 
there was an association between enrollment in the New Mexico Medical Cannabis 
Program (MCP) and opioid prescription use.142  The patients were enrolled in the MCP 
from April 1, 2010 to October 5, 2015 (i.e., 21 months), and it was determined that MCP 
enrollment was associated with higher age- and gender-adjusted odds of ceasing opioid 
prescriptions (95% CI 1.89 to 157.36, p = 0.012) and reducing daily prescriptions opioid 
dosages (95% CI 1.56 to 16.88, p = 0.007).142 
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Since these early studies and commentaries, research has been conducted to 
determine whether marijuana use has an effect on NMUPO; in a study published in 2018, 
Olfson et al. analyzed data from Waves I and II of the NESARC to evaluate whether 
marijuana use is associated with a  change in the risk of incident NMUPO.143  The results 
of the prospective association analyses between cannabis use and NMUPO showed that 
those who reported cannabis use in Wave I had significantly increased odds of incident 
NMUPO in Wave 2, even after adjusting for demographics and clinical characteristics 
(e.g., other SUDs, depression, family history of drug use disorders) [aOR (95% CI): 2.62 
(1.86-3.69)].143  The results of this study may be explained by the idea that cannabis use 
could lead to behavioral disinhibition, possibly increasing the risk of using other 
substances, including opioids.144  
    
 
Prescription stimulants 
 Prescription stimulants are drugs that are generally provided to individuals with 
attention-deficit hyperactivity disorder (ADHD) and narcolepsy because they function to 
increase alertness, attention, and energy.145  Commonly prescribed stimulants include 
dextroamphetamine (Dexedrine ®), dextroamphetamine/amphetamine combination 
product (Adderall ®), and methylphenidate (Ritalin ®, Concerta ®).145  Although 
observational studies on the co-use of opioids and prescription stimulants were extremely 
limited, a few studies have surfaced in recent years which focus on higher risk 
populations, such as those with ADHD as well as working adults.146,147   
In a recent study by Wei et al., an analysis of 66,406 Medicaid-enrolled adults 
(aged 20 to 64) with ADHD was conducted using cross-sectional data from 1999 to 
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2010.146  Their goal was to assess the prevalence and secular trends of concurrent 
stimulant and opioid use, as well as the factors associated with long-term use.146  It was 
determined that of the 21,723 adults with ADHD (32.7% of total eligible patients), 5,004 
(23.0%) received prescription stimulants and opioids for a short time period (1-29 days), 
and 3,560 (16.5%) received both drugs for at least 30 days (i.e., long term).146  Also, 
those who were prescribed stimulants were more likely to have been prescribed opioids 
for long term use compared to those who were not prescribed stimulants.146  Furthermore, 
the investigators found a significant increase in the prevalence of long-term concurrent 
stimulant-opioid use from 1999 to 2010 [adjusted prevalence relative ratio (95% CI): 
1.12 (1.10-1.14)].146  
Another recent study published by Perlmutter et al. investigated whether 
employment status was associated with NMUPO and nonmedical use of prescription 
stimulants (NMUPS).148  The study included adults aged 26 and older who participated in 
the 2011 to 2013 NSDUH and examined covariates that related to their employment 
status (i.e., employed full-time, employed part-time, unemployed, and not in the 
workforce) and past year NMUPO and NMUPS use.148  They found that the overall past 
year prevalence of NMUPO and NMUPS were 3.48 and 0.72%, respectively; among 
those unemployed, the prevalence of NMUPO and NMUPS were the highest of the four 
employment groups, at 6.91 and 7.01%, respectively.148  The researchers also determined 
that unemployed respondents had the highest odds of NMUPO [aOR (95% CI): 1.45 
(1.15-1.82)], while those not in the workforce had the highest odds of NMUPS [aOR 




Set Factors: Individual Level Characteristics Associated with Opioid Misuse 
 
Age at prescription opioid initiation 
In recent years, the number of prescription opioid initiates in the adolescent 
population has prompted researchers to investigate whether age at initiation affects other 
substance use behaviors.  In a previously described study, Lankenau et al. found that the 
age of initiation of stimulants, heroin, and prescription opioids may serve as a pathway to 
the misuse of other, especially illicit, substance use.93  Additionally, Cerda et al. analyzed 
data from the 2004 to 2011 NSDUH and developed discrete-time hazard models to 
estimate the age-specific hazards of heroin initiation if the respondent had a prior history 
of prescription opioid use in adolescents and young adults.63  Overall, it was revealed that 
heroin initiation was strongly affected by a prior history of prescription opioid misuse 
[hazard ratio (95% CI): 13.12 (0.73, 16.04)], however, when stratifying the results by 
age, those who were between the ages of 10 and 12 had the highest risk of transitioning to 
heroin use, regardless of race/ethnicity or income [hazard ratio (95% CI): 1.84 (1.13, 
2.99)].63   
Stronger evidence that suggested the significance of ‘age at initiation’ comes from 
the analyses of data drawn from a prospective cohort study called Monitoring the Future 
(MTF).149  McCabe et al. examined the relationships among various factors such as 
NMUPO frequencies, NMUPO motives, and initiation of medical prescription opioid use 
and NMUPO during adolescence in relation to substance use disorders (SUDs) at age 
35.149  From the descriptive analysis, the prevalence rates of SUD symptoms at age 35 
were the highest for adolescents who either: 1) reported the medical use of prescription 
opioids after initiating NMUPO or 2) reported only NMUPO.149  Furthermore, 
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adolescents in these two groups had significantly higher odds of alcohol use disorder 
(AUD), cannabis use disorder (CUD), and the other drug use disorders (ODUD) 
compared to adolescents who had no history of medical or nonmedical use of prescription 
opioids (refer to Table 2.3 for all adjusted odds ratios).149  
 
Table 2.3 | Adjusted odds of NMUPO and SUD symptoms in early midlife as a function 
of medical use history with NMUPO during adolescence 
 
Baseline characteristics 










age 35; aOR 
(95% CI)a 




age 35; aOR 
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Any substance use 
disorder (SUD) 
symptoms at age 






No medical or 
nonmedical use  
(n = 6167) 
Reference 
Medical use only  











nonmedical use  























(n = 259) 
1.95  
(1.39, 2.74)**                  
(n = 76333)b 
2.27  
(1.44, 3.58)** 
(n = 7770)b 
4.29  
(2.57, 7.18)** 
(n = 7365)b 
2.47  
(1.74, 3.52)** 
(n = 7158)b 
p < 0.05*, p < 0.001** 
aAll analyses control for race/ethnicity, sex, the highest level of parental education, geographic region, 
metropolitan statistical area, baseline cohort year, and baseline measures of past-year alcohol use, past-year 
marijuana use, and past-year other drug use. 
bSample sizes vary due to missing data on the outcome measures (i.e., AUD, CUD, ODUD, and any SUD 
symptoms at age 35) 
 
 
Opioid use disorder (OUD) 
OUD is defined in the DSM-5 as a problematic pattern of opioid use which leads 
to significant clinical impairment or distress.150  At least two of 11 criteria must be 
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observed within a 12-month period, before a diagnosis of OUD is conferred; these criteria 
are listed below.150 
 
1. Opioids are often taken in larger amounts or over a longer period than was 
intended. 
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid 
use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the 
opioid, or recover from its effects. 
4. Craving, or a strong desire or urge to use opioids. 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, 
school, or home. 
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids. 
7. Important social, occupational, or recreational activities are given up or reduced 
because of opioid use. 
8. Recurrent opioid use in situations in which it is physically hazardous. 
9. Continued opioid use despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or 
exacerbated by the substance. 
10. Exhibits tolerance. 
11. Exhibits withdrawal. 
 
It should be noted that prior to the release of the DSM-V manual, guidelines from 
the DSM-IV-Text Revision categorized substance abuse and dependence separately.151  
However, from the time of the publication of the DSM-IV in 1994, several concerns were 
raised which was related to the classification of substance use disorders, including 
whether substance use dependence and abuse should be retained as two main disorders.152  
Ultimately, the decision was made to combine abuse and dependence criteria into one 
43 
 
disorder in the DSM-V.152  (This revised definition was reflected in the NSDUH surveys 
starting in 2015).153 
Overdose deaths due to the misuse of prescription opioids and use of heroin occur 
because of the significant clinical impairment and distress as a result of abuse or 
dependence on opioids and other substances.154  In a meta-analysis by Degenhardt et al., 
pooled mortality rates (MR) were calculated using data from 51 cohorts all over the 
world.155  All eligible studies had to include measures on the specific causes of death 
among people who regularly use or are dependent on heroin and other opioids.155  Of the 
51 studies, 38 provided data on opioid-related overdose mortality, and the investigators 
determined that the pooled crude MR was 0.65 per 100 person-years (95% CI: 0.55, 
0.75).155 
Further complicating this narrative is the fact that those who are dependent, or 
abuse opioids may also be at higher risk of other substance use disorders (SUD).  Wu et 
al. used nationally representative data from the NSDUH from 2005 to 2013, to compute 
estimates for the overall prevalence of opioid abuse and dependence among those with 
OUD (n = 6,125), which were 24.73% and 75.27%, respectively.156  The prevalence 
included all eligible participants (including adolescents), with a total sample size of 
503,101 participants.156  Additional results from this study revealed that those with a 
heroin use disorder (HUD) were more likely to have other drug use disorders in the past 
year than those with a prescription opioid use disorder (Rx-OUD) [aOR (95% CI): 1.80 






Having a mental illness (including depression, anxiety disorders, and mood 
disorders) has been shown as a major comorbidity when it comes to opioid misuse.92  A 
study on young adult ecstasy polydrug users, aged 18 to 29, was conducted by Keyes et 
al. using Wave I data from the NESARC.92  The purpose of their study was to determine 
the polydrug use profile in this population and to compute the prevalence of lifetime and 
past-year DSM-IV Axis I disorders (e.g., depression, mania; panic disorders, social 
phobia) and Axis II disorders (e.g., personality disorder, antisocial disorder).92  The 
weighted prevalence of having any mood disorder among those who used illicit drugs 
other than ecstasy, including opioids, was 21.6%, and those who used any other illicit 
drug were more likely to have a mood disorder compared to individuals who had never 
used drugs [aOR (99% CI): 2.4 (1.9-3.0)].92  Furthermore, the risk of having all other 
Axis I and Axis II disorders were increased in the illicit drug use population compared to 
non-drug users.92  
Extended work regarding psychopathology and opioid use was also conducted 
using NESARC data from Waves I and II.157  The investigators were able to show that 
among those with no history of psychopathologies, the risk for certain mental disorders 
significantly increased when past year NMUPO was reported, including substance use 
disorder [aOR (95% CI): 3.13 (1.42-6.89)], depressive disorders [aOR (95% CI): 1.21 
(1.11-1.32)], bipolar disorders [aOR (95% CI): 2.81 (2.47-3.21)], and anxiety disorders 
[aOR (95% CI): 1.38 (1.03-1.83)].157 
In a recent study by Olfson et al., patient characteristics prior to their opioid-
related death among nonelderly (i.e., less than 64 years of age) Medicaid patients were 
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analyzed.158  The investigators found that the majority of the decedents had received a 
diagnosis of chronic noncancer pain conditions in the last year of life (n = 8,050; 
61.5%).158  Furthermore, a diagnosis of depression (n = 2,383; 29.6%) or anxiety (n = 
2,077; 25.8%) occurred much more often among the chronic pain patients compared to 
those without chronic pain.158   
 
Employment status 
Current research regarding the role of employment status and opioid-related 
polydrug use is mixed.  There is some evidence to suggest that being employed is 
associated with the decreased misuse of any prescription drug.159,160   However, other 
studies focus on types of employment where individuals are at higher risk of misusing 
prescription opioids due to workplace injuries which necessitate long term opioid 
analgesic treatment.161  Conversely, it has also been suggested that workplace injuries 
may be the result of substances such as prescription opioids and benzodiazepines.162  
Another important factor that may confound the association between opioid-related 
polydrug use and employment is the effect of work provided health insurance.  While it 
would be difficult to establish this connection using data from the NSDUH, it has been 
well established that individuals with health insurance plans generally have a greater 
level of access to medical care.163-165   
 
Health Insurance 
 The ability to receive healthcare under the protection of health insurance is a 
factor that plays into all types of illness, including accidental overdose.  Therefore, it 
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comes as no surprise that many of the studies revolving opioid-related overdose consider 
an individual’s health insurance type.  Hasegawa et al. conducted a retrospective cohort 
study which sought to quantify the rate of emergency departments (ED) for opioid 
overdose, and to examine whether frequent ED visits are associated with more 
hospitalizations, near-fatal events, and in-hospital mortality.166  In their multivariable 
model predicting frequent ED visits for opioid overdose between 2010 and 2011 (n = 
19,831), those with private insurance, Medicare [OR (95% CI): 2.06 (1.70-2.51)] and 
Medicaid [OR (95% CI): 1.77 (1.47-2.14)] patients were more likely to be admitted into 
the ED for opioid overdose.166   
 
 
Setting Factors: Environmental Characteristics Associated with Opioid Misuse 
 
Urban and rural differences 
 
Living in rural areas has also been attributed as a risk factor for OPR overdose 
morbidity and mortality.167,168  Paulozzi et al. analyzed data from the NVSS to quantify 
changes in drug-poisoning rates in urban and rural communities, and to determine the 
types of drugs involved in these deaths.167  They found that a dramatic increase in opioid-
related mortality from 1999 to 2004 was occurring in areas that were smaller than large 
central metro areas (i.e., rural areas).167  In an observational study by Young et al., rural 
populations in Kentucky were also determined to have significantly earlier ages of onset 
for prescription opioids (e.g., oxycodone and hydrocodone), compared to their urban 
counterparts.168  
In a more recent study by Rigg and Monnat, data from the 2011 and 2012 
NSDUH was analyzed to determine whether differences existed in prescription opioid 
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misuse among living, nationally representative adults.161  A difference of proportion t-test 
analysis comparing the two populations found that the urban communities had a 
significantly (p = 0.0002) higher proportion of NMUPO (5.7%) compared to rural 
communities (4.9%).161  Additionally, the unadjusted and adjusted logistic regression 
models reported by the investigators showed a significant decrease in the odds of rurality 
in predicting NMUPO.161   
However, it should be noted that there are regional differences in opioid misuse 
and overdose rates.89  In a briefing released by the Assistant Secretary for Planning and 
Evaluation (ASPE), areas where the prevalence of drug overdose deaths and opioid 
prescriptions include both rural and urban areas, more specifically Appalachia, New 
England, and certain areas of the West and Midwest.89  And although it was shown that 
poverty and unemployment was greatly associated with drug overdose deaths and opioid-
related hospitalizations, these relationships remained clustered in specific areas of the 
U.S. 89  However, this association was not constant because there were still some counties 
that did not have high substance use and opioid prevalence indicators despite having high 
poverty and unemployment (see Figure 2.7).89  
 
Figure 2.7 | Drug Overdose Death Rates and Poverty Rates, United States 201689 
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Residential Transience  
 Residential transience is a concept related to homelessness and housing 
instability.169  It has been shown that individuals who are either homeless or have 
unstable housing options are more likely to report the use of substances, including heroin 
and prescription opioids.169-173   Possible mechanisms for this relationship are complex, 
and may include life stress and social disruption (e.g., loss of employment, starting a new 
routine, financial distress) or may even have occurred as a result of substance use.174,175  
To date, very limited studies examine the association between polydrug use among 
PWUO and residential transiency, especially studies using a nationally representative 
sample.  However, the link between housing instability and mortality has been previously 
established.  In a study by Baggett et al., adults aged 18 years and older were 
retrospectively sampled between January 2003 to December 2008 from the Boston 
Health Care for the Homeless Program (BHCHP) to assess the overall and cause-specific 
mortality rates.173  The investigators found that drug overdose accounted for 
approximately 16.8% of deaths among adults who were less than 45 years of age [crude 
mortality rate (95% CI): 242.1 (210.1 – 274.2)].173      
 
 
What This Study Contributes 
 Currently, limited studies have documented the trends in substance use among 
different subgroups of PWUO.  Studies found in this arena have assessed polydrug use on 
those who have reported the nonmedical use of prescription opioids, have reported 
primary heroin use, or have focused on the co-use of one or two other substances (e.g., 
alcohol, benzodiazepines, marijuana).19,176  Additionally, the trend in polydrug latent 
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classes from 2002 to 2017 will further elucidate the trajectories of opioid-related 
subpopulations.  Finally, associations between covariates belonging to the drug, set, and 
setting framework and polydrug latent classes will help to characterize the polydrug 





RESEARCH DESIGN AND METHODOLOGY 
 
Introduction 
 This chapter will provide a detailed description of the NSDUH, including the 
eligibility criteria of the participants and the complex sampling procedure used by the 
collection agency, the Center for Behavioral Health Statistics and Quality (CBHSQ).  
Additionally, the dependent and independent variables that will be used in this study will 
be defined following a discussion on the conceptual framework used to guide this study.  
Data analysis related to the construction of the dependent variables will be provided 
under the analytical strategy of their respective Aim.  
 
National Survey of Drug Use and Health (2002-2017)40 
Description and source of the study population 
 The NSDUH is a nationwide study that is sponsored by SAMHSA.  The survey is 
conducted every year by the Research Triangle Institute (RTI International) and provides 
information on tobacco, alcohol, and other types of substance use, along with mental 
health and other health-related issues in the United States.  Data collected in the survey is 
authorized by Section 505 of the Public Health Service Act, which states that the national 
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incidence and prevalence of the various forms of mental illness and substance abuse be 
collected every year6.  As a cross-sectional study, participants are not followed up every 
year, which prohibits any analyses related to establishing temporality or causality. 
Since 1999, data collection consisted of a computer-assisted self-interview (CAI) 
by a field interviewer and an audio computer-assisted self-interview (ACASI).  Questions 
included age at first use, lifetime, annual, and past month usage for major substance 
classes such as marijuana, cocaine, heroin, hallucinogens, inhalants, tobacco, alcohol, and 
a variety of prescription medications (e.g., pain relievers, tranquilizers, stimulants, and 
sedatives).  Additionally, participants were questioned about their substance abuse 
treatment history, health care access and coverage, and standard demographic variables 
(e.g., gender, race, ethnicity, etc.).  And because the dataset used in this study is publicly 
available, all files have been deidentified (including geographic variables) for the 
protection of all respondents.  
 
NSDUH eligibility criteria 
The study population consists of noninstitutionalized U.S. civilians who are at 
least 12 years of age.  However, about three percent of the U.S. population are excluded 
from this survey, including members of active-duty military and individuals living in 
institutional group quarters (e.g., hospitals, prisons, nursing homes, and treatment 
centers).  After the final dwelling units (DU) are selected, field interviewers are 
dispatched to homes in a random fashion.  Potential participants are asked a series of 
screening questions and recorded on the computer.  Screening questions covered age, 
                                                 
642 U.S.C. § 505 (2012) 
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race, gender, DU residency status, and their spoken language.177  Because the survey is 
only available in English and Spanish, households where neither were spoken were 
excluded from participation.  
 
Sampling procedure 
 Since 1999, independent, multistage area probability sampling has been used for 
all 50 States and the District of Columbia.  Although slightly different target populations 
were recruited from year to year, each year averaged over 65,000 participants.178  The 
general concept of the multistage sampling involves the division of a State into 
progressively smaller geographic areas until individuals within dwelling units are 
screened and formally recruited (as shown in Figure 3.1).  It must be noted that slight 
variations of the sampling procedure do exist across different time frames and are 
summarized in Table 3.1 at the end of this section.  
 








Table 3.1 Summary and Differences in Sampling Procedures in the NSDUH, 2002 to 2017 
 
Stage 2002 - 2004 2005 - 2013 2014 - 2017 
1 
Large sample States (CA, FL, 
NY, TX, IL, MI, OH, PA) 
divided into 48 field 
interviewer (FI) regions, while 
all other States divided into 12 
FI regions. 
Approximately equally sized state sampling regions (SSRs) formed 
based on composite size measures. Once SSRs were determined, 48 
census tracts within the SSR were chosen. 
2 
Partitioning of each FI region 
into groups of adjacent census 
blocks called segments. 
Selected census block 
groups were partitioned into 
smaller areas called 
segments, which are defined 
by joining contiguous census 
blocks within each census 
block group. 
Adjacent census block groups were 
aggregated within selected census 
tracts. A total of 48 census block 
groups were chosen within each 
SSR. 
3 Dwelling units (DUs) were selected within each segment. 
Selected census block groups were 
partitioned into smaller areas called 
segments, which are defined by 
joining contiguous census blocks 
within each census block group. 
4 
Individuals within screened DUs are chosen based on age 
group. 
Dwelling units (DUs) were selected 
within segments. 
5 n/a 
Individuals within screened DUs 






Format of self-administered substance use sections 
 The 2002 to 2014 NSDUH survey had a total of 12 substance use sections, which 
may be broadly characterized as follows: 2) legal substances with age restrictions (i.e., 
tobacco, alcohol); 2) illicit substances (i.e., marijuana, cocaine, crack, heroin, 
hallucinogens, inhalants); and 3) prescription drugs (i.e., pain relievers, tranquilizers, 
stimulants, sedatives).  A 13th substance use section was added starting in 2015, for illicit 
methamphetamines, which was not previously captured under the broader stimulant 
substance category.  Another motivation to include this as a separate category was to 
maximize the likelihood of the participant’s self-report of illicit stimulants (e.g., crystal 
methamphetamine) since the context of the original ‘stimulants’ module revolved around 
prescription stimulants.153  Questions were designed to ask the participant about his or her 
frequency of use related to their lifetime use, past year use, and past month use. Many of 
the substance use modules are general when asking about the participant’s history of use; 
for example, in the tobacco section, the question that appears on the self-administered 
questionnaire include: “have you ever smoked part or all of a cigarette?”, to which the 
respondent may select either ‘yes’ or ‘no.’  
 However, it should be noted that many of the variables used in this study were 
imputed based on responses from a different question then recoded to simplify analysis 
efforts.  An example of this is for past month cigarette use (CIGMON); the original survey 
question asks the participant “how long has it been since you last smoked part or all of a 
cigarette?”.40  For all other core substance modules, questions are asked in almost the 
same sequence, with extremely similar (if not exact) wording as the example provided 




marijuana, and cocaine modules were those that included a greater variety of substances 
namely, hallucinogens and inhalants.  However, each substance (i.e., LSD, PCP; amyl 
nitrite, lighter fluid) included within these two modules were given their own ‘ever used’ 
question, with a collective “how long has it been since you last used 
[hallucinogens/inhalants]…?”.    
 
 
Survey design changes 
 Changes in the NSDUH have occurred throughout the life of its administration, 
and several must be noted to provide a methodological context of the possible changes in 
the frequencies in reported substance use behavior from 2002 to 2017.  Although this 
study does not include data prior to 2002, improvements to the 2002 NSDUH were made 
based on data collection changes that were instituted for the 1999 survey (then called the 
National Household Survey on Drug Abuse; NHSDA).40  Prior to the 1999 NHSDA, 
participants were asked to complete the survey using a paper-and-pencil interviewing 
(PAPI) method; additionally, the sampling strategy went from a strictly national design to 
being state-based (as detailed in the previous Sampling procedure section).40  For the 
2002 survey, a name change was instituted, and the NHSDA became henceforth known 
as the National Survey on Drug Use and Health.40  Other changes in 2002 included the 
use of a $30 incentive, the improved data collection and quality control procedures (that 
had been introduced in the 2001 survey), and the use of the 2000 decennial census for 
sample weighting procedures.40 
In 2015, the questionnaire underwent several substantial changes to improve the 




researchers about substance use and mental health issues.179  Of notable concern for this 
study, questionnaire changes in 2015 included the following179: 
▪ The response categories were revised in the question about the highest level of 
education that was completed, including whether respondents received a high 
school diploma, General Educational Development (GED®) certificate of high 
school completion or college degree. 
▪ Smokeless tobacco sections (snuff and chewing tobacco) were combined into one 
section. "Snus" was added as an example of smokeless tobacco. 
▪ The threshold for binge alcohol use was changed from five or more drinks to four 
or more drinks for female respondents. 
▪ Questions that previously were included in the special drugs module for 
hallucinogens were moved to the core hallucinogens module. This includes 
ketamine; tryptamines (dimethyltryptamine [DMT], alpha-methyltryptamine 
[AMT], and 5-MeO-DIPT [N, N-diisopropyl-5-methoxytryptamine], also known 
as "Foxy"); and Salvia divinorum. 
▪ A new methamphetamine module was added, separate from questions about 
misuse of prescription stimulants. 
▪ The approach and definition for measuring the misuse of prescription drugs were 
revised to include questions about any use of prescription drugs in addition to 
questions about misuse (i.e., nonmedical use), and, for questions about misuse, to 
focus on specific behaviors that indicate misuse. 
▪ Prescription drugs that previously were included elsewhere in the main 
questionnaire (i.e., Adderall®, Ambien®) were moved to the appropriate 
prescription drug module. 
▪ Demographic questions about moves in the past 12 months, immigrant status, 
marital status, education, and employment were moved from being interviewer-
administered through CAPI to being self-administered through ACASI. 
 
However, it should be noted that changes beyond those mentioned in this section have 
been seen to occur, particularly in the operational definition of certain mental health 
disorders.  Changes outside of those detailed in this section are addressed in each of the 







The Current Study: Polydrug Use in PWUO, 2002-2017 
Inclusion criteria 
 Because the focus of this study is on the reported polydrug use behaviors in those 
who use opioids, there were two delimitations imposed on the entire NSDUH study 
population.  First, only individuals that reported being 18 years of age or older at the time 
of the survey were included.  Adolescents aged 12 to 17 were excluded because of two 
reasons: 1) modules related to mental health and substance use behavior were not 
comparable between the adult and adolescents and 2) adolescents are less likely to report 
having used either heroin or prescription pain relievers, despite reports that the misuse of 
opioids is the fastest growing drug problem in this age group.180,181  Second, only those 
who answered ‘yes’ to having used heroin or misused prescription pain relievers in the 
past 30 days were included in the study.  Past month measures were used to limit recall 
bias and to restrict the time frame to include only those currently using the substances.  
Once these restrictions were imposed, the total number of participants surveyed from 
2002 to 2017 (N = 621,571) decreased to 16,985 (2.73%).  
 
Definition of the drug, set and setting variables 
 All variables assessed in this study are taken from the publicly available NSDUH 
datasets from 2002 to 2017.  Again, all data are self-reported measures by the participant.  
However, picture cards were used during portions of the survey that asked about 
prescription drugs (e.g., pain relievers, tranquilizers, sedatives) to help participant recall. 
The following subsections will describe all variables that will be used based on their 






 All the core substances surveyed in the NSDUH will be used in the analysis (i.e., 
tobacco, alcohol, marijuana, cocaine, crack, heroin, hallucinogens, inhalants, pain 
relievers, tranquilizers, stimulants, sedatives). It should be noted that the 
methamphetamine module was excluded from analyses because it was only included in 
the survey beginning in 2015.   
 
a. Alcohol use 
The original alcohol variable used in this study reflected past month use with four 
levels: 1) heavy alcohol use, 2) “binge” but not heavy use, 3) past month but not “binge,” 
and 4) did not use alcohol in the past month.  This categorical variable was recoded by 
the CBHSQ by combining three separate variables: ‘past month binge alcohol use,’‘ past 
month heavy alcohol use,’ and ‘past month alcohol use.’  (The heavy alcohol use 
category also included binge alcohol users; however, binge alcohol users excluded heavy 
alcohol users, and past month alcohol users were individuals who were not/never “binge” 
alcohol users).  The data for these three separate variables were originally asked in the 
interview using the following question: “on the … days that you drank during the past 30 
days, how many drinks did you usually have? Count as a drink a can or bottle of beer; a 
wine cooler or a glass of wine, champagne, or sherry; a shot of liquor or a mixed drink or 
cocktail.”   
The responses to this question were entered as a continuous variable but later 
recoded by CBHSQ with specific definitions for ‘binge drinking’ and ‘heavy drinking.’   




on at least one day in the past 30 days, while ‘heavy drinking’ is defined as having had 
five or more drinks on the same occasion on each of five or more days in the past month.  
But starting in 2015, female participants were asked to report the number of days that 
they had four or more drinks on the same occasion as the definition of ‘binge 
drinking.’153     
After the initial use of the four-category alcohol use variable in the prevalence 
analyses, it was observed that heavy and binge alcohol had been reported at higher 
proportions, and the decision was made to create two dummy variables from the original 
four-category variable.  Heavy alcohol use and binge alcohol use were recoded into 
dichotomous (yes/no) variables for past 30-day use.  It should be noted that the 
dichotomous (yes/no) variable for past 30-day heavy drinking was the only variable 
included in the LCA model for two reasons:  
1. Heavy alcohol use was significant in the bivariable association among 
most opioid use groups (i.e., PPR-only and heroin-only).  (See 
Supplemental Table 4.13 in Appendix A). 
 
2. It included binge alcohol users, which has been found significantly 
associated with PWUO.  
 
b. Cigarettes and other tobacco products use 
Questions related to the use of cigarettes and other tobacco products were 
contained in the same overall substance module titled “Tobacco.”  For cigarette use, 
respondents were asked, “Now think about the past 30 days, that is, from [DATEFILL] 
up to and including today. During the past 30 days, have you smoked part or all of a 




Responses were later recoded by the CBHSQ into binary (yes/no) variables that indicated 
past year, past month, and lifetime use.   
While the final variable used in this study for other tobacco product use was a 
dichotomous (yes/no) variable, several variables were used to create it.  For the 2002 to 
2014 surveys, other tobacco products consisted of cigars, pipe tobacco, smokeless 
tobacco (including separate questions for chewing tobacco or snuff), and the original 
interviews for each of these were queried the same way as the cigarettes.  For surveys 
that occurred after 2014, the changes in survey methodology led to the removal of the 
individual chewing tobacco and snuff questions, leaving only broader questions to assess 
smokeless tobacco use, such as: “The next questions are about your use of "smokeless" 
tobacco such as snuff, dip, chewing tobacco, or ‘snus.’   Have you ever used "smokeless" 
tobacco, even once?’ or “Now think about the past 30 days -- that is, from [DATEFILL] 
up to and including today. During the past 30 days, have you used "smokeless" tobacco, 
even once? How long has it been since you last used "smokeless" tobacco?”  The 
responses for cigars, pipe tobacco, and smokeless tobacco were then recoded by CBHSQ 
to reflect dichotomous (yes/no) variables.  
 
c. Hallucinogen and inhalant use 
For hallucinogens and inhalants, interviewers were trained to ask the participants: 
whether they had taken specific examples for different hallucinogens or inhalants (in their 
respective module); those who responded in the affirmative were then asked when the 
last time the participant had used different types of tranquilizers, or simply, an inhalant.  




year,’ and ‘past month’), and finally recoded into dichotomous (yes/no) variables.  For 
this study, one new variable was created using separate NSDUH variables for past month 
use of hallucinogens and inhalants.  This was done for two reasons: 1) to increase overall 
sample size for this category and 2) combining the two substances was supported by 
evidence from a study that evaluated their psychometric properties using factor analysis 
and item response theory (IRT) analysis.182  The results of this study suggested that it 
would be appropriate to combine hallucinogen and inhalant/solvent abuse and 
dependence criteria in future editions of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM).182   
 
d. Tranquilizer and sedative use 
Data for tranquilizer and sedative use were collected in similar fashions before 
and after 2015, with the largest difference being the use of showcards with pill images in 
surveys before 2015.  However, regardless of the survey year, participants were asked: 
“have you ever, even once, used any type of prescription tranquilizer/sedative that was 
not prescribed for you or that you took only for the experience or feeling it caused?”.  
Those who responded ‘yes’ were followed up with: “how long has it been since you last 
used any prescription tranquilizer that was not prescribed for you or that you took only 
for the experience or feeling it caused?”.  Depending on the response (i.e., ‘within the 
past 30 days’, ‘more than 30 days but within the past 12 months’, or ‘more than 12 
months ago’), dichotomous (yes/no) variables for ‘ever use’, ‘past year use’, and ‘past 
month use’ were recoded by CBHSQ.  For this study, another level of recoding was 




benzodiazepines can be classified into both groups, and have been found to play a major 
role in opioid overdose rates.183   
  
e. Use of all other core substances 
The remaining core substance modules followed the same interview structure as 
those described above.  For this study, the final dichotomous (yes/no) variables for past 
month use of marijuana, cocaine, crack, and stimulants were kept as their original 
definitions and not recoded for analyses.   
 
Set variables  
All variables within this designation were used as independent variables to 
examine their associations with polydrug latent class membership.  Demographic 
variables assessed in this study were age, sex, race/ethnicity, total household income, 
education status, and marital status.   
 
a. Age at time of survey administration 
‘Age at the time of the survey’ was calculated from the stated birthdate of the 
respondent; the interviewee was asked “what is your date of birth?” and the computer-
assisted interview program automatically calculated the age by “subtracting” the 
participant’s date of birth from the date of the interview.  The interviewer then confirmed 
the age with the participant by asking “I have entered your date of birth as [age]. Is this 
correct?”  This information was then recoded by the data management team into several 




five levels.  However, after the inclusion criteria were imposed for this study, the number 
of age groups decreased to just four levels: 18 to 25 years, 26 to 34 years, 35 to 49 years, 
and 50 and older.  But due to small sample sizes in the older age categories, age was 
further recoded.  Therefore, the final number of levels in the age variable was three: 1) 18 
to 25 years, 2) 26 to 34 years, and 3) 35 years and older.   
 
b. Sex 
Based on the final computer-assisted interview (CAI) specifications handbook, 
interviewers were instructed to record the respondent’s gender, with only two options: 
male or female.177  (It is unclear whether a formal question was asked of the respondent). 
For this study, sex was left as a dichotomous variable with these two levels. 
 
c. Race/ethnicity 
To establish a participant’s race/ethnicity, they were first asked: “are you of 
Hispanic, Latino, or Spanish origin or descent?”; if they answered ‘yes,’ a showcard with 
a list of specific groups (e.g., Mexican, Puerto Rican, Dominican, etc.) was shown, and 
the participant was asked to select the number that corresponded to the appropriate 
Hispanic, Latino, or Spanish population.  If they answered ‘no’ to that question, they 
were shown a different card with non-Hispanic/Latino groups (e.g., White, Black, Asian, 
etc.) and asked to select the appropriate number that corresponded to the non-
Hispanic/Latino group.  Although the original race/ethnicity variable included seven 
groups, small sample sizes in the ‘Non-Hispanic Native American or Alaskan Native’, 




Hispanic more than one race’ populations necessitated the recoding of these groups into a 
general ‘Other race/ethnicity’ category. The final number of race/ethnicity categories was 
four: 1) Non-Hispanic White, 2) Non-Hispanic Blacks, 3) Hispanics, and 4) other 
race/ethnicities. 
 
d. Total household income 
Respondents were originally asked, “before taxes and other deductions, was your 
total personal (or total personal income from all sources) during [current year] more or 
less than $20,000?”.  For those who answered ‘yes,’ the following question was asked: 
“Of these income groups, which category best represents total personal during [current 
year]?”.  Yearly household income was originally a categorical variable with seven 
levels: less than $10,000; $10,000 to $19,999; $20,000 to $29,999; $30,000 to $39,999; 
$40,000 to $49,999; $50,000 to $74,999; and $75,000 or more.  However, this variable 
was recoded to reflect a total of three levels due to small sample sizes.  The final three 
levels were: 1) less than $30,000, 2) $30,000 to $74,999, and 3) $75,000 or more.  The 
recoding of these levels were guided by income levels used in previous research related 
to substance use.19,184 
 
e. Employment status 
Because employment status was measured differently in surveys that occurred 
prior to 2015, two variables were used to indicate employment status in this study.  Pre-
2015 surveys determined employment status by asking respondents whether they worked 




relevant), reasons why they did not work in the past week.  The responses to these 
questions were then recoded into a 9-level categorical variable and finally recoded into a 
4-level variable, which is described at the end of this section.  In surveys conducted 
starting in 2015, respondents were asked a variety of questions to establish their 
employment status.  These questions were:   
1. Do you usually work 35 hours or more per week at all jobs or businesses? 
2. The next questions are about working. Did you work at a job or business at any 
time last week? 
3. Did you work at a job or business at any time during the past 12 months? 
4. During the past 30 days, did you make specific efforts to find work? Include any 
contacts you made with anyone about a job, sending out resumes or applications, 
placing or answering ads. Do not include only reading job ads. 
5. Which one of these reasons best describes why you did not have a job or business 
last week? 
6. Which one of these reasons best describes why you did not work last week? 
 
The answers to these six questions were then imputed by the CBHSQ and recoded into 
the four-category variable that was used in this study: 1) employed full time, 2) employed 
part-time, 3) unemployed, and 4) other (including not in the labor force).  For this study, 
no additional recoding was performed on the four-category variable. 
 
f. Education status 
The original survey question asked the participant “what is the highest grade or 
year of school you have completed?”.  Twenty answers were possible and ranged from 
‘no school completed’ to ‘doctorate degree’ and ‘professional degree.’  This was then 
imputed into nine levels and finally recoded into four levels: less than high school, high 




by previous research, education was further collapsed into three categories: 1) less than 
high school, 2) high school graduate, and 3) greater than or equal to college.19,184 
 
g. Marital status 
At the interview, respondents were asked: “Are you now married, widowed, 
divorced or separated, or have you never married?”, then imputed into four levels: 
married, widowed, divorced or separated, and never been married.  For this study, marital 
status was recoded into two levels: married and not married.  This recode was used 
because of the social implications of being married versus not married as it related to 
substance use, which has been explored in previous research.185-187   
 
h. Age at prescription pain reliever initiation 
 Two variables were used to recode for ‘age at prescription pain reliever initiation’ 
due to the differing survey methodologies after the 2014 NSDUH survey.  From 2002 to 
2014, participants were simply asked: “how old were you the first time you used any 
prescription pain reliever that was not prescribed for you or that you took only for the 
experience of feeling it caused?”  After 2014, participants were asked, “at any time 
before [the past 12 months], did you ever use any prescription pain reliever in a way a 
doctor did not direct you to use it?”.  For those who responded ‘no,’ they were labeled as 
past year initiates, and their age during the past 12 months at the time of use was entered.  
These two variables were originally entered as continuous values but were recoded for 
this study into three-levels: 1) less than 18 years of age, 2) 18 to 25 years old, and 3) 26 




    i. Opioid use disorder 
 The past year opioid use disorder (OUD) variable was a single recoded variable in 
NSDUH starting in 2016.  The CBHSQ used several different responses from questions 
within the substance dependence and abuse module. Several different questions were 
asked in the module to classify whether an individual had either a heroin use disorder 
(i.e., dependence or abuse), or pain reliever use disorder related to their misuse of 
prescription pain relievers in the past year, or if they had both disorders.  The questions 
were formulated based on the DSM definition of OUD, and included questions such as: 
“did you continue to use heroin even though you thought it caused problems with family 
or friends?” or “during the past 12 months, did you notice that using the same amount of 
prescription pain relievers had less effect on you than it used to?”. 
 But because 2002 to 2015 NSDUH surveys did not already have the single 
recoded variable that can be found in the 2016 and newer surveys, additional levels of 
recoding had to be completed for this study to harmonize the OUD variable.  For starters, 
the variables for past year pain reliever dependence and abuse had to be combined into a 
dichotomous (yes/no) variable from 2002 to 2015; this was also done with the past year 
heroin dependence and abuse variables for 2002 to 2015.   These two dichotomous 
variables were then combined into a four-level categorical variable that the 2016 and 
newer variable contained: 1) only heroin dependence or abuse, 2) only pain reliever 
dependence or abuse, 3) heroin and pain reliever dependence or abuse, and 4) neither 
heroin nor pain reliever dependence or abuse.  However, due to the small sample size, 
this four-level variable was collapsed into a dichotomous (yes/no) variable indicating that 




j. Depression  
 Two variables from the NSDUH were used as the ‘depression’ variable in this 
study.  The first was drawn from the 2005 to 2007 NSDUH, while the second was drawn 
from surveys starting in 2008.  (Prior to 2005, NSDUH did not ask specific questions 
about depression).  From 2005 to 2007, depression was included as a part of the 
‘Pregnancy and Health Care’ module and was ascertained by asking: “Which, if any, of 
these conditions, did a doctor or other medical professional tell you that you have in the 
past 12 months?”.  The response for the section was then recoded by the CBHSQ to 
reflect a yes/no variable for ‘past year depression.’  Questions related to adult depression 
was separated into its own module starting in 2008 with more detailed questions to try 
and ascertain whether a respondent had depressive symptoms.  Additionally, ‘depression’ 
was renamed ‘major depressive episode’ which was defined as having five or more of the 
following nine criteria: 
1. Having felt sad, empty, depressed, or discourage most of the day 
2. Having lost interest or pleasure in most things 
3. Having changes in appetite or weight 
4. Having sleep problems 
5. Having others notice that the respondent was restless or lethargic 
6. Having felt tired or low in energy nearly every day 
7. Having felt worthless nearly every day 
8. Being unable to concentrate or make decisions 
9. Having any thoughts or plans of suicide 
This variable was also later recoded into a dichotomous (yes/no) variable by the CBHSQ.  






k. Health insurance status 
 The variable used in this study related to the current health insurance status of the 
participant was a dichotomous (yes/no) variable that was imputed from multiple variables 
in the dataset.  These variables were derived from separate interview questions and 
related to whether the participant had different health insurance plans (e.g., 
Medicaid/CHIP, Medicare, private health insurance, etc.).  In order to be classified as 
having no insurance, the participant must have answered ‘no’ to all questions regarding 
different health plans.   
 
Setting variables 
a. County type 
 Two county type variables were used for the analyses in this study because the 
definition of the county variable beginning in 2015 (COUTYP4) relied upon the 2013 
Rural/Urban Continuum Codes.  This replaced the county variable used prior to 2015 
(COUTYP2), which had been based on the 2003 Rural/Urban Continuum Codes.  The rural-
urban continuum codes are an effort by the Economic Research Service at the U.S. 
Department of Agriculture to measure the degree of rurality or relative isolation, in a 
county and are based on their metropolitan-nonmetropolitan status and size of their 
metropolitan or urban populations.188  Although not completely comparable, the two 
variables were renamed as one variable (COUNTY), since they are based on similar 
concepts, with the same three levels are the original variables: 1) large metro, 2) small 





b. Residential transience 
 Residential transience was determined by a single question in the non-core 
demographics portion of the NSDUH.  Participants were asked “how many times in the 
past 12 months have you moved? Please include moves from one residence to another 
within the same city/town as well as those from one city/town to another.”  The responses 
were entered as a continuous variable but later recoded as a four-level categorical 
variable: 1) none, 2) one time, 3) two times, and 4) three or more times.  For this study, 
the last two levels were collapsed as one, leaving a total of three-levels in the analysis.   
 
Data Analysis Methods 
Analyses using complex survey data 
 The section will address the sampling weight variables that were used for all 
analyses in this study.  As previously stated, NSDUH utilizes a complex 50-state 
sampling design using independent, multistage area probability sampling.  This required 
specific statistical coding that can handle the different sampling weights, which is not 
possible with regular coding in statistical software since it would treat the data as if it 
were a simple random sample.189  In SAS 9.4, coding that incorporates survey weights 
begin with the prefix ‘survey’; for example, a regular SAS procedure to calculate simple 
means and standard deviations is proc means, while proc surveymeans, is used when 
sample weights are available.189  The advantage of using ‘survey-’ procedures is that it 
allows the computation of variance estimates using complex multistage survey design 
with stratification, clustering, and unequal weighting.  Additionally, it provides a choice 




ignoring sample weights in complex survey data are inaccurate point estimates and 
inaccurate standard errors.189  In the public-use NSDUH files, the following variance 
estimation variables are included: 
 
- variance estimation stratum (VESTR)  
 
- variance estimation cluster replicates (VEREP)  
- final analysis weight (ANALWT_C) 
 
Because several years of data are being analyzed in this study, a new analysis weight 
variable was created by dividing ‘ANALWT_C’ by the total number of years (i.e., 16 years) 
included in the study, as specified in the NSDUH codebook.40  This results in a final 
person-level analysis weight which is more appropriate to use across successive years.40  
  
Joinpoint analysis 
For Aims 1 and 2, joinpoint regression analysis was used to determine whether a 
significant trend (or trends) exist in the weighted prevalence of reported past month 
substance use.  Joinpoint regression was performed using the National Cancer Institute’s 
(NCI) Joinpoint Trend Analysis software, version 4.7.0.0 (updated February 2019).  
Joinpoint regression is a statistical technique that identifies points in time where linear 
trends change significantly in both magnitude or direction.190  Results from this type of 
regression analyses would allow us to determine the specific year(s) where the trajectory 
of the weighted prevalence significantly changes.191  Although the NCI software selects 
the final model using a variety of tests which is selected by the user, the permutation test 




longest track record of all the other methods, such as traditional Bayesian Information 
Criterion (BIC) and data-driven BIC methods.192  It should also be noted that if the 
prevalence of the test variable was normally distributed, log-transformation was not 
selected in the software, and the analysis reported the slope (m).  However, if the 
prevalence of the test variable is not normally distributed, the data were log-transformed, 
which yielded a measure called the ‘annual percent change’ (APC) instead of reporting 
slopes. 
 
Latent class analysis  
LCA is a nonparametric approach that assigns class membership on a 
probabilistic basis depending on the response to a set of discrete indicator variables.193  
Although LCA has been likened to factor analysis, it is a considered a person-centered 
approach because the focus is on the relationships in a specific subpopulation.194,195  
Another difference between LCA and factor analysis is the nature and distribution of the 
latent variable; LCA uses categorical variables which have multinomial distributions, 
while classic factor analysis uses continuous (i.e., dimensional) variables with a normal 
distribution.194  Using a person-centered approach is useful in establishing associations 
with a multitude of covariates where populations are the unit of measurement.  In 
contrast, variable-centered approaches focus on the relationship between individual 
variables.195  Additionally, LCA is useful in representing heterogeneity in developmental 







  A continuous time variable (in years), survyr, was created within each separate 
NSDUH dataset from 2002 to 2017.  While this variable was meant to remain as a 
continuous variable during analysis, the low sample size for a few independent variables 
necessitated the recoding of the variable into periods.  The period variable used for this 
study consisted of four levels: 1) 2002 to 2005, 2) 2006 to 2009, 3) 2010 to 2013, and 4) 
2014 to 2017.  However, it should be noted that because joinpoint analysis was conducted 
to examine linear trends of prevalence, the continuous survey year variable (i.e., survyr) 
was used. 
 
Aim 1 analytic strategy 
Aim 1 sought to examine the prevalence of polydrug use among all PWUO and 
each opioid use group in the U.S. from 2002 to 2017.  The two outcome variables used 
for Aim 1 were categorical.  The first outcome variable was a recoded dichotomous 
(yes/no) variable that designated PWUO-status (pwuo).  The second outcome variable was 
a recoded three-level categorical variable that designated membership in each opioid use 
group (aim1).  Two subaims and their corresponding analytic strategies are described 
below to achieve Aim 1.  SAS version 9.4 (Cary, NC, USA) was used as the main 
statistical analysis software for the whole study. 
 
Subaim 1.1: To ascertain the prevalence of the all PWUO as well as opioid 
use groups (i.e., heroin only, prescription opioid only, and combination 





The overall and period-stratified weighted prevalence (%) of all PWUO and 
opioid use groups was calculated using proc surveyfreq.   The period-stratified 
frequencies were then plotted on a line graph to visualize changes over time.  A Rao-
Scott Chi-square (χ2) test statistic was also calculated to determine whether the 
prevalence of all PWUO and each opioid use group was significantly associated with 
period.  The Rao-Scott χ2 test is a design-adjusted version of the Pearson χ2 test, with the 
same null hypothesis that there is no association between the row and column 
variables.196  Because both outcome variables were found to be significantly associated 
with period, weighted prevalence and standard errors were calculated for each survey 
year for all groups in order to upload into the NCI Joinpoint Trend software.   
 
Subaim 1.2: To ascertain the prevalence of all substance use in all PWUO as 
well as all opioid use groups and determine whether they differ over time. 
  
The period-stratified weighted prevalence of the self-reported use of all other core 
substances (pain relievers, heroin, alcohol, tranquilizers/sedatives, tobacco, marijuana, 
cocaine, crack, hallucinogens/inhalants, and stimulants) was calculated for all PWUO and 
opioid use groups.  The reported weighted prevalence in the Results chapter is based on 
the sample size of each core substance category within each period.  A Rao-Scott χ2 test 
statistic was also calculated to test whether the prevalence was significantly associated 
with period.  Again, a post hoc analysis of each substance that was significantly 
associated with period for each outcome group (i.e., all PWUO; each opioid use group) 
was conducted using joinpoint regression to identify the point(s) in time where the linear 




Aim 2 analytic strategy  
 
Subaim 2.1: To identify the latent class variable of polydrug use in PWUO 
using the past month use variables of the 11 core substance indicators (pain 
relievers, heroin, heavy alcohol, tranquilizers/sedatives, cigarettes, other 
tobacco products, marijuana, cocaine, crack, hallucinogens/inhalants, and 
stimulants). 
 
Latent class analysis was performed using Mplus version 8.2 using the recoded 
“past 30-day use” variables for each all 11 core substance indicators.  It should be noted 
that the alcohol variable used in the latent class analysis model was limited to a recoded 
dichotomous (yes/no) dummy variable for heavy alcohol drinking, which included those 
who reported binge drinking in the past month.  Figure 3.2 is a diagram of the 
relationship between the polydrug latent variable and the substance indicators used in this 
study.
 






To begin to model the latent variable, the number of classes specified in the 
Mplus code started at one, with the stepwise addition of classes to obtain fit statistics; the 
highest specified number of classes was eight.  Also, to avoid the potential for estimation 
issues (e.g., singularities, local solutions), a high number of random starts was specified 
in the Mplus coding.  The following established fit statistics and heuristics for LCA were 
utilized to guide the selection of the final number of latent classes:    
▪ Akaike’s Information Criteria (AIC)  
▪ Bayes’ Information Criteria (BIC)  
▪ sample size adjusted Bayesian Information Criteria (ssBIC) 
▪ entropy 
Information criteria (IC) is used as a descriptive measure of comparing models in 
terms of relative fit and were developed to balance fit with parsimony. While there are a 
variety of ICs to choose from, the AIC, BIC, and ssBIC are commonly used for 
comparing competing models and differ only by the manner they penalize the likelihood-
ratio statistic (G2).194  LCA models with lower AIC and BIC values are deemed more 
parsimonious and are the preferred models. 
Comparing entropy-based measures (e.g., a standardized entropy measure, E) is 
another strategy to determine the model with the best fit. The overall goal of using 
entropy-based measures is to determine whether the model produces classes that are well 
separated.197  Entropy values range from zero to one, with higher E values indicating 
better latent class separation.197   
Although the most commonly used method of determining the final class 




Likelihood Ratio Test (LMR-LRT), ssBIC, adjusted LMR, and Bootstrapped Likelihood 
Ratio Test (BLRT),198  the selection of the final number of latent classes was ultimately 
determined using BIC and entropy values, and heavily guided by a priori theory as well 
as prevalence results from Aim 1.  While LMR-LRT‡‡ has been used by previous LCA 
researchers to help determine the final number of classes, it was ultimately excluded 
because of the highly restrictive and uninterpretable results generated, likely due to the 
inclusion of the sampling weights.  (Results of the LMR-LRT test for models without 
complex sample weights yielded significant p-values when testing the fit of up to eight 
classes).  Additionally, specific guidance on final model selection for complex samples 
other than the use of BIC on a Mplus discussion page by Muthén and Muthén, could not 
be found in the literature.    
Also, because many published studies have reported the use of an additional 
statistical software (e.g. SAS, STATA, SUDAAN, SPSS) when further analyzing the 
associations between polydrug latent classes (assessed in Mplus) with a multitude of 
independent variables of interest,19,99,199,200  it was decided that SAS version 9.4 will be 
used to carry out all further analyses.  A .csv file was generated using Mplus, imported 
into SAS version 9.4 (Cary, NC, USA) after determining the final number of classes, and 




                                                 
‡‡The LMR-LRT is a statistical test that compares the improvement in fit between neighboring class models 
(i.e., comparing K-1 and K class models), ultimately providing a p-value that can be used to determine if the 





Subaim 2.2: To determine whether the prevalence of each latent class has 
remained constant. 
 
For this subaim, the Rao-Scott χ2 analysis was performed to test whether the 
weighted prevalence of the polydrug latent classes differed over time.  Post hoc analysis 
was also conducted using the NCI joinpoint regression software to determine the year(s) 
where the linear trend of the weighted prevalence of each polydrug latent class may have 
significantly changed. 
 
Aim 3 analytic strategy  
 The purpose of Aim 3 was to establish the associations between polydrug groups 
among PWUO and various set and setting correlates, but with a focus on latent classes 
that existed following Wave II of high opioid mortality in the U.S.10 
 
Subaim 3.1: To determine the prevalence and bivariable associations of the 
following covariates using the latent class variable as an outcome: age, sex, 
race/ethnicity, total household income, education level, employment status, 
marital status, age at prescription pain reliever initiation, opioid use 
disorder, depression, health insurance status, past year substance use 
treatment, county type, and residential transience. 
 
Prior to analyzing the prevalence and bivariable associations, LCA was used to 
model the polydrug latent classes among PWUO using data from 2010 to 2017; this was 




PWUO, but also to examine polydrug latent classes that existed after the start of the 2nd 
wave of high opioid mortality.10  (However, it should be noted that patterns of substance 
use endorsement probabilities for the polydrug latent variable using the 2010 to 2017 data 
were very comparable to those enumerated for Aim 2).  Using SAS 9.4, the prevalence of 
the following covariates was calculated for each latent polydrug class: age, sex, 
race/ethnicity, total household income, education level, employment status, marital status, 
age at prescription pain reliever initiation, opioid use disorder, depression, health 
insurance status, county type, and residential transience.  It should be stressed that the 
correlates chosen for Aim 3 has been to be interconnected with one another, especially in 
the context of the opioid crisis.201  Finally, bivariate analyses using Rao-Scott χ2 tests 
were also performed to assess the associations between polydrug latent class membership 
and each of the set and setting variables listed above. 
 
 
Subaim 3.2: To determine the multivariable associations of specific 
combinations of variables using the drug, set, and setting model of substance 
use behavior to predict membership of the polydrug latent class. 
 
Because the basis of the drug, set, and setting framework suggests that all 
correlates are interconnected and affect a person’s risk of substance use, a full 
multinomial logistic regression model with all covariates listed in Subaim 3.1 will be 
executed after testing for multicollinearity.  The results of this logistic regression model 
were used to assess the previously mentioned hypotheses and sub-hypotheses, but are 





Hypothesis 1: Polydrug latent classes will differ by sociodemographic characteristics. 
  
Sub-hypothesis 1.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
opioid polydrug Class’ more likely than other Classes to be male, non-Hispanic 
white, unemployed, younger at time of survey, uninsured, and having less 
education and less total household income. 
 
 
Hypothesis 2: Polydrug latent classes will differ by their opioid use history and OUD 
status. 
Sub-hypothesis 2.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
opioid polydrug Class’ more likely than other Classes to have initiated 




Hypothesis 3: Polydrug latent classes will differ by their environment.  
Sub-hypothesis 3.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
opioid polydrug Class’ more likely than other Classes to reside in a large metro 










Deciding on the final number of latent classes 
 
 Statistical power is the probability that the null hypothesis is correctly rejected 
when the alternative hypothesis is true.  In traditional epidemiologic studies, not only is 
power affected by study design, it may be calculated using a number of values such as 
sample size, percent confidence level, ratio of unexposed to exposed (or ratio of controls 
to cases in case-control studies), and effect size.  However, when discussing sample size 
and power in studies that involve LCA, the concern centers around obtaining the correct 
number of classes in the latent variable, rather than an effect size for a population (e.g., 
relative risk).  Therefore, the null and alternative hypotheses for power tests in LCA are 
as follows: 
H0: The true number of latent classes is K-1. 
H1: The true number of latent classes is K. 
 
Statistical power in LCA requires multiple simulations to be conducted for each 
fit statistic (i.e., AIC, BIC, ssBIC, etc.), to discern whether a particular fit statistic would 
be able to reject the H0.  Ideally, to determine the exact power for this study, simulations 
should also be completed; unfortunately, this could not be feasibly done.  Therefore, 
provided in this section are the power results of a Monte Carlo simulation study 





Figure 3.3 | Percentage of Times the Lowest Value Occurred in Each Class Model 
for the AIC, CAIC, BIC, and Adjusted BIC202 
 
In this current study, we determined that the best fit model had a somewhat 
simple structure (i.e., models with item probabilities that are particularly high or low for a 
given class), with four classes of unequal sizes using 11 items, and over 16,000 subjects.  
As shown in Figure 3.3, BIC and ssBIC were the best indicators to determine the most 
parsimonious number of latent classes given the structure of the final model, suggesting 
that the current sample size is sufficient to use BIC or ssBIC to determine final class 
sizes.202  It should also be noted that while missing data may pose an issue to the validity 
of the results, Mplus can factor in missing variables through a simple Missing are 
command.  Once missing values are excluded, Mplus uses all available data to estimate 
the model using full information maximum likelihood (FIML), which assumes that data 








Aim 1 Results 
Subaim 1.1: To ascertain the prevalence of all PWUO and the opioid use 
groups (i.e., heroin only, prescription opioid only, and combination opioids) and 
determine whether they differ over time. 
 
 Prevalence among PWUO 
 
 From 2002 to 2017, a total of 621,571 individuals participated in the NSDUH 
survey.  Of these, the weighted prevalence of respondents (n = 16,985) reported having 
used either heroin or prescription pain relievers was 1.78% (SE = 0.042).  Overall sample 
sizes with their respective weighted prevalence rate (PR) and standard errors (SE) by past 
month opioid use status and period are shown in Table 4.1.  Overall, individuals 
reporting past month opioid use were the vast minority in the U.S., with the highest PR 
occurring in period 2 (i.e., 2006 to 2009) [PR (SE): 2.01% (0.49)] and lowest in period 4 





The longitudinal trend of PWUO prevalence 
 
Also shown in Table 4.1 are the results of the bivariable analysis of the 
prevalence of opioid use and period using a Rao-Scott Chi-square (χ2) test.  Based on the 
results, there was a significant association between the weighted prevalence of PWUO 
and period [χ2 (df), (p-value): 58.30(3), (< 0.0001)].  Examining the change in 
prevalence visually, the weighted prevalence of PWUO increases from period 1 to 2 but 
decreases in subsequent periods, as shown in Figure 4.1.  Joinpoint regression was 
performed to provide a quantitative examination of prevalence trends of past month 
PWUO.  While the full results of the joinpoint regression may be found in Supplemental 
Table (ST) 4.1 in Appendix A, the main results of this analysis are presented in Figure 
4.2.  Joinpoint analysis established two time-segments that had statistically significant 
slopes (m): 1) 2002 to 2010 [m (p-value): 0.028 (0.020)], and 2) 2010 to 2017 [m (p-
value): -0.117 (< 0.001)].  Time-segment 1 had a significantly positive increase in the 
weighted prevalence of past month PWUO, while time-segment 2 showed a significant 





Figure 4.1 | Weighted prevalence of people who reported past month use of opioids by period  



























































(n = 16,985) 








143,474 98.20 0.04 144,897 97.99 0.13 148,986 98.14 0.12 167,229 98.52 0.10 
 
Abbreviations: n = total number of survey respondents; % = weighted column percentage; SE = standard error; χ2 (df) = Chi-square statistic 
(degrees of freedom)  
Note: 95% confidence intervals for all reported prevalence indicated reliable measures 
Note: Bolded χ2 and p-value denotes statistical significance at p < 0.05. 
aWeighted prevalence was based on the total number of survey participants within each period 
bPWUO were defined as participants who had reported that they had used heroin in the past month; had nonmedically used prescription pain 









Prevalence among opioid use groups 
 
 After stratifying the entire population of PWUO into three past month opioid use 
groups (i.e., PPR-only, heroin-only, and combination opioid), it was clear that the number 
and proportion of individuals who reported past month PPR-only use vastly exceeded 
those in the heroin-only and combination opioid use groups.  The overall weighted 
prevalence and standard errors for each opioid use group were: past month PPR-only [PR 
(SE) 93.36% (SE = 0.11)], heroin-only [PR (SE) = 3.61% (0.16)], and combination 
opioid use groups [PR (SE) = 3.03% (0.12)]. 
Table 4.2 shows the weighted prevalence of the opioid use groups by period.  
(Because the focus was on PWUO, individuals who did not report past month opioid use 
were excluded from prevalence measures).  Those who reported the use of only PPRs in 
the past month composed the majority with the highest weighted prevalence in period 1 
[PR (SE): 96.46 (0.32)], and the lowest prevalence in period 4 [PR (SE): 87.51% 
(0.021)].  Conversely, the weighted prevalence of the past month heroin-only use group 
was highest in period 4 [PR (SE): 7.64% (0.38)], and lowest in period 1 [PR (SE): 
1.27% (0.17)].  The prevalence of the past month combination opioid use group was also 
highest in period 4 [PR (SE): 96.46% (0.32)], and the lowest in period 1 [PR (SE): 















(1) 2002 to 2005 (2) 2006 to 2009 (3) 2010 to 2013 (4) 2014 to 2017 
χ2 (df) p-value 
n % SE n % SE n % SE n % SE 
PPR-only  





















(n = 553) 
80 2.27 0.15 88 2.31 0.25 144 2.78 0.66 241 7.64 0.377 
Combinatio
n opioid 
(n = 535) 
71 1.27 0.17 129 2.59 0.28 156 3.54 0.54 179 4.86 0.356 
 
Abbreviations: n = total number of survey respondents; % = weighted column percentage; SE = standard error; χ2 (df) = Chi-square statistic 
(degrees of freedom) 
Note: Bolded χ2 and p-value denote statistical significance at p < 0.05. 
aAll weighted prevalence were based on the total number of individuals for all opioid use groups within each period 
bPPR use was defined as participants who had reported that they had nonmedically used or misused any PPR in the past month and did not 
heroin in the past month. 
cHeroin use was defined as participants who had reported that they had used heroin in the past month and did not nonmedically use or misuse 
PPRs in the past month. 
dCombination opioid use was defined as participants who had reported that they had used both heroin in the past month, as well as 






The longitudinal trend of opioid use group prevalence 
 
Also shown in Table 4.2 are the results of the bivariable association between 
opioid use group prevalence and period, again using the Rao-Scott χ2 test.  The results of 
this test indicated that there was a significant association between the prevalence of all 
opioid use groups and period [χ2 (df), (p-value): 134.79 (6), (< 0.0001)].  As shown in 
Figures 4.3 and 4.4, the overall weighted prevalence of those who reported past month 
PPR-only use has been decreasing since period 1, while the overall weighted prevalence 
of the past month heroin-only and combination opioid use groups had been increasing 
since period 1.  
Joinpoint regression was also performed, and the main results of this analysis are 
presented in Figures 4.5 through 4.7.  The prevalence of participants who reported 
having used only PPRs in the past month significantly decreased from 2002 to 2017 [m 
(p-value): -0.45 (0.0004)].  For the past month heroin-only use group, a significant 
change in the prevalence trend was detected from 2010 to 2017 [m (p-value): 1.062 (< 
0.001)].  Among the past month combination opioid use group, no joinpoint was found, 
but there was an overall positive prevalence trend from 2002 to 2017 [m (p-value): 0.35 






Figure 4.3 | Weighted prevalence of all past-month opioid use categories among PWUO by 
period (n = 16,985), NSDUH 2002 to 2017 
 
 
Figure 4.4 | Weighted prevalence of past-month heroin only and combination opioid use groups 

































































Figure 4.5 | Joinpoint analysis of the weighted prevalence of past month PPR-only use group  
(n = 15,897) 
 
 
Figure 4.6 | Joinpoint analysis of the weighted prevalence of past month heroin-only use group  






Figure 4.7 | Joinpoint analysis of the weighted prevalence of past month combination opioid use 




Subaim 1.2: To ascertain the prevalence of all substance use in all PWUO as 
well as all opioid use groups and determine whether they differ over time 
 
Prevalence of substance use among all PWUO 
As shown in Figure 4.8, the core substance most frequently reported as having 
been used among PWUO was cigarettes, followed by marijuana and binge alcohol.  The 
weighted prevalence of illicit substance use (i.e., cocaine, crack, hallucinogens/inhalants) 
and prescription stimulants were the lowest among PWUO. (For full overall prevalence 
results, see ST 4.5 in Appendix A). 
 
Figure 4.8 | Overall weighted prevalence of past month core substance use among PWUO  
(n = 16,985), NSDUH 2002 to 2017 
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Longitudinal trends of substance use among PWUO 
 
The prevalence of reported core substance use among PWUO is shown in Figures 
4.9, 4.10, and 4.11.  (For the full table of results, see ST 4.6 in Appendix A). It should be 
noted that Figures 4.9 through 4.11 break down the core substances into three groups: 
a. Past month binge or heavy alcohol use 
b. Past month cigarette smoking, other tobacco product use, and marijuana smoking 
c. Past month prescription tranquilizers/sedatives, prescription stimulants, cocaine, 
crack, and hallucinogen/inhalant use 
The weighted prevalence of reported binge and heavy alcohol drinking was 
shown to have declined after period 2.  Table 4.3 shows the bivariable analysis results 
for the association of core substance prevalence and period among PWUO.  The weighted 
prevalence of core substances that differed significantly over time for all PWUO were 
heavy alcohol, cigarettes, other tobacco products, hallucinogens and inhalants, and 
stimulants use.  
 
Figure 4.9 | Weighted prevalence of past month heavy and binge alcohol drinking among past 




























Weighted prevalence of past month alcohol use among PWUO by period, 





Figure 4.10 | Weighted prevalence of reported past month cigarette smoking, other tobacco use, 
and marijuana use among past month PWUO by period (n = 16,985), NSDUH 2002 to 2017 
 
 
Figure 4.11 | Weighted prevalence of reported past month tranquilizer/sedative, cocaine, crack, 
hallucinogen/inhalant, and stimulant use among past month PWUO by period (n = 16,985), 






























Weighted prevalence of past month cigarette, other tobacco products, and marijuana use by period among PWUO, 





































Table 4.3 | Rao-Scott χ2 analyses for the association of prevalence of each core substance 








Binge use in the past month 
0.93 
(3) 
0.82 Never or 'no' binge use in 
past month 
Heavy alcohol 








Used in the past month 3.10 
(3) 
0.38 
Not used in the past month 
Cigarettes 
Used in the past month 15.54 
(3) 
0.001 
Not used in the past month 
Other tobacco 
products 
Used in the past month 14.35 
(3) 
0.003 
Not used in the past month 
Marijuana 
Used in the past month 2.25 
(3) 
0.52 
Not used in the past month 
Cocaine 
Used in the past month 3.74 
(3) 
0.29 
Not used in the past month 
Crack 
Used in the past month 0.43 
(3) 
0.93 
Not used in the past month 
Hallucinogens/ 
inhalants 
Used in the past month 8.14 
(3) 
0.043 
Not used in the past month 
Stimulants 
Used in the past month 11.31 
(3) 
0.01 
Not used in the past month 
Abbreviations: χ2 (df) = Chi-square statistic (degrees of freedom) 
Note: Bolded χ2 and p-values denote statistical significance at p < 0.05. 
 
Joinpoint regression was used again to examine trends in the substances that were 
significantly associated with period.  The results for all five of these substances were 
shown in Figures 4.12 through 4.16.  (For full joinpoint regression results, see ST 4.7a-e 
in Appendix A).  Although not significant, the trend in the prevalence of heavy alcohol 




Annual Percent Change (APC) indicated a significant negative trajectory of reported 
heavy alcohol drinking [APC (p-value): -2.70 (< 0.001)].  For past month cigarette use 
among PWUO, no significant trend was found using joinpoint regression [APC (p-value): 
0.11 (0.50)].  Also, no significant trends were found for the prevalence of other tobacco 
product use [APC (p-value): 0.20 (0.50)] and hallucinogen/inhalant use [APC (p-value): 
0.10 (0.80)].  However, joinpoint regression modeled three time-segments in the 
prevalence trend of stimulant use in PWUO.  Although the trends for the time-segments 1 
and 2 were not significant, the trend from 2007 to 2017 indicated a significant increase in 
the APC for the prevalence of past month stimulant use in PWUO [APC (p-value): 5.4 (< 
0.001)].   
 
 
Figure 4.12 | Joinpoint analysis of the weighted prevalence of past month heavy alcohol use 





Figure 4.13 | Joinpoint analysis of the weighted prevalence of past month cigarette use among all 
PWUO (n = 16,985) 
 
 
Figure 4.14 | Joinpoint analysis of the weighted prevalence of past month other tobacco products 







Figure 4.15 | Joinpoint analysis of the weighted prevalence of past month hallucinogen/inhalant 
use among all PWUO (n = 16,985) 
 
 
Figure 4.16 | Joinpoint analysis of the weighted prevalence of past month stimulant use among 




Prevalence of substance use among opioid use groups 
Past month PPR-only use group 
Figure 4.17 shows the overall weighted prevalence for the past month reported 
use of all core substances found in the NSDUH among the past month PPR-only group.  
The substances that were reported by the past month PPR-only use group from largest to 
smallest prevalence were cigarettes, marijuana, binge alcohol drinking, heavy alcohol 
drinking, other tobacco use, tranquilizers and sedatives, cocaine, stimulants, 
hallucinogens and inhalants, and crack.  One distinguishing characteristic of this group 
was the low prevalence of reported misuse of prescription drugs (stimulants, 
tranquilizers/ sedatives) and illicit substances (cocaine, hallucinogens/inhalants, crack).  
(For all overall prevalence results for this use group, see ST 4.8 in Appendix A). period 
 
Figure 4.17 | Overall weighted prevalence of past month use of all core substances among the 
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Past month heroin-only use group 
As shown in Figure 4.18, the prevalence of past month cigarette use was highest 
in this group, which was followed by the prevalence of past month marijuana, cocaine, 
binge alcohol, other tobacco products, crack, heavy alcohol, tranquilizer/sedative, 
hallucinogen/inhalant, and stimulant use.  One distinguishing characteristic of this group 
was the increase in the prevalence of reported past month use of cocaine and crack use, 
especially when compared to the past month PPR-only use group. (For all overall 
prevalence results among this use group, see ST 4.9 in Appendix A). 
 
Figure 4.18 | Overall weighted prevalence of past month use of all core substances among the 
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Past month combination use group 
As shown in Figure 4.19, cigarettes continued to make up the highest proportion 
of reported substance use, followed by the prevalence of reported past month marijuana, 
cocaine, tranquilizer/sedative, other tobacco products, heavy alcohol, crack, binge 
alcohol, stimulant, and hallucinogen/inhalant use.  Also, the prevalence of past month 
cocaine and tranquilizer/sedative use in this group exceeded that of the past month 
heroin-only use group.  On average, the prevalence of heavy and binge alcohol use 
ranged from 25% to 30% which was comparable to the past month PPR-only use group 
and was greater than among members of the heroin-only use group.  (For all overall 
prevalence results in this use group, see ST 4.10 in Appendix A). 
 
Figure 4.19 | Overall weighted prevalence of past month use of all core substances among the 
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Longitudinal trends of substance use among opioid use groups 
 
Past month PPR-only use group 
From a qualitative assessment of Figures 4.20, 4.21, and 4.22, the trajectory of 
the prevalence of the reported use of all substances generally shows an increase from 
period 1 to 2.  However, prevalence declined for most substances after period 2.  Also, 
there were only a few substances whose prevalence were significantly associated with 
period; the bivariable χ2 analysis indicated significant associations between period and 
the weighted prevalence of past month heavy alcohol drinking [χ2 (df), (p-value): 27.26 
(3), (< 0.0001)], past month cigarette use [χ2 (df), (p-value): 57.54 (3), (< 0.0001)], past 
month other tobacco products use [χ2 (df), (p-value): 20.87 (3), (0.0001)], and past month 
hallucinogen/inhalant use [χ2 (df), (p-value): 8.12 (3), (0.044)], as shown in Table 4.4.  
(For detailed prevalence results by period for this use group, see ST 4.11 in Appendix 
A). 
Joinpoint regression was again used to determine whether a significant trend 
existed for the prevalence of cigarette, other tobacco products, and hallucinogen/inhalant 
use for this group, and the results are shown in Figures 4.23 through 4.26.  Trend 
analysis of the prevalence of past month heavy alcohol drinking revealed a significant 
decrease from 2007 to 2017 [APC (p-value): -2.70 (< 0.001)].  Although no joinpoints 
were found in any of the trajectories for the other three substances, the results indicated 
that the prevalence trend of cigarettes [APC (p-value): -0.90 (< 0.001)] and 
hallucinogens/inhalants [APC (p-value): -1.10 (0.10)] were decreasing from 2002 to 




increased from 2002 to 2017 [APC (p-value): 0.40 (< 0.001)].  (For detailed joinpoint 
regression results for this use group, see ST 4.12a-c in Appendix A). 
 
Figure 4.20 | Weighted prevalence of all levels of past month alcohol drinking among past month 


































Figure 4.21 | Weighted prevalence of reported past month cigarette smoking, other tobacco use, 




Figure 4.22 | Weighted prevalence of reported past month tranquilizer/sedative, cocaine, crack, 
hallucinogen/inhalant, and stimulant use among past month PPR-only use group by period 































































Table 4.4 | Rao-Scott χ2 analyses for the association of prevalence of each core substance 
and period for past month PPR-only use group (n = 15,897), NSDUH 2002 to 2017 
Core substances 
Rao-Scott analysis 
χ2 (df) p-value 
Binge alcohol 




Never or 'no' binge use in 
past month 
Heavy alcohol 








Used in the past month 6.52 
(3) 
0.089 
Not used in the past month 
Cigarettes 
Used in the past month 57.54 
(3) 
<0.0001 
Not used in the past month 
Other tobacco 
products 
Used in the past month 20.87 
(3) 
0.0001 
Not used in the past month 
Marijuana 
Used in the past month 0.32 
(3) 
0.96 
Not used in the past month 
Cocaine 
Used in the past month 7.46 
(3) 
0.059 
Not used in the past month 
Crack 
Used in the past month 3.07 
(3) 
0.38 
Not used in the past month 
Hallucinogens/ 
inhalants 
Used in the past month 8.12 
(3) 
0.044 
Not used in the past month 
Stimulants 
Used in the past month 7.15 
(3) 
0.067 
Not used in the past month 
Abbreviations: χ2 (df) = Chi-square statistic (degrees of freedom) 






Figure 4.23 | Joinpoint analysis of the weighted prevalence of past month heavy alcohol use 
among past month PPR-only use group (n = 15,897) 
 
 
Figure 4.24 | Joinpoint analysis of the weighted prevalence of past month cigarette use among 





Figure 4.25 | Joinpoint analysis of the weighted prevalence of past month other tobacco use 
among past month PPR-only use group (n = 15,897) 
  
 
Figure 4.26 | Joinpoint analysis of the weighted prevalence of past month hallucinogen/inhalant 




Past month heroin-only use group 
Initial assessment of the visual trends displayed in Figures 4.27, 4.28, and 4.29 
shows that weighted prevalence of reported past month cigarette use continued to 
dominate the prevalence of all other substances from period 1 to 4.  While patterns of 
prevalence were heterogeneous, many of the longitudinal differences in weighted 
prevalence for most substances appeared to be decreasing or remaining somewhat 
constant (e.g., other tobacco products, stimulants, crack, cocaine).  Also, the prevalence 
of past month cigarette use decreased from 95.34% (SE = 2.52) in period 1 to 85.75% 
(SE = 1.81) in period 2, with a gradual increase from period 3 to 4.  Additionally, the 
weighted prevalence of past month use of marijuana and binge alcohol drinking showed a 
consistent increase after period 2.  (For all prevalence results by period, see ST 4.13 in 
Appendix A for full results) 
The results of the χ2 analysis between period and prevalence of reported past 
month substance use are shown in Table 4.5.  They indicated that the weighted 
prevalence of two substances had a significant association with period: heavy alcohol 
use [χ2 (df), (p-value): 8.13 (3), (0.0434)] and cigarettes [χ2 (df), (p-value): 8.26 (3), 
(0.041)].  Although no joinpoints were detected, a non-significant negative trend in the 
prevalence of past month heavy alcohol [m (p-value): -0.66 (0.10)] was detected as 
shown in Figure 4.30.  From 2002 to 2008, cigarette use among this group increased, but 
subsequently significantly decreased from 2008 to 2017 [APC (p-value): -2.3 (< 0.001)] 
as shown in Figure 4.31.  (For full joinpoint regression results for this opioid use group, 





Figure 4.27 | Weighted prevalence of past month binge and heavy alcohol drinking among past 
month heroin-only use group by period (n = 553), NSDUH 2002 to 2017 
 
 
Figure 4.28 | Weighted prevalence of reported past month cigarette smoking, other tobacco use, 

































































Figure 4.29 | Weighted prevalence of reported past month tranquilizer/sedative, cocaine, crack, 
hallucinogen/inhalant, and stimulant use among past month heroin-only use group by period  
























































Table 4.5 | Rao-Scott χ2 analyses for the association of prevalence of each core substance 
and period for past month heroin-only use group (n = 553), NSDUH 2002 to 2017 
Core substances 
Rao-Scott analysis 
χ2 (df) p-value 
Binge alcohol 




Never or 'no' binge use in 
past month 
Heavy alcohol 








Used in the past month 2.81 
(3) 
0.42 
Not used in the past month 
Cigarettes 
Used in the past month 8.26 
(3) 
0.041 
Not used in the past month 
Other tobacco 
products 
Used in the past month 1.94 
(3) 
0.58 
Not used in the past month 
Marijuana 
Used in the past month 3.65 
(3) 
0.30 
Not used in the past month 
Cocaine 
Used in the past month 1.04 
(3) 
0.79 
Not used in the past month 
Crack 
Used in the past month 0.14 
(3) 
0.99 
Not used in the past month 
Hallucinogens/ 
inhalants 
Used in the past month 4.32 
(3) 
0.23 
Not used in the past month 
Stimulants 
Used in the past month 2.45 
(3) 
0.48 
Not used in the past month 
Abbreviations: χ2 (df) = Chi-square statistic (degrees of freedom) 







Figure 4.30 | Joinpoint analysis of the weighted prevalence of past month heavy alcohol use 
among past month heroin-only use group (n = 553) 
 
 
Figure 4.31 | Joinpoint analysis of the weighted prevalence of past month cigarette use among 




Past month combination opioid use group 
Figures 4.32 to 4.34 show the weighted prevalence of all past month core 
substance use from period 1 to 4.  The substances that showed increases in reported 
prevalence were tranquilizers/sedatives and stimulants.  It should be noted that the 
prevalence of most substances for all periods among the past month combination opioid 
use groups exceeded those of the past month PPR-only use group.  (Graphs comparing 
the weighted prevalence of core substance use stratified by opioid use group and period 
are provided in Supplemental Graphs (SG) 4.1a-d, 4.2a-d, 4.3a-d, and 4.4a-d in 
Appendix B).  
As shown in Table 4.6, χ2 analysis identified three core substances whose 
prevalence were significantly associated with period: crack [χ2 (df), (p-value): 8.88 (3), 
(0.031)], hallucinogens/inhalants [χ2 (df), (p-value): 10.58 (3), (0.014)], and stimulants [χ2 
(df), (p-value): 26.58 (3), (< 0.0001)].  Joinpoint regression results for the prevalence of 
these three substances are shown in Figures 4.35 through 4.37.  Although no joinpoints 
were modeled, the trends in the prevalence of the reported past month use of crack [m (p-
value): 0.46 (0.004)] and stimulants [m (p-value): 1.78 (0.004)] were significant and 
positive in this population.  However, the trend in the prevalence of past month 
hallucinogen/inhalant use showed two joinpoints: 2006 and 2011, which indicated two 
trends in the prevalence of past month hallucinogen/inhalant use.  From 2002 to 2006, 
there was a decrease in the prevalence of reported past month hallucinogen/inhalant use, 
followed by an increase from 2006 to 2011, although neither of these trends were 




negative [m (p-value): -3.99 (0.013)].  (For all joinpoint results for this opioid use group, 





Figure 4.32 | Weighted prevalence of all levels of past month alcohol drinking among past month 
combination opioid use group by period (n = 535), NSDUH 2002 to 2017 
 
 
Figure 4.33 | Weighted prevalence of reported past month cigarette smoking, other tobacco use, 
and marijuana use among past month combination opioid use group by period (n = 535), NSDUH 
































































Figure 4.34 | Weighted prevalence of reported past month tranquilizer/sedative, cocaine, crack, 
hallucinogen/inhalant, and stimulant use among past month combination opioid use group by 


































Table 4.6 | Rao-Scott χ2 analyses for the association of prevalence of each core substance 




χ2 (df) p-value 
Binge alcohol 




Never or 'no' binge use in 
past month 
Heavy alcohol 








Used in the past month 4.73 
(3) 
0.19 
Not used in the past month 
Cigarettes 
Used in the past month 1.45 
(3) 
0.69 
Not used in the past month 
Other tobacco 
products 
Used in the past month 3.86 
(3) 
0.28 
Not used in the past month 
Marijuana 
Used in the past month 2.84 
(3) 
0.42 
Not used in the past month 
Cocaine 
Used in the past month 1.66 
(3) 
0.65 
Not used in the past month 
Crack 
Used in the past month 8.88 
(3) 
0.031 
Not used in the past month 
Hallucinogens/ 
inhalants 
Used in the past month 10.58 
(3) 
0.014 
Not used in the past month 
Stimulants 
Used in the past month 26.58 
(3) 
<0.0001 
Not used in the past month 
Abbreviations: χ2 (df) = Chi-square statistic (degrees of freedom) 





Figure 4.35 | Joinpoint analysis of the weighted prevalence of past month crack use among past 
month combination opioid use group (n = 535) 
 
 
Figure 4.36 | Joinpoint analysis of the weighted prevalence of past month hallucinogen/inhalant 





Figure 4.37 | Joinpoint analysis of the weighted prevalence of past month stimulant use among 





Aim 2 Results 
Subaim 2.1: To identify the latent class variable of polydrug use in PWUO 
using the past-month use variables of the 11 core substance indicators (pain 
relievers, heroin, heavy alcohol, tranquilizers/sedatives, cigarettes, other 
tobacco products, marijuana, cocaine, crack, hallucinogens/inhalants, and 
stimulants). 
 
 Four primary subpopulations were identified using latent class analysis.  This 
final number of classes were enumerated primarily using the results of the BIC and 
entropy fit statistics.  Aim 1 results were also used to confirm likely patterns of use 
among Classes whose primary opioid use population were akin to the opioid use groups.  
Figure 4.38 compares the three information criteria (i.e., AIC, BIC, ssBIC) used to guide 
final class enumeration.  As shown in Figure 4.38, all IC statistics were extremely 
comparable, with the BIC being the most conservative measure.  And although all ICs 
continued to decrease beyond the four-class model, the decline was extremely modest.  
Entropy values were also used to determine the final class size; Figure 4.39 shows the 
plotted entropy values for models fitting two to eight polydrug use classes.  (For all fit 





Figure 4.38 | Information criteria comparisons for one to eight polydrug use classes in PWUO  




Figure 4.39 | Entropy comparisons for two to eight polydrug use classes in PWUO (n = 16,985), 
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Additionally, to assess whether a five-class model yielded a better fit, 
endorsement probabilities were graphed and compared to the four-class model.  It was 
determined that Class 5 yielded an additional class that was not logical based on the 
prevalence results from Aim 1.  And while most of the other classes in the five-class 
model remained comparable to the four-class model, the extra class from the five-class 
model included a combination opioid subpopulation that had 100% endorsement 
probabilities for cocaine and crack, which was not supported by Aim 1 results.   
Table 4.7 shows the sample size and weighted prevalence of the four polydrug 
latent classes, while Table 4.8 shows all endorsement probabilities for past month core 
substance use among each latent class.  Figure 4.40 shows the profiles of polydrug use 
behavior using a four-class model.  Classes were named based on substance use 
categories that exhibited higher endorsement probabilities.  It should be noted that 
‘cigarettes’ were not included in the name of any latent class because of its high 
endorsement probability for all latent classes.  Class 1 (mainly PPR) was characterized by 
PPR use with low probabilities of endorsing all other core substances, making up 
approximately 44.1% of all PWUO.  Class 2 was characterized by high endorsement 
probabilities for PPR, heavy alcohol, prescription tranquilizers/sedatives, prescription 
stimulants, and marijuana use; it comprised 42.6% of all PWUO.  Class 3 was 
characterized by heroin, marijuana, and other illicit substances (i.e., cocaine and crack) 
and made up 3.6% of all polydrug latent classes.  Finally, Class 4 was characterized by 
combination opioid use and high endorsement probabilities for all other core substances 





Table 4.7 | Overall size and weighted prevalence of the latent polydrug use 
subpopulations among PWUO (n = 16,985), NSDUH 2002 to 2017 
Polydrug latent class n % SE 
95% CI 
LL UL 
1: mainly PPR  5817 44.13 0.57 42.33 45.93 
2: PPR - heavy alcohol – benzo - 
stimulant - marijuana 
8709 42.64 0.81 40.06 45.22 
3: Heroin - marijuana - illicit 
substances 
553 3.61 0.16 3.10 4.12 
4: Combination opioid - polydrug  1906 9.62 0.34 8.55 10.70 
Abbreviations: n = total number of survey respondents; % = weighted percentage; SE = standard 




Table 4.8 | Endorsement probabilities for each core substance by latent polydrug class  
(n = 16,985), NSDUH 2002 to 2017 
Substances used in the 
past 30-days 
Polydrug latent classes among PWUO 
1: mainly PPR  
2: PPR - heavy 
alcohol - benzo - 
stimulant - drugs 
- marijuana  








PPR 1 1 0.022 0.999 
Heroin 0.001 0.037 1 0.159 
Heavy alcohol 0.088 0.385 0.164 0.516 
Cigarettes 0.299 0.814 0.887 0.862 
Other tobacco products 0.072 0.379 0.226 0.396 
Tranquilizers/sedatives 0.092 0.291 0.134 0.459 
Stimulants 0.014 0.121 0.039 0.217 
Marijuana 0.096 0.669 0.478 0.75 
Cocaine 0.008 0.025 0.354 1 
Crack 0 0 0.199 0.346 









Figure 4.40 | Four Class Model Endorsement Probability Plot (n = 16,985), NSDUH 2002 to 2017 
Class 1: PPR 
(n = 5,817) 
Class 2: PPR - heavy 




Class 3: Heroin -
marijuana - illicit 
substances (n = 553)



























Longitudinal trends of the weighted prevalence of the polydrug latent classes 
 
Figure 4.41 shows the longitudinal trend of each polydrug latent class from 
period 1 to 4.  While the overall trend in the prevalence of these latent classes over time 
remains relatively constant, Class 3 (heroin-marijuana-illicit substance), appear to be 
increasing over time.  Chi-square results found in Table 4.9 also indicated a significant 
association between period and the prevalence of the latent classes [χ2 (df), (p-value): 
42.06 (9), (< 0.0001)].  
 
Figure 4.41 | Weighted prevalence of polydrug latent classes by period (n = 16,985), 
NSDUH 2002 to 2017 
Class 1: mainly PPR
Class 2: PPR - heavy 





















































n %a SE n %a SE n %a SE n %a SE   
1: mainly PPR 
(n = 5,817) 




2: PPR - heavy 
alcohol – benzo - 
stimulant - 
marijuana  
(n = 8,709) 
2269 42.36 3.32 2663 43.78 1.98 2286 43.23 1.03 1491 40.81 1.30 
3: Heroin - 
marijuana - 
illicit substances  
(n = 553) 




(n = 1,906) 
653 12.47 0.99 558 9.53 1.89 416 8.96 1.09 279 7.52 1.25 
Abbreviations: n = total number of survey respondents; % = weighted column percentage; SE = standard error; χ2 (df) = Chi-square statistic 
(degrees of freedom)  
Note: 95% confidence intervals for all reported prevalence indicated reliable measures 
Note: Bolded χ2 and p-values denote statistical significance at p < 0.05. 
aWeighted prevalence was based on the total number of survey participants within each period 
 




Joinpoint regression results for the change in prevalence of each latent class 
indicated that the trajectory for Class changed over time.  Figures 4.42 through 4.45 
show the trend lines for the prevalence of Class 1 (mainly PPR), Class 2 (PPR-heavy 
alcohol-benzo-stimulant-marijuana), Class 3 (heroin-marijuana-illicit substance), and 
Class 4 (combination opioid-polydrug), respectively.  For Class 1 (mainly PPR), two 
joinpoints were detected: 2009 and 2012.  The overall trajectory of the prevalence of 
Class 1 (mainly PPR) from 2002 to 2012 was positive, although not significant; however, 
from 2012 to 2017, there was a significant decrease in the prevalence of Class 1 (mainly 
PPR) [m (p-value): -0.71 (< 0.001)].  For Class 2, one joinpoint was assessed: 2009.  
From 2002 to 2009, the prevalence of Class 2 significantly increased [m (p-value): 0.87 
(0.029)].  However, a significant decrease in the trend in prevalence for Class 2 occurred 
from 2009 to 2017 [m (p-value): -0.73 (< 0.001)].  While the overall trend in the 
prevalence of Class 3 was positive, one joinpoint in 2010 was detected, with a significant 
positive increase from 2010 to 2017 [m (p-value): 1.06 (< 0.001)].  Finally, although no 
joinpoints were found in the trajectory of the prevalence of Class 4, its overall trend from 
2002 to 2017 significantly decreased [m (p-value): -0.32 (0.001)].  (Full results of the 





Figure 4.42 | Joinpoint analysis of the weighted prevalence of Class 1 (n = 5,817) 
 
 





Figure 4.44 | Joinpoint analysis of the weighted prevalence of Class 3 (n = 553) 
 
 




Aim 3 Results 
Subaim 3.1: To determine the prevalence and bivariable associations of the 
following covariates using the latent class variable as an outcome: age, sex, 
race/ethnicity, total household income, education level, marital status, 
employment status, health insurance status, age at prescription opioid 
initiation, opioid use disorder, depression, county type, and residential 
transience. 
 
 Before assessing the prevalence and bivariable associations between polydrug 
latent classes and its correlates, substance use indicator data from 2010 to 2017 was 
evaluated to determine the best fit number of classes for the subset (n = 7,541).  (The 
subset data was used because the goal was to the determine the most current polydrug 
latent classes starting from the beginning of Wave II of the high opioid mortality).  A 
total of four classes were enumerated using LCA, which were very comparable to those 
discussed in the results for Aim 2.  A description of the four classes were provided 
below:  
▪ Class 1: PPR - characterized predominantly by PPR and cigarette use, with low 
endorsement probabilities of other core substances (n = 3,432; PR = 0.55) 
▪ Class 2: PPR-heavy alcohol-benzodiazepines-stimulants-marijuana - 
characterized by heroin, heavy alcohol, cigarette, prescription benzodiazepines 
and stimulants, and marijuana use (n = 3,508; PR = 0.37) 
▪ Class 3: Heroin-marijuana - characterized mainly by heroin and marijuana use, 




▪ Class 4: Combination opioid-polydrug - characterized by equal probabilities of 
heroin and PPR use, with higher levels of all other substance use (n = 260; PR = 
0.039) 
(Full results of the fit statistic comparisons, weighted prevalence of the latent classes, and 
endorsement probabilities for core substance use may be found in ST 4.19 through 4.21 
in Appendix A). 
After excluding cases with missing data for any correlates used in the model, the 
total sample size used in the analysis for Aim 3 was 5,103 (67.67% of the total sample 
size from 2010 to 2017).  (It should be noted that the exclusion of these cases was 
assumed to be missing at random, judging from the sample size comparisons between 
Table 4.7 and 4.10).  Table 4.10 shows the weighted distributions of the latent classes 
for the subset data. 
 
Table 4.10 | Overall size and weighted prevalence of the polydrug latent classes among 
PWUO (n = 5,103), NSDUH 2010 to 2017 
Polydrug latent class n % SE 
95% CI 
LL UL 
1: mainly PPR  2286 55.12 0.93 51.13 59.12 
2: PPR - heavy alcohol - benzo - 
stimulant - marijuana  
2436 37.00 0.61 34.37 39.63 
3: Heroin - marijuana 215 4.02 0.34 2.57 5.47 
4: Combination opioid - polydrug  166 3.85 0.36 2.32 5.39 
Abbreviations: n = total number of survey respondents; % = weighted percentage; SE = standard 
error; 95% CI = 95% confidence interval; LL = lower limit; UL = upper limit 
 
Prevalence of classes characterized predominantly by PPR use represented the majority 
of PWUO from 2010 to 2017, while groups with high endorsement probabilities of heroin 




 When the relationship between the latent classes and the correlates of interest 
were assessed, significant associations were found to exist for almost all correlates based 
on χ2 analysis, with one exception: past year depression.  Table 4.11 details the 








 Table 4.11 | Prevalence of set and setting correlates of polydrug latent classes (n = 5,103), NSDUH 2010 to 2017 
Independent variables of interest 
 
  
Polydrug latent class 
Class 1: mainly PPR 
(n = 2286) 
Class 2: PPR - heavy 
alcohol - benzo - 
stimulant - marijuana  
(n = 2436) 
Class 3: Heroin - 
marijuana  
(n = 215) 
Class 4: Combination 
opioid - polydrug  
(n = 166) 
n % SE n % SE n % SE n % SE 
Age (years)                         18 to 25 1089 18.27 0.81 1703 42.97 2.97 108 26.98 1.08 69 20.34 2.00 
                                            26 to 34 453 24.10 0.80 448 30.91 1.45 60 30.76 2.49 30 25.01 9.75 
                                     35 and older 744 57.62 1.58 285 26.12 2.62 47 42.26 3.58 67 54.65 7.84 
Sex                                                   Female 1258 50.07 2.16 915 33.77 1.21 78 34.75 2.71 67 33.87 1.59 
                                                Male 1028 49.93 2.16 1521 66.23 1.21 137 65.25 2.71 99 66.13 1.59 
Race/ethnicity                  NH white 1442 66.31 1.07 1788 77.43 2.10 152 65.60 1.86 106 64.51 3.57 
                                         NH black 298 10.60 0.20 186 8.14 0.15 20 14.04 4.33 22 19.86 0.86 
                                          Hispanic 386 18.35 0.68 259 9.79 1.14 31 17.14 2.73 23 10.46 2.03 
                            Other NH Groups 160 4.73 1.16 203 4.65 0.93 12 3.22 1.84 15 5.18 2.34 
Total household                < $30,000 956 33.53 0.96 1128 42.49 0.93 111 52.82 2.39 91 61.45 4.70 
 income            $30,000 to $74,999 830 37.48 1.85 865 36.14 1.41 65 26.92 3.48 52 25.49 3.39 
(dollars)                 $75,000 or more 500 28.99 1.12 443 21.37 0.49 39 20.26 3.50 23 13.06 1.48 
Education     Less than high school 432 16.57 1.01 542 20.70 0.64 46 21.48 2.71 50 23.39 3.57 
level               High school graduate 751 28.62 2.31 897 34.94 1.88 94 37.87 0.77 69 38.56 2.08 















(Table 4.11 continued) 
Independent variables of 
interest 
Polydrug latent class 
Class 1: mainly PPR  
(n = 2286) 
Class 2: PPR - heavy 
alcohol - benzo - 
stimulant - marijuana  
(n = 2436) 
Class 3: Heroin - 
marijuana 
(n = 215) 
Class 4: Combination 
opioid - polydrug 
(n = 166) 
n % SE n % SE n % SE n % SE 
Employment                 Full-time 1070 53.18 1.40 1128 50.00 0.49 55 29.74 0.90 50 30.66 2.95 
status                             Part-time 399 14.84 1.66 482 17.93 0.14 38 12.64 0.50 15 9.65 1.95 
                                  Unemployed 279 8.69 1.24 410 15.04 1.12 45 17.66 3.53 51 28.06 5.11 
              Other employment status 538 23.28 1.01 416 17.03 1.67 77 39.96 4.68 50 31.63 2.90 
Marital status                 Married 685 41.74 0.86 299 19.60 1.34 23 13.04 3.12 12 10.31 3.57 
                                   Not married 1601 58.26 0.86 2137 80.40 1.34 192 86.96 3.12 154 89.69 3.57 
Age at prescription              0-17 587 18.05 1.23 912 30.08 0.19 44 15.15 0.78 49 21.60 1.84 
opioid initiation                  18-25 691 23.42 1.23 783 30.22 1.58 34 11.78 0.81 24 19.56 1.40 
(years)                       26 and older 1008 58.53 0.77 741 39.71 1.77 137 73.07 0.37 93 58.84 2.76 
Opioid use disorder                No 1817 80.53 0.56 1647 67.87 0.27 41 25.09 2.33 52 31.05 1.60 
                                                Yes 469 19.47 0.56 789 32.13 0.27 174 74.91 2.33 114 68.95 1.60 
Depression                               No 2010 87.59 0.20 2127 86.66 1.57 185 84.22 2.49 136 82.97 5.53 
Yes 276 12.41 0.20 309 13.34 1.57 30 15.78 2.49 30 17.03 5.53 
Has health insurance              No 56 38.94 7.01 710 30.03 1.76 512 21.43 1.65 62 24.91 3.28 
Yes 110 61.06 7.01 1726 69.97 1.76 1774 78.57 1.65 153 75.09 3.28 
County type              Large metro 1094 59.38 0.86 1065 52.90 1.77 130 74.53 2.69 97 61.22 6.69 
Small metro 833 29.15 0.29 910 31.82 1.27 61 20.98 3.37 52 31.94 4.81 
Nonmetro 359 11.47 0.57 461 15.28 0.82 24 4.49 1.34 17 6.84 1.98 
Residential             Did not move 1340 67.96 0.82 1144 53.96 4.96 114 56.82 7.67 71 49.51 4.09 
transience                 Moved once 511 19.58 0.61 668 24.04 0.61 48 22.36 9.31 39 23.77 3.78 
in past year        Moved 2+ times 435 12.46 1.13 624 22.01 4.36 53 20.82 2.00 56 26.71 6.84 




Table 4.12 | Rao-Scott χ2 analyses for the association of latent class membership and set 
and setting correlates among PWUO (n = 5,103), NSDUH 2010 to 2017 
 
Independent variables of interest 
Rao-Scott Analyses 
χ2 (df) p-value 
Age (years) 
18 to 25 
193.30 (6) < 0.0001 26 to 34 
35 and older 
Sex 
Female 




63.68 (9) < 0.0001 
Non-Hispanic black 
Hispanic 
Other Non-Hispanic Groups 
Total household 
income (dollars) 
Less than $30,000 
132.80 (6) < 0.0001 $30,000 to $74,999 
$75,000 or more 
Education level 
Less than high school 
38.76 (6) < 0.0001 High school graduate 
Currently enrolled or completed college 
Employment status 
Employed full-time 
104.04 (9) < 0.0001 
Employed part-time 
Unemployed 
Other employment status 
Marital status 
Married 
209.02 (3) < 0.0001 
Not married 




203.06 (6) < 0.0001 18-25 
26 and older 
Abbreviations: χ2 (df) = Chi-square statistic (degrees of freedom) 




(Table 4.12 continued) 
 
Independent variables of interest 
Rao-Scott Analyses 
χ2 (df) p-value 







1.77 (3) 0.62 
Yes 
Has health insurance 
Yes 




36.50 (6) < 0.0001 Small metro 
Nonmetro 
Residential transience 
in past year2 
Did not move 
28.49 (6) < 0.0001 Moved once 
Moved two or more times 
Abbreviations: χ2 (df) = Chi-square statistic (degrees of freedom) 




Subaim 3.2: To determine the multivariable associations of specific 
combinations of variables using the drug, set, and setting model of substance 
use behavior to predict membership of polydrug latent classes. 
 
To understand the full extent of these significant associations using the drug, set, 
setting framework, a full multinomial logistic regression model was analyzed with all 
correlates, excluding past year depression.  As previously stated, three hypotheses and 
their related sub-hypotheses were examined using the results of the multinomial logistic 
regression model. It should be noted that while all results were important to address, only 
those that were significant were discussed for the remainder of this section due to the 
number of group comparisons and correlates. 
 
Hypothesis 1: Polydrug latent classes will differ by sociodemographic 
characteristics. 
Sub-hypothesis 1.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination 
opioid polydrug Class’ more likely than other Classes to be male, non-Hispanic 
white, unemployed, younger at time of survey, uninsured, and having less 
education and less total household income. 
 
The multivariable associations described in the following subsections will address 
all correlates emphasized in this hypothesis.  Table 4.13 shows the associations between 
sociodemographic factors with latent class membership after adjusting for the other set 




 Associations with age 
Relative to Class 1 (mainly PPR), Class 2 (PPR-heavy alcohol-benzo-stimulant-
marijuana) [aOR (95% CI): 3.71 (2.96, 4.66)] and Class 3 (heroin- marijuana) [aOR 
(95% CI): 2.16 (1.49, 3.12)] were significantly more likely to be younger (i.e., 18 to 25 
years of age) than older (i.e., 35 and older) at the time of the survey.  Also, Class 2 (PPR-
heavy alcohol-benzo-stimulant-marijuana) [aOR (95% CI): 2.32 (1.90, 2.82)] and Class 3 
(heroin- marijuana) [aOR (95% CI): 1.88 (1.42, 2.50)] were more likely to be between 
the ages of 26 to 34 than 35 years and older relative to Class 1 (mainly PPR). 
 
Associations with sex 
As hypothesized, Class 4 was more likely to be male than female when compared 
to Class 1 (mainly PPR) [aOR (95% CI): 2.09 (1.46, 3.00)].  However, Class 2 (PPR-
heavy alcohol-benzo-stimulant-marijuana) [aOR (95% CI): 1.97 (1.55, 2.50)] and Class 3 
(heroin- marijuana) [aOR (95% CI): 2.28 (1.63, 3.20)] were also more likely to be male 
than female relative to Class 1 (mainly PPR).  
 
Associations with race/ethnicity 
Of all group comparisons, Class 2 (PPR-heavy alcohol-benzo-stimulant-
marijuana) was the only class to have any significant associations with race/ethnicity 
when compared to Class 1 (mainly PPR).  Compared to non-Hispanic whites, non-
Hispanic blacks [aOR (95% CI): 0.56 (0.53, 0.59)], Hispanics [aOR (95% CI): 0.39 




lower odds of belonging to Class 2 (PPR-heavy alcohol-benzo-stimulant-marijuana) 
relative to Class 1 (mainly PPR).   
 
Associations with total household income 
Relative to Class 1 (mainly PPR), Class 2 (PPR-heavy alcohol-benzo-stimulant-
marijuana) [aOR (95% CI): 1.30 (1.14, 1.47)], Class 3 (heroin- marijuana) [aOR (95% 
CI): 1.59 (1.10, 2.29)], and Class 4 (combination opioid-polydrug) [aOR (95% CI): 1.94 
(1.12, 3.38)] had significantly increased odds of earning a household income that was less 
than $30,000 per year (compared to $75,000 or more per year).   
 
Associations with education level 
Although education level was found not to impact the prediction of class 
membership significantly, the point estimates indicated positive associations between 
lower education levels (i.e., less than high school or high school graduate status) and 
membership in Class 2 (PPR-heavy alcohol-benzo-stimulant-marijuana), Class 3 (heroin- 
marijuana), and Class 4 (combination opioid-polydrug) relative to Class 1 (mainly PPR). 
 
Associations with employment status 
As hypothesized, Class 4 had the highest odds of being unemployed (versus 
employed) relative to Class 1 (mainly PPR) [aOR (95% CI): 3.40 (3.17, 3.65)] of all 
other Classes.  This association was also true for Class 3 (heroin- marijuana) when 
compared to Class 1 (mainly PPR) [aOR (95% CI): 2.42 (1.14, 5.31)].  Other significant 




non-full-time employment categories.  Relative to Class 1 (mainly PPR), Class 2 (PPR-
heavy alcohol-benzo-stimulant-marijuana) [aOR (95% CI): 1.18 (1.13, 1.22)] and Class 3 
[aOR (95% CI): 1.57 (1.38, 1.79)] were significantly more likely to hold part-time 
employment than full-time employment.  Also, Class 3 (heroin- marijuana) [aOR (95% 
CI): 2.51 (1.64, 3.85)] and Class 4 [aOR (95% CI): 1.67 (1.51, 1.84)] had higher odds of 
holding other types of employment.  However, relative to Class 1 (mainly PPR), Class 2 
(PPR-heavy alcohol-benzo-stimulant-marijuana) had significantly lower odds of having 
other types of employment [aOR (95% CI): 0.82 (0.71, 0.95)]. 
 
Associations with marital status 
As hypothesized, Class 4 had the highest odds of being ‘not married’ relative to 
Class 1 (mainly PPR) [aOR (95% CI): 4.13 (1.98, 8.59)] of all other Classes.  However, 
Class 2 (PPR-heavy alcohol-benzo-stimulant-marijuana) [aOR (95% CI): 1.70 (1.55, 
1.88)] and Class 3 (heroin- marijuana) [aOR (95% CI): 3.25 (2.69, 3.93)] were also more 
significantly likely not to be married relative to Class 1 (mainly PPR). 
 
Associations with health insurance status 
Although no significant associations were found between each group comparison 
relative to Class 1 (mainly PPR), the point estimates indicated that all Classes were less 
likely to have health insurance compared to Class 1 (mainly PPR).  Additionally, the 
adjusted point estimate for Class 4 (combination opioid-polydrug) indicated that 
members in this Class had the lowest odds of having insurance relative to Class 1 (mainly 








Table 4.13 | Multivariable associations between latent class membership and sociodemographic factors (n = 5,103), NSDUH 2010 
to 2017a,b  
Independent variables of interest 
Class 2 (PPR-heavy 
alcohol-benzo-stimulant-
marijuana) vs. Class 1 
(mainly PPR) 
Class 3 (Heroin- 
marijuana) vs. Class 1 
(mainly PPR)  
Class 4 (Combination 
opioid - polydrug) vs. Class 
1 (mainly PPR) 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Age (years) 
18 to 25 3.71 (2.96, 4.66) < 0.0001 2.16 (1.49, 3.12) < 0.0001 0.78 (0.58, 1.06) 0.12 
26 to 34 2.32 (1.90, 2.82) < 0.0001 1.88 (1.42, 2.50) < 0.0001 0.91 (0.25, 3.40) 0.89 
35 and older referent group 
Sex 
Female referent group 
Male 1.97 (1.55, 2.50) < 0.0001 2.28 (1.63, 3.20) < 0.0001 2.09 (1.46, 3.00) < 0.0001 
Race/ethnicity 
Non-Hispanic white referent group 
Non-Hispanic black 0.56 (0.53, 0.59) < 0.0001 0.93 (0.31, 2.76) 0.89 1.40 (0.88, 2.23) 0.16 
Hispanic 0.39 (0.27, 0.57) < 0.0001 0.91 (0.68, 1.23) 0.54 0.57 (0.26, 1.26) 0.17 
Other Non-Hispanic 
Groups 




Less than $30,000 1.30 (1.14, 1.47) < 0.0001 1.59 (1.10, 2.29) 0.013 1.94 (1.12, 3.38) 0.019 
$30,000 to $74,999 1.05 (0.87, 1.26) 0.61 0.74 (0.47, 1.18) 0.21 0.89 (0.74, 1.08) 0.26 
$75,000 or more referent group 
 
Abbreviations: aOR (95% CI) = adjusted odds ratio (95% confidence interval) 
aAll bolded aORs, 95% CIs, and p-values indicated significance at p < 0.05 
bModel was adjusted for the following set and setting variables: age at prescription opioid initiation, opioid use disorder, health insurance 













(Table 4.13a,b continued) 
Independent variables of interest 
Class 2 (PPR-heavy alcohol-
benzo-stimulant-marijuana) 
vs. Class 1 (mainly PPR) 
Class 3 (Heroin- marijuana) 
vs. Class 1 (mainly PPR) 
Class 4 (Combination opioid 
- polydrug) vs. Class 1 
(mainly PPR) 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Education 
level 
Less than high 
school 
1.28 (1.00, 1.64) 0.05 1.05 (0.71. 1.56) 0.80 1.08 (0.90, 1.30) 0.40 
High school 
graduate 
1.18 (0.89, 1.56) 0.24 1.33 (0.99, 1.78) 0.059 1.26 (0.87, 1.83) 0.22 
Currently enrolled 




Employed full-time referent group 
Employed part-time 1.18 (1.13, 1.22) < 0.0001 1.57 (1.38, 1.79) < 0.0001 1.16 (0.84, 1.62) 0.37 
Unemployed 1.24 (0.86, 1.78) 0.25 2.42 (1.14, 5.13) 0.021 3.40 (3.17, 3.65) < 0.0001 
Other employment 
status1 
0.82 (0.71, 0.95) 0.01 2.51 (1.64, 3.85) < 0.0001 1.67 (1.51, 1.84) < 0.0001 
Marital status 
Married referent group 
Not married 1.70 (1.55, 1.88) < 0.0001 3.25 (2.69, 3.93) < 0.0001 4.13 (1.98, 8.59) 0.0001 
Has health 
insurance 
No referent group 
Yes 0.92 (0.67, 1.27) 0.61 0.95 (0.57, 1.59) 0.84 0.59 (0.24, 1.47) 0.26 
 
Abbreviations: aOR (95% CI) = adjusted odds ratio (95% confidence interval) 
aAll bolded aORs, 95% CIs, and p-values indicated significance at p < 0.05 
bModel was adjusted for the following set and setting variables: age at prescription opioid initiation, health insurance status, county type, and 
residential transience. 
1Other employment status included: ‘has a job or volunteer worker,’ ‘did not work past week’; ‘disabled’; ‘keeping house full-time’; ‘in 







Hypothesis 2: Polydrug latent classes will differ by their age at prescription opioid 
initiation and OUD status.  
Sub-hypothesis 2.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination opioid 
polydrug Class’ more likely than other Classes to have initiated prescription opioid use at 
an early age and to have opioid use disorder in the past year. 
 
Table 4.14 shows the associations between age at prescription opioid initiation 
and past year OUD status with latent class membership after adjusting the other set and 
setting correlates using Class 1 (mainly PPR) as the referent group. 
 
Associations with age at prescription opioid initiation 
The association between Class 2 (PPR-heavy alcohol-benzo-stimulant-marijuana) 
membership and age at prescription opioid initiation relative to Class 1 (mainly PPR) was 
not significant.  However, Class 3 (heroin- marijuana) [aOR (95% CI): 0.42 (0.30, 0.57)] 
and Class 4 (combination opioid-polydrug) [aOR (95% CI): 0.81 (0.68, 0.97)] were 
significantly less likely than Class 1 (mainly PPR) to be less than 17 years of age at the 
time of prescription opioid initiation.  Furthermore, Class 3 (heroin- marijuana) was also 
significantly less likely to have initiated prescription opioids between the ages of 18 and 








Associations with opioid use disorder 
Relative to Class 1 (mainly PPR), all other polydrug latent classes were more 
likely to be classified as having an OUD in the past year, with Class 3 (heroin- 








Table 4.14 | Multivariable associations between latent class membership and age at prescription opioid initiation and past year 
OUD status (n = 5,103), NSDUH 2010 to 2017a,b  
Independent variables of interest 
Class 2 (PPR-heavy 
alcohol-benzo-stimulant-
marijuana) vs. Class 1 
(mainly PPR) 
Class 3 (Heroin- marijuana) 
vs. Class 1 (mainly PPR) 
Class 4 (Combination 
opioid - polydrug) vs. Class 
1 (mainly PPR) 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Age at prescription 
opioid initiation 
(years) 
0-17 1.22 (0.84, 1.78) 0.30 0.42 (0.30, 0.57) < 0.0001 0.81 (0.68, 0.97) 0.021 
18-25 1.07 (0.63, 1.82) 0.80 0.30 (0.28, 0.32) < 0.0001 0.72 (0.49, 1.04) 0.082 
26 and older referent group 
Opioid use 
disorder 
No referent group 
Yes 1.60 (1.38, 1.86) < 0.0001 11.03 (6.46, 18.82) < 0.0001 7.90 (5.50, 11.36) < 0.0001 
 
Abbreviations: aOR (95% CI) = adjusted odds ratio (95% confidence interval) 
aAll bolded aORs, 95% CIs, and p-values indicated significance at p < 0.05 
bModel was adjusted for the following set and setting variables: age, sex, race/ethnicity, total household income, education level, employment 


















Hypothesis 3: Polydrug latent classes will differ by their environment.  
 
Sub-hypothesis 3.1: The differences between the associations will be driven by 
the types and number of substances used within each Class, with the ‘combination opioid 
polydrug Class’ more likely than other Classes to reside in a large metro and to have 
moved at least twice in the past year. 
 
Table 4.15 shows the associations between county type and residential transience 
with latent class membership after adjusting for the other set and setting correlates using 
Class 1 (mainly PPR) as the referent group.   
 
Associations with county type 
Relative to Class 1 (mainly PPR), Class 3 (heroin- marijuana) and Class 4 
(combination opioid-polydrug) were more likely to reside in either a large metro or small 
metro versus a nonmetro area.  Class 3 (heroin- marijuana) was almost five times more 
likely than Class 1 (mainly PPR) to reside in a large metro [aOR (95% CI): 4.59 (2.54, 
8.32)], and almost three times more likely to live in a small metro area. [aOR (95% CI): 
2.33 (1.20, 4.52)].  Also, Class 4 (combination opioid-polydrug) was three times more 
likely to live in a large metro [aOR (95% CI): 3.28 (1.02, 10.56)], or to reside in a small 
metro [aOR (95% CI): 2.93 (1.53, 5.62)] relative to Class 1 (mainly PPR).   
 
Associations with residential transience in the past year 
While no associations were significant between residential transience and 
polydrug class membership, point estimates suggested that Class 2 (PPR-heavy alcohol-




opioid-polydrug) [aOR (95% CI): 1.42 (0.93, 2.16)] were more likely to have moved 















Table 4.15 | Multivariable associations between latent class membership and county type and residential transience (n = 5,103), 
NSDUH 2010 to 2017a,b  
Independent variables of interest 
Class 2 (PPR-heavy 
alcohol-benzo-stimulant-
marijuana) vs. Class 1 
(mainly PPR) 
Class 3 (Heroin- 
marijuana) vs. Class 1 
(mainly PPR) 
Class 4 (Combination opioid 
- polydrug) vs. Class 1 
(mainly PPR) 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
County type 
Large metro 0.97 (0.72, 1.31) 0.83 4.59 (2.54, 8.32) < 0.0001 3.28 (1.02, 10.56) 0.047 
Small metro 0.94 (0.77, 1.15) 0.54 2.33 (1.20, 4.52) 0.012 2.93 (1.53, 5.62) 0.0012 




Did not move referent group 
Moved once 1.07 (0.69, 1.64) 0.77 1.00 (0.30, 3.40) 0.995 1.22 (0.98, 1.53) 0.076 
Moved two or 
more times 
1.33 (0.77, 2.28) 0.31 0.92 (0.76, 1.12) 0.40 1.42 (0.93, 2.16) 0.11 
 
Abbreviations: aOR (95% CI) = adjusted odds ratio (95% confidence interval) 
aAll bolded aORs, 95% CIs, and p-values indicated significance at p < 0.05 
bModel was adjusted for the following set and setting variables: age, sex, race/ethnicity, total household income, education level, employment 














 The current opioid overdose epidemic continues to affect many Americans with 
uncertainties about how to stop its progression.  An aspect that is drawing increased 
attention is the polydrug use patterns among PWUO, including the trends of co-used 
substances.  Recent articles and CDC reports document an increase in the use of complex 
combinations multiple drugs in opioid overdose cases.18,35,94,176,204,205  Thus, closer 
attention is needed to track polydrug use patterns among PWUO, trends over time, and 
risk factors associated with these populations,206 to improve policies group-specific 
interventions targeting this high-risk population.  This section provides a concise 
summary for each Aim in this research, with supporting citations and interpretations for 
the overall significance of the study.  Recommendations based on results from each Aim, 
as well as final conclusions, were made using the “Cascade of Care” framework.207  
 
Longitudinal Prevalence of People Who Use Opioids and Their Substance Use 
Patterns 
The analyses presented in this dissertation document the decrease over time from 
2002 to 2017 in the prevalence of all PWUO. When stratified into the three opioid use 




that of the heroin-only and combination opioid groups, however the prevalence of past 
month heroin-only and combination opioid use groups increased over time, while the past 
month PPR-only use group steadily decreased from 2002 to 2017.  The decrease in the 
prevalence of the latter group may support the possible success of certain federal and 
state policies (e.g., Prescription Drug Abuse Prevention Plan, prescription drug 
monitoring programs – PDMPs).208,209  However, another macro-level factor that could 
have contributed to these opposing trends is the reformulation of OxyContin, which may 
have led to the initiation of heroin use among those who only use PPR,210 explaining the 
increases in the prevalence of the past month heroin-only and combination opioid use.  
Because it has been shown that individuals that co-use PPR and heroin experience a high 
burden of polydrug use, the second step in assessing overdose risk among PWUO should 
be to track the patterns of reported polydrug use among the three opioid use groups.21   
In the past month heroin-only use group, other core substances which were 
reported by at least 20% of the subgroup were cocaine, binge alcohol, other tobacco 
products, and crack use.  In the past month combination opioid use group, all substances 
except for stimulants and hallucinogen/inhalants were reported by at least 20% of the 
subgroup.  These results indicate a progressively larger number of substances being used 
in these two subgroups, especially illicit substances such as cocaine and crack.  These 
results align with previous research where mortality rates related to cocaine and opioid 
use were shown to be increasing after 2010.18   
In terms of substance use trajectories, the only core substance whose prevalence 
significantly increased during the later years among all PWUO was past month 




use of other tobacco products significantly increased in prevalence, with a simultaneous 
significant decrease in the trend of cigarette use.  While it is encouraging to see the 
decrease in cigarette use, this remains a concern because it has been shown that 
smokeless tobacco is not a safer alternative to cigarettes.211  Products such as snuff, 
chewing tobacco, and even nicotine gum remain in the circulatory system at higher 
concentrations for longer amounts of time.212  Therefore, chronic pain patients who use 
smokeless tobacco products as an option to alleviate their pain symptoms may experience 
a prolonged sense of pain relief, which could exacerbate addictive behaviors.  Finally, 
among the past month combination opioid use group, the core substances whose 
prevalence significantly increased over time were crack and prescription stimulants.     
 As evident from the results of the prevalence and trends of reported substance use 
behavior among the three opioid use groups, patterns of use appeared to be dependent on 
the opioid use group.  In general, those belonging to the past month heroin-only and 
combination opioid groups had a higher prevalence of reporting use of core substances.  
The number of core substances that were reported to have been in use by more than 20% 
of past month combination opioid users included illicit substances (i.e., cocaine and 
crack), which is of concern.   
The results from Aim 1 lead to the following policy recommendations.  Greater 
attention needs to be directed towards detecting and tracking changes in patterns of 
polydrug use among PWUO.  Clinicians and drug dispensaries need to be more cognizant 
of a patient’s prescription history, especially given the continued rise of the co-use of 
opioids and prescription stimulants.  To achieve this goal, health management leadership 




Records system, improve the interoperability of data from the prescription drug 
monitoring programs (PDMP) to be used among all States, and even the integration of 
both platforms to improve tracking efforts of prior substance use history.213,214  The 
merging of electronic health record and PDMP systems could resolve issues that may 
physicians have reported in regards to the difficulty of use, which has been shown as 
being an ineffective method to reduce the practice of prescribing opioids.215  
Additionally, tobacco use cessation programs could be leveraged to promote long-term 
abstinence among those who have sought treatment for an OUD.216  Finally, more formal 
policies on the use of medications for cocaine withdrawal and abstinence initiation (e.g., 
propranolol) and relapse prevention (e.g., baclofen) could be put into standard use in 
emergency rooms nationwide for patients presenting with positive screens for cocaine 
and other opioids.217 
 
Polydrug Latent Class Composition and Trends  
Four different polydrug use patterns were identified for this study using latent 
class analysis, which captured one dimension of use: type of substance.  Class 1 was 
characterized by the past month use of mainly PPR and low levels of all other core 
substances and represented the highest probabilities of all opioid-related polydrug use 
groups [PR (SE): 0.55 (0.93)].  Class 2 was characterized by high probabilities of heroin, 
heavy alcohol, cigarette, prescription tranquilizers/sedatives (i.e., benzodiazepines), 
prescription stimulants, and marijuana use, and was the second largest opioid-related 
polydrug latent class [PR (SE): 0.37 (0.61)].  Class 3 was largely characterized by heroin 




almost four percent of all the opioid-related polydrug latent classes [PR (SE): 0.0361 
(0.16)].  Finally, Class 4 was characterized by prescription pain reliever and heroin use, 
with a high prevalence of all other core substances [PR (SE): 0.096 (0.34)].   
This study indicates that, while prevalence trends for Class 1 (mainly PPR), Class 
2 (PPR - heavy alcohol-benzo-stimulant–marijuana), and Class 4 (combination opioid-
polydrug) has decreased since 2010, the prevalence of Class 3 (heroin-marijuana-illicit 
substances) has increased.  
 The results of Aim 2 for the LCA composition and time trends in this study 
clarified and reinforced those of Aim 1.  The pattern identified as Class 3 (heroin-
marijuana-illicit substance users) showed a significant, recent doubling in prevalence 
during the period 2014-2017.  This suggests that the prevalence of populations with 
riskier substance use behaviors (i.e., Class 3) is increasing over time, and may possibly be 
drawn from lower risk populations such as Class 1 (mainly PPR), given their diminishing 
prevalence.  Therefore, one policy recommendation based on the results of Aim 2 would 
be to establish a routine surveillance program to promote pharmacovigilance among 
PWUO.218  This may require yearly or semi-yearly analyses of polydrug use behavior 
which draws from surveys such as the NSDUH, or online platforms (e.g., Twitter, 
Instagram, Reddit, etc.).218  Other avenues that could be pursued would necessitate the 
involve pharmaceutical companies to conduct their own pharmacoepidemiologic studies 
as a means of post-marketing surveillance in order to inform public health authorities, 
especially given their expansive resources.  Finally, because the abuse of and dependence 
on substances are considered mental health disorders, alternative therapies beyond 




One type of alternative therapy that has been shown in recent years to aid in opioid use 
outcomes is cognitive behavioral therapy (i.e., psychotherapy), with some evidence of its 
efficacy without the use of an additional MAT (e.g., buprenorphine).219,220  
 
Polydrug Latent Classes During Wave II of High Opioid Mortality and Associations 
with Set and Setting Correlates 
 As previously discussed, Wave II of high opioid mortality in the U.S. was due to 
the use of heroin and was said to begin in 2010.76  Because this was arguably the start of 
the changing risk environment of opioid overdose risk, it was decided that a polydrug 
latent class would be modeled using data from 2010 to 2017.  This provided a more 
current assessment of the associations with the set and setting correlates during a time of 
riskier polydrug use.       
 As expected, most correlates used in this study were significantly associated with 
membership in the polydrug latent classes, except for past year depression when using χ2 
testing.  Results of the multinomial logistic regression model clarified these significant 
associations but in a manner that was not expected.  It was hypothesized that Class 4 
(combination opioid - polydrug) would be more likely: 
1. To be male, non-Hispanic white, unemployed, unmarried, younger at the time of 
the survey, uninsured, and having less education and less total household income.  
(Set characteristics) 
2. To have initiated prescription opioid use at an earlier age and to have past year 




3. To be more likely to reside in a large metropolitan area and to have moved at least 
twice in the past year.  (Setting characteristics) 
 
These sub-hypotheses were formed based on findings from past research on multiple 
substance use, particularly those studies that have determined that subpopulations of 
PWUO who exhibit less polydrug use behavior are less likely to be characterized with 
higher overdose risk behaviors.19,36,37  Although the substance use indicators in this study 
do not necessarily inform on the biological effects of polydrug use (i.e., null, overlapping, 
additive, or antagonistic effects),221  it stands to reason that a higher number of possible 
substance use combinations, especially within a relatively short amount of time, would 
result in a higher likelihood of overdose. 
 Overall, the hypothesized relationship between Class 4 (combination opioid - 
polydrug) and all of the set and setting correlates were supported the hypothesized 
pattern; however, Class 3 was shown to have a stronger association for several correlates,   
Not only did Class 4 (combination opioid - polydrug) have the greatest odds of being 
unemployed and not being married, members of this class were more likely to reside in a 
small metropolitan area.  However, compared to Classes 2 and 4, members of Class 3 
(heroin-marijuana), had the highest odds of OUD [aOR (95% CI): 11.03 (6.46, 18.82)] 
relative to Class 1 (mainly PPR). Additionally, relative to Class 1, Class 3 was least likely 
to have initiated prescription opioid use at a younger age, which suggests that substance 
use experience during adolescence did not greatly affect whether Classes that exhibit 
greater polydrug use behaviors eventually develop an OUD.  Additionally, while 
employment status varied for Class 2, 3, and 4 relative to Class 1, overall results indicate 




implications with increased access to health insurance and other work-related benefits.163-
165 
 These results lead to the following inferences and recommendations.  Although 
health insurance status was not significantly associated with predicting polydrug latent 
class membership, lower income level was shown to be more likely among Class 2 (PPR-
heavy alcohol-benzo-stimulant-marijuana) and Class 4 (combination opioid-polydrug) 
groups.  This supports the idea that affordable substance abuse treatment services might 
be made more available, especially in small and large metropolitan areas.  Substance use 
services within any major locale should involve the local community, local government, 
and State government support (via Medicaid expansion).  If executed properly, expanded 
access at a reasonable cost for services like medication-assisted treatment (MAT) and 
even substance use counseling (e.g., cognitive behavioral therapy) could be provided to 
those who are suffering from substance use disorders.  Finally, community programs that 
provide counseling and therapeutic environments (e.g., The Living Room)222 may 
provide an additional outlet of mental and physical support for those suffering from 
substance use disorders. 
 
Strengths and Limitations 
The primary strengths of this study were the use of a large, national database 
consisting of repeated surveys of drug use over a 16-year period (NSDUH) and the 
application of statistical methods for tracking changes in patterns of use over this period 
(LCA and joinpoint regression).  The research was also based on a strong theoretical 




among PWUO were documented and analyzed using joinpoint regression, which allows 
direct tests of whether trends are statistically significant, as well as identifying specific 
times where trends may shift.  These analyses provided a clearer identification of both 
when and how patterns of polydrug use changed in PWUO.  Also, the person-centered 
LCA approach used uncovered and clarified subpopulations of PWUO polydrug patterns 
and allowed a better assessment of their associations with demographic and behavioral 
correlates within the drug, set, and setting framework.  Thus, this research adds 
meaningfully to the literature in this area by providing a more detailed assessment of both 
patterns of polydrug use and changes over time.  Other strengths inherent in the NSDUH 
include a large number of yearly participants resulting in precise prevalence estimates. 
There are several limitations of this study, mostly related to the survey 
methodology.  First, the data collected in the NSDUH relies on the self-report of 
participants, which may affect final results in the study because of different types of 
information bias, including (but not limited to) recall bias and non-response or 
participation bias, especially given the sensitive nature of the survey questions.  While all 
efforts were made to promote truthfulness in answering sensitive survey questions, the 
likelihood of this may be questioned when participants are asked about illicit substance 
use.  However, participants in NSDUH were allowed to complete an audio computer-
assisted self-interview (ACASI) for all substance use and other sensitive questions which 
may have helped overcome some of this potential information bias.  With regard to 
participation bias, individuals who were homeless, served in the military, or were 
incarcerated were excluded because they do not have fixed home addresses.223  The 




prevalence of opioid use is systematically undercounted.224  However, it is difficult to 
determine whether this undercounting necessarily biased findings with regard to latent 
class patterns of use or time trends.  This problem might be addressed, given appropriate 
data, through similar analyses of other community-based samples, such as community 
centers focused on substance use rehabilitation or mental health treatment, publicly 
managed halfway homes for recent parolees, or patients at the Veteran’s Administration 
(VA).225-227 
Second, NSDUH is a cross-sectional survey, which technically does not allow 
longitudinal analyses of changes within persons.  Nonetheless, repeated surveys within a 
well-defined target sample may be used to describe changes in a population over time.  
Third, the survey methodology from 2002 to 2017 has changed at various stages making 
results from some years incomparable to others, particularly when the change is related to 
the wording of a survey question.  Also, the inclusion of illicit methamphetamine use 
could not be included in the analyses because that module was not available until 2015.  
Lastly, this study utilized the publicly available data from the 2002 through 2017 
cycles of NSDUH, statewide variations in substance use behavior were not be assessed, 
and some sociodemographic variables could not be included in characterizing latent 
polydrug groups among PWUO.  Also, due to the design of the survey questions, 
simultaneous and concurrent use could not be distinguished in this study, which hinders 
any specific interpretation about co-use behaviors.  
 Some limitations may also be viewed from an analytical standpoint.  Non-
significant associations between Class 3 (heroin-marijuana) or Class 4 (combination 




a result of small sample size (n = 341), which may have increased the likelihood of 
making a Type II error.  Also, while the total sample size was large after the exclusion of 
all individuals who reported not having used heroin or PPR in the past month, 
examination of the sample size by each opioid use group across 16 years necessitated the 
collapse of certain categories, including time, race, education, income, marital status, 
OUD status, etc.  Finally, this study assumed that the two latent classes enumerated for 
Aims 2 and 3 are the same or closely similar and that any time-dependent differences will 
be reflected in the associations of the set and setting covariates.    
And because the latent class analysis was the focus of this study, several 
limitations arise from this complex modeling technique.  First, deciding the number of 
classes in a latent variable has been a topic of discussion among many social science 
statisticians, with varying guidelines to assist in the determination of the total number of 
classes.202,228,229  Second, while power may be inferred using simulation studies from 
external researchers, this is limited only to the ability of a fit statistic in aiding in the 
determination of the final number of classes.  Power was not considered once the latent 
class variable is used in inferential testing because there is no true prevalence that could 
be used in determining sample size and power formulas, given the probabilistic nature of 
modeling a latent variable. Finally, although no formal discussion has been found on the 
co-use of Mplus and SAS for analysis, it may be likely that robustness of point estimates 






Simultaneous use of these core substances among PWUO should be incorporated 
into the NSDUH.  Understanding polydrug use with a simultaneous and concurrent 
distinction would provide more information on the prospective effects of polydrug use 
and set a rudimentary basis upon which to prompt clinical or animal trials for the 
pharmacological interactions of multiple substance use.  Additionally, because illicitly 
manufactured fentanyl (IMF) was not able to be assessed within the context of this study, 
it may be advisable for a separate module related to IMF use to be added into future 
versions of the NSDUH.  Questions for this module could help to sort out an individual’s 
history into using fentanyl; whether this use was intentional or unintentional; and reasons 
for intentional use.  Moreover, the prevalence of intentional IMF use may be assessed in 
order to further advocate for higher level measures of overdose prevention strategies, 
including the use of mass distribution of fentanyl test strips.230    
 
Conclusions 
The trends of the reported substance use among each of the opioid use groups 
demonstrate the growing need for expanded programs that recognize the growing trend 
towards polydrug use in the provision of substance use treatment and rehabilitation.  The 
results of this study also may provide public health practitioners with better substance use 
information that may be used to develop screening programs for problematic, polydrug 
use, with the hope of stemming the progression of increased polydrug use especially 
among those with have only reported the past month use of PPRs.   
The present results, including trends, suggest that the polydrug latent class that 




mainly by the increased odds of having OUD in the past year relative to all other classes, 
even after adjusting for the set and setting risk factors.  While the other characteristics of 
Class 3 do not necessarily conform to the sociodemographic and environmental factors 
that have been attributed to higher overdose risk, Class 3 (heroin-marijuana) has been 
significantly increasing since 2010, so its identification and further study is warranted.  
However, prevention must begin at the level of lower polydrug use populations among 
PWUO (e.g., Class 1).  
Policy recommendations based on the results of this study fall into three broad 
categories: clinical interventions directed at individuals, population-level interventions 
which seek to address polydrug surveillance, and community-level social support and 
treatment.  These recommendations were formed using the “Cascade of Care 
Framework” for the opioid epidemic.231  The Cascade of Care Framework may be 
summarized as follows:231 prevention, identification, treatment, and recovery. 
Prevention initiatives may be in the form of using universal electronic health 
records to prevent an individual from possibly receiving excessive prescription pain 
relievers in an ED or urgent care facility, especially if integrated with prescription drug 
monitoring program systems.  Identifying individuals at high risk of developing OUD 
should include higher level pharmacovigilance efforts by local, state, and federal 
governments or pharmaceutical companies.  These efforts may necessitate using data 
from the NSDUH or following social platforms online.  Treatment should include 
medication-assisted treatments, but also holistic approaches (e.g., cognitive behavioral 
therapy), or community-level substance use and mental health initiatives, in order to 




In summary, the research conducted in the present study provides a model for 
improved understanding of the growing problem of polydrug use within PWUO, changes 
over time in patterns of polydrug use, and identification of those at greatest risk, that may 
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ST 4.1 | Joinpoint regression results of longitudinal changes in prevalence of PWUO, 











1 2002 2010 0.028^ 0.01023 2.72 0.020 
2 2010 2017 -0.117^ 0.01019 -11.51 < 0.001 
Abbreviations: SE = standard error  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of past month PWUO and survey year. 
^Slope is significantly different from zero at alpha = 0.05. 
 
ST 4.2 | Joinpoint regression results of longitudinal changes in prevalence of past month 











1 2002 2017 -0.455^ 0.099 -4.59 0.0004 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of past month PPR-only use group and survey year. 
^Slope is significantly different from zero at alpha = 0.05. 
 
ST 4.3 | Joinpoint regression results of longitudinal changes in prevalence of past month 











1 2002 2010 0.051 0.245 0.21 0.84 
2 2010 2017 1.062^ 0.218 4.87 < 0.001 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of past month heroin-only use group and survey year. 
^Slope is significantly different from zero at alpha = 0.05. 
 
ST 4.4 | Joinpoint regression results of longitudinal changes in prevalence of past month 











1 2002 2017 0.35^ 0.013 27.83 < 0.001 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of past month PPR-only use group and survey year. 




ST 4.5 | Overall weighted prevalence of reported past month core substances use among 
PWUO, NSDUH 2002 to 2017 (n = 16,985) 
 




Binge use in the past 
month 
5523 28.80 0.62 26.82 30.78 
Never or 'no' binge 
use in past month 
11462 71.20 0.62 69.22 73.18 
Heavy alcohol 
Heavy use in the 
past month 
5211 25.32 0.60 23.41 27.23 
Never or 'no' heavy 
use in past month 
11774 74.68 0.60 72.77 76.59 
Tranquilizers/ 
sedatives 
Used in the past 
month 
3860 20.91 0.40 19.64 22.17 
Not used in the past 
month 
13125 79.09 0.40 77.83 80.36 
Cigarettes 
Used in the past 
month 
11346 58.74 0.37 57.57 59.92 
Not used in the past 
month 
5639 41.26 0.37 40.08 42.43 
Other tobacco 
products 
Used in the past 
month 
4971 23.56 0.34 22.47 24.65 
Not used in the past 
month 
12014 76.44 0.34 75.35 77.53 
Marijuana 
Used in the past 
month 
8672 40.89 0.58 39.03 42.75 
Not used in the past 
month 
8313 59.11 0.58 57.25 60.97 
Cocaine 
Used in the past 
month 
2122 11.21 0.41 9.90 12.52 
Not used in the past 
month 
14863 88.79 0.41 87.48 90.10 
Crack 
Used in the past 
month 
527 3.66 0.44 2.2588 5.06 
Not used in the past 
month 
16458 96.34 0.44 94.94 97.74 
Hallucinogens/ 
inhalants 
Used in the past 
month 
1602 6.76 0.26 5.91 7.60 
Not used in the past 
month 
15383 93.24 0.26 92.40 94.09 
Stimulants 
Used in the past 
month 
1609 7.78 0.20 7.14 8.41 
Not used in the past 
month 
15376 92.23 0.20 91.59 92.86 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% 







ST 4.6 | Weighted prevalence of reported substance use for all PWUO by period (n = 16,985), NSDUH 2002 to 2017 
Core substances 
Period 
(1) 2002 to 2005 (2) 2006 to 2009 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 1423 28.13 1.66 22.84 33.42 1565 30.04 0.46 28.57 31.51 
Never or 'no' binge use in past 
month 
3034 71.87 1.66 66.58 77.16 3331 69.96 0.46 68.49 71.43 
Heavy alcohol 
Heavy use in the past month 1571 28.06 1.72 22.60 33.53 1687 27.96 0.54 26.25 29.66 
Never or 'no' heavy use in past 
month 
2886 71.94 1.72 66.47 77.40 3300 72.04 0.54 70.34 73.75 
Tranquilizers/ 
sedatives 
Used in the past month 1019 21.61 0.44 20.22 23.00 1166 20.50 0.30 19.53 21.46 
Not used in the past month 3438 78.39 0.44 77.00 79.78 3821 79.50 0.30 78.54 80.47 
Cigarettes 
Used in the past month 3039 59.95 1.04 56.63 63.27 3439 60.57 0.61 58.62 62.52 
Not used in the past month 1418 40.05 1.04 36.73 43.37 1548 39.43 0.61 37.48 41.38 
Other tobacco 
products 
Used in the past month 1314 23.89 1.07 20.48 27.31 1523 24.74 0.33 23.68 25.80 
Not used in the past month 3143 76.11 1.07 72.69 79.52 3464 75.26 0.33 74.20 76.32 
Marijuana 
Used in the past month 2287 40.54 2.33 33.14 47.95 2547 39.71 1.11 36.18 43.24 
Not used in the past month 2170 59.46 2.33 52.05 66.86 2440 60.29 1.11 56.76 63.82 
Cocaine 
Used in the past month 692 13.56 1.06 10.20 16.92 603 10.98 1.95 4.76 17.20 
Not used in the past month 3765 86.44 1.06 83.08 89.80 4384 89.02 1.95 82.80 95.24 
Crack 
Used in the past month 144 4.00 1.08 0.5431 7.45 151 3.634 1.30 0.00 7.79 
Not used in the past month 4313 96.01 1.08 92.55 99.46 4836 96.37 1.30 92.21 100.00 
Hallucinogens/ 
inhalants 
Used in the past month 468 6.86 0.40 5.59 8.13 472 6.41 0.28 5.52 7.31 
Not used in the past month 3989 93.14 0.40 91.87 94.41 4515 93.59 0.28 92.69 94.48 
Stimulants 
Used in the past month 448 7.85 0.37 6.66 9.03 436 7.47 0.55 5.72 9.22 
Not used in the past month 4009 92.15 0.37 90.97 93.34 4551 92.53 0.55 90.78 94.28 







(ST 4.6 continued) 
Core substances 
Period 
(3) 2010 to 2013 (4) 2014 to 2017 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 1454 28.70 2.30 21.39 36.01 990 28.09 1.244 24.13 32.05 
Never or 'no' binge use in past 
month 
2905 71.30 2.30 63.99 78.61 2192 71.91 1.244 67.95 75.87 
Heavy alcohol 
Heavy use in the past month 1215 23.35 0.88 20.53 26.16 738 21.50 0.392 20.26 22.75 
Never or 'no' heavy use in past 
month 
3144 76.65 0.88 73.84 79.47 2444 78.50 0.392 77.25 79.74 
Tranquilizers/ 
sedatives 
Used in the past month 963 21.21 1.06 17.85 24.57 712 20.30 0.483 18.77 21.84 
Not used in the past month 3396 78.79 1.06 75.43 82.15 2470 79.70 0.483 78.16 81.23 
Cigarettes 
Used in the past month 2895 57.85 0.49 56.29 59.41 1973 56.26 1.088 52.79 59.72 
Not used in the past month 1464 42.15 0.49 40.59 43.71 1209 43.74 1.088 40.28 47.21 
Other tobacco 
products 
Used in the past month 1299 23.23 0.14 22.79 23.66 835 22.12 0.064 21.92 22.33 
Not used in the past month 3060 76.77 0.14 76.34 77.21 2347 77.88 0.064 77.67 78.08 
Marijuana 
Used in the past month 2251 40.68 1.19 36.88 44.48 1587 42.96 0.883 40.15 45.77 
Not used in the past month 2108 59.32 1.19 55.52 63.12 1595 57.04 0.883 54.23 59.85 
Cocaine 
Used in the past month 465 10.13 0.54 8.40 11.85 362 10.31 0.998 7.14 13.49 
Not used in the past month 3894 89.87 0.54 88.15 91.60 2820 89.69 0.998 86.51 92.86 
Crack 
Used in the past month 116 3.215 0.37 2.02 4.41 116 3.868 0.482 2.33 5.40 
Not used in the past month 4243 96.79 0.37 95.59 97.98 3066 96.13 0.482 94.60 97.67 
Hallucinogens/ 
inhalants 
Used in the past month 416 7.79 0.62 5.83 9.76 246 5.831 0.656 3.743 7.92 
Not used in the past month 3943 92.21 0.62 90.24 94.17 2936 94.17 0.656 92.08 96.26 
Stimulants 
Used in the past month 353 6.79 0.05 6.63 6.94 372 9.27 0.820 6.66 11.88 







Table notes for ST 4.6 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% CI = 95% confidence interval; LL 
= lower limit; UL = upper limit 








ST 4.7a-e | Joinpoint regression results of longitudinal changes in prevalence of 
significantly different past month core substance use among all PWUO, NSDUH 2002 to 
2017a,b,c 
 
(Full table notes appear after ST 4.7e). 
 














1 2002 2006 1.50 -0.9 3.8 1.40 0.20 
2 2006 2017 -2.70^ -4.2 -1.3 -4.10 < 0.001 
 














1 2002 2017 0.10 -0.2 0.4 0.80 0.50 
 














1 2002 2017 0.20 -0.4 0.4 3.90 0.50 
 














1 2002 2017 0.10 -1.0 1.3 0.30 0.80 
 














1 2002 2004 5.70 -23.8 46.7 0.40 0.70 
2 2004 2007 -14.10 -50.6 49.2 -0.60 0.50 
3 2007 2017 5.4^ 2.3 8.5 4.1 < 0.001 
Abbreviations: APC = annual percentage change; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: 1) the weighted 
prevalence of Rao-Scott significant past month core substance use and 2) survey year among 
PWUO. 




ST 4.8 | Weighted prevalence of reported past month core substances use among the past 
month PPR-only use group (n = 15,897), NSDUH 2002 to 2017 
 




Binge use in the past 
month 
5221 29.14 0.55 27.37 30.90 
Never or 'no' binge 
use in past month 
10676 70.86 0.55 69.10 72.63 
Heavy alcohol 
Heavy use in the 
past month 
4955 25.53 0.59 23.66 27.39 
Never or 'no' heavy 
use in past month 
10942 74.47 0.59 72.61 76.34 
Tranquilizers/ 
sedatives 
Used in the past 
month 
3547 20.43 0.35 19.31 21.55 
Not used in the past 
month 
12350 79.57 0.35 78.45 80.69 
Cigarettes 
Used in the past 
month 
10358 56.66 0.31 55.68 57.63 
Not used in the past 
month 
5539 43.34 0.31 42.37 44.32 
Other tobacco 
products 
Used in the past 
month 
4619 23.09 0.31 22.11 24.07 
Not used in the past 
month 
11278 76.91 0.31 75.93 77.89 
Marijuana 
Used in the past 
month 
7998 39.83 0.54 38.13 41.54 
Not used in the past 
month 
7899 60.17 0.54 58.46 61.87 
Cocaine 
Used in the past 
month 
1703 9.15 0.35 8.05 10.25 
Not used in the past 
month 
14194 90.85 0.35 89.75 91.95 
Crack 
Used in the past 
month 
304 2.28 0.41 0.98 3.57 
Not used in the past 
month 
15593 97.72 0.41 96.43 99.02 
Hallucinogens/ 
inhalants 
Used in the past 
month 
1441 6.37 0.20 5.72 7.01 
Not used in the past 
month 
14456 93.63 0.20 92.99 94.28 
Stimulants 
Used in the past 
month 
1483 7.63 0.23 6.91 8.35 
Not used in the past 
month 
14414 92.37 0.23 91.65 93.09 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% 





ST 4.9 | Weighted prevalence of reported past month core substances use among the past 
month heroin-only use group (n = 553), NSDUH 2002 to 2017 
 




Binge use in the past 
month 
138 23.37 1.33 19.13 27.61 
Never or 'no' binge 
use in past month 
415 76.63 1.33 72.39 80.87 
Heavy alcohol 
Heavy use in the past 
month 
99 16.74 2.35 9.26 24.21 
Never or 'no' heavy 
use in past month 
454 83.26 2.35 75.79 90.74 
Tranquilizers/ 
sedatives 
Used in the past 
month 
79 13.39 0.91 10.48 16.29 
Not used in the past 
month 
474 86.61 0.91 83.71 89.52 
Cigarettes 
Used in the past 
month 
495 88.63 1.06 85.25 92.01 
Not used in the past 
month 
58 11.37 1.06 7.99 14.75 
Other tobacco 
products 
Used in the past 
month 
148 22.75 2.35 15.27 30.22 
Not used in the past 
month 
405 77.25 2.35 69.78 84.73 
Marijuana 
Used in the past 
month 
303 48.13 4.84 32.71 63.55 
Not used in the past 
month 
250 51.87 4.84 36.45 67.29 
Cocaine 
Used in the past 
month 
189 35.36 1.50 30.57 40.15 
Not used in the past 
month 
364 64.64 1.50 59.85 69.43 
Crack 
Used in the past 
month 
102 20.00 2.45 12.19 27.81 
Not used in the past 
month 
451 80.00 2.45 72.19 87.81 
Hallucinogens/ 
inhalants 
Used in the past 
month 
58 8.66 1.45 4.04 13.28 
Not used in the past 
month 
495 91.34 1.45 86.72 95.96 
Stimulants 
Used in the past 
month 
26 3.96 1.50 0.00 8.74 
Not used in the past 
month 
527 96.04 1.50 91.26 100.00 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% 





ST 4.10 | Weighted prevalence of reported past month core substances use among the 
past month combination opioid use group (n = 535), NSDUH 2002 to 2017 
 
Core Substance n % SE 95% CI 
LL UL 
Binge alcohol Binge use in the past 
month 
164 24.95 2.86 15.85 34.06 
Never or 'no' binge 
use in past month 
371 75.05 2.86 65.94 84.15 
Heavy alcohol Heavy use in the past 
month 
157 29.27 5.37 12.17 46.37 
Never or 'no' heavy 
use in past month 
378 70.73 5.37 53.63 87.83 
Tranquilizers/ 
sedatives 
Used in the past 
month 
234 44.48 2.88 35.32 53.65 
Not used in the past 
month 
301 55.52 2.88 46.35 64.68 
Cigarettes Used in the past 
month 
493 87.38 2.02 80.96 93.80 
Not used in the past 
month 
42 12.62 2.02 6.21 19.04 
Other tobacco 
products 
Used in the past 
month 
204 38.91 0.70 36.67 41.14 
Not used in the past 
month 
331 61.09 0.70 58.86 63.33 
Marijuana Used in the past 
month 
371 64.75 2.41 57.08 72.43 
Not used in the past 
month 
164 35.25 2.41 27.57 42.92 
Cocaine Used in the past 
month 
230 45.96 2.88 36.81 55.11 
Not used in the past 
month 
305 54.04 2.88 44.89 63.19 
Crack Used in the past 
month 
121 26.80 1.14 23.18 30.42 
Not used in the past 
month 
414 73.20 1.14 69.58 76.82 
Hallucinogens/ 
inhalants 
Used in the past 
month 
103 16.45 2.99 6.93 25.97 
Not used in the past 
month 
432 83.55 2.99 74.03 93.07 
Stimulants Used in the past 
month 
100 16.75 2.20 9.76 23.75 
Not used in the past 
month 
435 83.25 2.20 76.25 90.24 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% 








ST 4.11 | Weighted prevalence of reported substance use for past month PPR-only use group by period (n = 15,897), NSDUH 
2002 to 2017  
Core substances 
Period 
(1) 2002 to 2005 (2) 2006 to 2009 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 1379 28.06 1.76 22.66 33.86 1598 27.96 0.15 30.15 31.11 
Never or 'no' binge use in 
past month 
2927 71.74 1.76 66.14 77.34 3172 69.37 0.15 68.89 69.85 
Heavy alcohol 
Heavy use in the past month 1526 28.25 1.71 22.81 33.68 1610 27.50 0.21 26.82 28.17 
Never or 'no' heavy use in 
past month 
2780 71.75 1.71 66.32 77.19 3160 72.50 0.21 71.83 73.18 
Tranquilizers/ 
sedatives 
Used in the past month 977 21.68 0.48 20.16 23.21 1101 20.56 0.04 20.44 20.67 
Not used in the past month 3329 78.32 0.48 76.79 79.84 3669 79.44 0.04 79.33 79.56 
Cigarettes 
Used in the past month 2905 59.09 0.94 56.10 62.08 3239 58.96 0.39 57.72 60.20 
Not used in the past month 1401 40.91 0.94 37.92 43.90 1531 41.04 0.39 39.80 42.28 
Other tobacco 
products 
Used in the past month 1267 23.81 1.03 20.52 27.09 1448 24.27 0.07 24.04 24.49 
Not used in the past month 3039 76.19 1.03 72.91 79.48 3322 75.73 0.07 75.51 75.96 
Marijuana 
Used in the past month 2193 40.11 2.10 33.42 46.80 2418 39.41 1.75 33.83 44.99 
Not used in the past month 2113 35.98 1.32 31.79 40.18 2352 60.59 1.75 55.01 66.17 
Cocaine 
Used in the past month 623 12.44 1.07 9.05 15.83 511 9.21 2.07 2.62 15.79 
Not used in the past month 3683 87.56 1.07 84.17 90.95 4259 90.80 2.07 84.21 97.38 
Crack 
Used in the past month 113 3.42 0.81 0.83 6.01 97 2.43 1.45 0.00 7.05 
Not used in the past month 4193 96.58 0.81 93.99 99.17 4673 97.57 1.45 92.95 100.00 
Hallucinogens/ 
inhalants 
Used in the past month 436 6.63 0.44 5.23 8.03 435 6.23 0.31 5.24 7.21 
Not used in the past month 3870 93.37 0.44 91.97 94.77 4335 93.77 0.31 92.79 94.76 
Stimulants 
Used in the past month 433 7.98 0.40 6.72 9.24 415 7.58 0.52 5.93 9.23 
Not used in the past month 3873 92.02 0.40 90.76 93.28 4355 92.42 0.52 90.78 94.07 








(ST 4.11 continued) 
Core substances 
Period 
(3) 2010 to 2013 (4) 2014 to 2017 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 1369 23.35 2.28 21.87 36.35 875 21.50 1.197 24.37 31.99 
Never or 'no' binge use in 
past month 
2690 70.89 2.28 63.65 78.13 1887 71.82 1.197 68.01 75.63 
Heavy alcohol 
Heavy use in the past month 1155 23.55 1.01 20.32 26.78 664 22.21 0.506 20.60 23.82 
Never or 'no' heavy use in 
past month 
2904 76.45 1.01 73.22 79.68 2098 77.79 0.506 76.18 79.40 
Tranquilizers/ 
sedatives 
Used in the past month 869 20.12 1.23 16.23 24.02 600 19.18 0.13 18.76 19.61 
Not used in the past month 3190 79.88 1.23 75.98 83.77 2162 80.82 0.13 80.39 81.24 
Cigarettes 
Used in the past month 2623 55.84 0.54 54.13 57.56 1591 51.73 0.94 48.75 54.71 
Not used in the past month 1436 44.16 0.54 42.44 45.87 1171 48.27 0.94 45.29 51.25 
Other tobacco 
products 
Used in the past month 1204 22.78 0.36 21.62 23.93 700 21.05 0.16 20.56 21.55 
Not used in the past month 2855 77.22 0.36 76.07 78.38 2062 78.95 0.16 78.45 79.44 
Marijuana 
Used in the past month 2063 39.44 1.37 35.07 43.81 1324 40.59 0.03 40.50 40.67 
Not used in the past month 1996 60.56 1.37 56.19 64.93 1438 59.41 0.03 59.33 59.50 
Cocaine 
Used in the past month 355 8.09 0.81 5.51 10.67 214 6.58 0.93 3.60 9.55 
Not used in the past month 3704 91.91 0.81 89.33 94.49 2548 93.42 0.93 90.45 96.40 
Crack 
Used in the past month 57 1.86 0.26 1.04 2.68 37 1.26 0.37 0.07 2.45 
Not used in the past month 4002 98.14 0.26 97.32 98.96 2725 98.74 0.37 97.55 99.93 
Hallucinogens/ 
inhalants 
Used in the past month 371 7.00 0.35 5.89 8.11 199 5.44 0.47 3.95 6.93 
Not used in the past month 3688 93.00 0.35 91.89 94.11 2563 94.56 0.47 93.07 96.05 
Stimulants 
Used in the past month 314 6.45 0.36 5.31 7.58 321 8.82 1.03 5.56 12.08 








Table notes for ST 4.11 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% CI = 95% confidence interval; LL 
= lower limit; UL = upper limit 







ST 4.12a-c | Joinpoint regression results of longitudinal changes in prevalence of 
significantly different past month core substance use among past month PPR-only use 
group, NSDUH 2002 to 2017a,b,c 
 














1 2002 2007 0.60 -1.1 2.3 0.80 0.40 
2 2007 2017 -2.70^ -3.9 -1.5 -4.80 < 0.001 
 
 














1 2002 2017 -0.90^ -1.8 -0.1 -2.40 < 0.001 
 














1 2002 2017 0.40^ 0.0 0.7 2.20 < 0.001 
 














1 2002 2017 -1.10 -2.5 0.2 -1.80 0.10 
Abbreviations: APC = annual percentage change; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: 1) the weighted 
prevalence of Rao-Scott significant past month core substance use and 2) survey year among past 
month PPR-only use group. 













ST 4.13 | Weighted prevalence of reported substance use for past month heroin-only use group by period (n = 553), NSDUH 2002 
to 2017  
Core substances 
Period 
(1) 2002 to 2005 (2) 2006 to 2009 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 19 22.86 2.35 15.37 30.35 22 18.50 7.50 0.00 42.36 
Never or 'no' binge use in 
past month 
61 77.14 2.35 69.65 84.63 66 81.50 7.50 57.64 100.00 
Heavy alcohol 
Heavy use in the past month 17 14.21 3.19 4.06 24.35 27 27.57 9.63 0.00 58.21 
Never or 'no' heavy use in 
past month 
63 85.80 3.19 75.65 95.94 61 72.43 9.63 41.79 100.00 
Tranquilizers/ 
sedatives 
Used in the past month 8 8.36 3.54 0.00 19.63 13 10.30 5.94 0.00 29.21 
Not used in the past month 72 91.64 3.54 80.37 100.00 75 89.70 5.94 70.79 100.00 
Cigarettes 
Used in the past month 69 86.70 2.53 78.64 94.76 82 95.43 2.52 87.42 100.00 
Not used in the past month 11 13.30 2.53 5.24 21.36 6 4.57 2.52 0.00 12.58 
Other tobacco 
products 
Used in the past month 19 20.27 3.24 9.95 30.58 23 25.50 12.26 0.00 64.52 
Not used in the past month 61 79.73 3.24 69.42 90.05 65 74.50 12.26 35.48 100.00 
Marijuana 
Used in the past month 40 39.94 14.25 0.00 85.27 45 33.39 11.05 0.00 68.57 
Not used in the past month 40 60.06 14.25 14.73 100.00 43 66.61 11.05 31.43 100.00 
Cocaine 
Used in the past month 34 42.32 6.18 22.65 61.99 34 38.29 8.72 10.52 66.05 
Not used in the past month 46 57.68 6.18 38.01 77.35 54 61.71 8.72 33.95 89.48 
Crack 
Used in the past month 14 18.47 13.26 0.00 60.66 21 22.11 1.75 16.54 27.69 
Not used in the past month 66 81.53 13.26 39.34 100.00 67 77.89 1.75 72.31 83.46 
Hallucinogens/ 
inhalants 
Used in the past month 11 5.28 1.87 0.00 11.22 6 5.85 2.70 0.00 14.43 
Not used in the past month 69 94.72 1.87 88.78 100.00 82 94.15 2.70 85.57 100.00 
Stimulants 
Used in the past month 3 1.09 0.46 0.00 2.56 3 6.09 2.76 0.00 14.86 
Not used in the past month 77 98.91 0.46 97.44 100.00 85 93.91 2.76 85.14 100.00 








(ST 4.13 continued) 
Core substances 
Period 
(3) 2010 to 2013 (4) 2014 to 2017 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 36 19.05 1.91 12.99 25.11 61 27.26 0.003 27.25 27.27 
Never or 'no' binge use in 
past month 
108 80.95 1.91 74.89 87.02 180 72.74 0.003 72.73 72.75 
Heavy alcohol 
Heavy use in the past month 21 17.68 2.64 9.28 26.08 34 13.04 1.588 7.98 18.09 
Never or 'no' heavy use in 
past month 
123 82.32 2.64 73.92 90.72 207 86.96 1.588 81.91 92.02 
Tranquilizers/ 
sedatives 
Used in the past month 17 12.87 0.40 11.59 14.15 41 16.37 1.09 12.90 19.84 
Not used in the past month 127 87.13 0.40 85.85 88.42 200 83.63 1.09 80.16 87.10 
Cigarettes 
Used in the past month 123 85.75 1.81 80.00 91.50 221 87.93 1.52 83.10 92.77 
Not used in the past month 21 14.25 1.81 8.50 20.00 20 12.07 1.52 7.23 16.90 
Other tobacco 
products 
Used in the past month 36 15.75 0.48 14.21 17.29 70 25.56 2.99 16.03 35.08 
Not used in the past month 108 84.25 0.48 82.71 85.79 171 74.44 2.99 64.92 83.97 
Marijuana 
Used in the past month 76 50.25 0.03 50.16 50.35 142 55.35 7.77 30.63 80.07 
Not used in the past month 68 49.75 0.03 49.65 49.84 99 44.65 7.77 19.93 69.37 
Cocaine 
Used in the past month 41 32.87 8.91 4.51 61.23 80 33.13 2.36 25.63 40.63 
Not used in the past month 103 67.13 8.91 38.77 95.49 161 66.87 2.36 59.37 74.37 
Crack 
Used in the past month 22 18.15 8.94 0.00 46.59 45 20.50 2.26 13.31 27.69 
Not used in the past month 122 81.85 8.94 53.41 100.00 196 79.50 2.26 72.31 86.69 
Hallucinogens/ 
inhalants 
Used in the past month 15 12.33 1.04 9.01 15.66 26 9.19 2.79 0.32 18.05 
Not used in the past month 129 87.67 1.04 84.34 90.99 215 90.81 2.79 81.95 99.68 
Stimulants 
Used in the past month 10 4.36 1.98 0.00 10.65 10 3.89 2.53 0.00 11.94 








Table notes for ST 4.13 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% CI = 95% confidence interval; LL 
= lower limit; UL = upper limit 






ST 4.14a-b | Joinpoint regression results of longitudinal changes in prevalence of 
significantly different past month core substance use among past month heroin-only use 
group, NSDUH 2002 to 2017a,b,c 
 










1 2002 2017 -0.66 0.4 -1.79 0.10 
 














1 2002 2008 2.60 -1.4 6.9 1.40 0.20 
2 2008 2017 -2.30^ -3.6 -0.9 -3.7 < 0.001 
Abbreviations: APC = annual percentage change; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: 1) the weighted 
prevalence of Rao-Scott significant past month core substance use and 2) survey year among past 
month heroin-only use group. 










ST 4.15 | Weighted prevalence of reported substance use for past month combination opioid use group by period (n = 535), 
NSDUH 2002 to 2017  
Core substances 
Period 
(1) 2002 to 2005 (2) 2006 to 2009 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 25 27.81 5.05 11.73 43.90 36 18.70 5.44 1.39 36.00 
Never or 'no' binge use in 
past month 
46 72.19 5.05 56.10 88.27 93 81.30 5.44 64.00 98.61 
Heavy alcohol 
Heavy use in the past month 28 39.05 12.32 0.00 78.27 50 45.23 19.57 0.00 100.00 
Never or 'no' heavy use in 
past month 
43 60.95 12.32 21.73 100.00 79 54.77 19.57 0.00 100.00 
Tranquilizers/ 
sedatives 
Used in the past month 34 39.60 6.59 18.62 60.58 52 27.39 9.45 0.00 57.47 
Not used in the past month 37 60.40 6.59 39.42 81.38 77 72.61 9.45 42.53 100.00 
Cigarettes 
Used in the past month 65 77.40 12.26 38.37 100.00 118 88.46 7.31 65.21 100.00 
Not used in the past month 6 22.60 12.26 0.00 61.63 11 11.54 7.31 0.00 34.79 
Other tobacco 
products 
Used in the past month 28 37.05 3.98 24.40 49.70 52 41.29 2.73 32.60 49.97 
Not used in the past month 43 62.95 3.98 50.30 75.60 77 58.71 2.73 50.03 67.40 
Marijuana 
Used in the past month 54 74.79 5.60 56.96 92.62 84 56.59 9.24 27.18 85.99 
Not used in the past month 17 25.21 5.60 7.38 43.04 45 43.41 9.24 14.01 72.82 
Cocaine 
Used in the past month 35 47.26 10.45 14.00 80.52 58 51.80 5.31 34.91 68.68 
Not used in the past month 36 52.74 10.45 19.48 86.00 71 48.20 5.31 31.32 65.09 
Crack 
Used in the past month 17 21.90 2.53 13.87 29.94 33 31.36 2.71 22.73 40.00 
Not used in the past month 54 78.10 2.53 70.06 86.13 96 68.64 2.71 60.00 77.27 
Hallucinogens/ 
inhalants 
Used in the past month 21 27.21 1.56 22.25 32.17 31 13.72 1.00 10.55 16.88 
Not used in the past month 50 72.79 1.56 67.83 77.75 98 86.28 1.00 83.12 89.45 
Stimulants 
Used in the past month 12 9.94 4.12 0.00 23.05 18 4.71 0.43 3.35 6.07 
Not used in the past month 59 90.06 4.12 76.95 100.00 111 95.29 0.43 93.93 96.65 








(ST 4.15 continued) 
Core substances 
Period 
(3) 2010 to 2013 (4) 2014 to 2017 
n %a SE 
95% CI 
n %a SE 
95% CI 
LL UL LL UL 
Binge alcohol 
Binge use in the past month 49 25.47 4.81 10.18 40.77 54 27.86 4.090 14.84 40.88 
Never or 'no' binge use in 
past month 
107 74.53 4.81 59.23 89.82 125 72.14 4.090 59.12 85.16 
Heavy alcohol 
Heavy use in the past month 39 22.27 1.10 18.78 25.77 40 22.07 2.142 15.26 28.89 
Never or 'no' heavy use in 
past month 
117 77.73 1.10 74.23 81.22 139 77.93 2.142 71.11 84.74 
Tranquilizers/ 
sedatives 
Used in the past month 77 56.48 9.73 25.51 87.46 71 46.68 8.06 21.03 72.33 
Not used in the past month 79 43.52 9.73 12.54 74.49 108 53.32 8.06 27.67 78.97 
Cigarettes 
Used in the past month 149 89.03 1.55 84.10 93.95 161 87.99 2.96 78.56 97.42 
Not used in the past month 7 10.97 1.55 6.05 15.90 18 12.01 2.96 2.58 21.44 
Other tobacco 
products 
Used in the past month 59 41.02 2.07 34.45 47.60 65 35.98 1.32 31.79 40.18 
Not used in the past month 97 58.98 2.07 52.40 65.55 114 64.02 1.32 59.82 68.21 
Marijuana 
Used in the past month 112 66.04 0.59 64.16 67.91 121 66.27 5.72 48.08 84.46 
Not used in the past month 44 33.96 0.59 32.09 35.84 58 33.73 5.72 15.54 51.92 
Cocaine 
Used in the past month 69 45.96 0.23 45.22 46.70 68 41.73 6.90 19.77 63.68 
Not used in the past month 87 54.04 0.23 53.30 54.78 111 58.27 6.90 36.32 80.23 
Crack 
Used in the past month 37 27.25 2.45 19.44 35.06 34 24.73 0.60 22.83 26.63 
Not used in the past month 119 72.75 2.45 64.94 80.56 145 75.27 0.60 73.37 77.17 
Hallucinogens/ 
inhalants 
Used in the past month 30 25.17 10.77 0.00 59.45 21 7.64 0.83 5.00 10.28 
Not used in the past month 126 74.83 10.77 40.55 100.00 158 92.36 0.83 89.72 95.00 
Stimulants 
Used in the past month 29 17.76 4.39 3.78 31.74 41 25.76 3.95 13.20 38.32 








Table notes for ST 4.15 
Abbreviations: n = number of respondents, % = weighted prevalence; SE = standard error; 95% CI = 95% confidence interval; LL 
= lower limit; UL = upper limit 







ST 4.12a-c | Joinpoint regression results of longitudinal changes in prevalence of 
significantly different past month core substance use among past month combination 
opioid use group, NSDUH 2002 to 2017a 
 










1 2002 2017 0.46 0.1 3.5 0.004 
 










1 2002 2006 -3.733 3.58 -1.04 0.33 
2 2006 2011 3.0843 4.90 0.63 0.55 
3 2011 2017 -3.985^ 1.25 -3.18 0.013 
 










1 2002 2009 0.034^ 0.0092 3.69 0.0036 
2 2009 2017 0.253^ 0.0458 5.53 0.00018 
Abbreviations: APC = annual percentage change; SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of past month core substance use and survey year for among PWUO. 









ST 4.13 | Comparison of different alcohol use levels by longitudinal prevalence differences and predicting PWUO/opioid use 







Opioid use groups 































































































Abbreviations: χ2 (df) = Chi-square (degrees of freedom); LR = logistic regression 









ST 4.14 | Fit statistics of latent class models with up to 8 classes using 11 categorical core substances from the NSDUH (n = 
16,985), 2002 to 2017  
 
Classes n Parameters 
Log 
Likelihood 
Lo, Mendell, Rubin 
Likelihood Ratio 




1 16985 12 -38103.378 n/a n/a 76230.756 76313.893 76275.760 n/a 
2 16985 25 -35816.954 1 versus 2 0.2063 71683.907 71857.11 71777.665 0.653 
3 16985 38 -34868.002 2 versus 3 0.223 69812.004 70075.272 69954.516 0.752 
4 16985 51 -34139.581 3 versus 4 0.3876 68381.162 68734.496 68572.429 0.804 
5 16985 64 -33729.321 4 versus 5 0.5195 67586.641 68030.04 67826.662 0.829 
6 16985 77 -33534.328 5 versus 6 0.5283 67222.656 67756.121 67511.431 0.779 
7 16985 90 -33457.214 6 versus 7 0.606 67094.427 67717.957 67431.956 0.794 
8 16985 103 -33390.517 7 versus 8 0.5693 66987.034 67700.629 67373.317 0.757 
Abbreviations: AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; ssBIC = sample size-adjusted 







ST 4.15 | Joinpoint regression results of longitudinal changes in prevalence of Class 1, 











1 2002 2009 0.04 0.5 0.1 0.939 
2 2009 2012 1.63 0.8 2.1 0.07 
3 2012 2017 -0.71^ 0.17 -4.16 < 0.001 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of Class 1 and survey year. 
^Slope is significantly different from zero at alpha = 0.05. 
 
 
ST 4.16 | Joinpoint regression results of longitudinal changes in prevalence of Class 2, 











1 2002 2009 0.87^ 0.3 2.5 0.029 
2 2009 2017 -0.73^ 0.0 -32.8 < 0.001 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of Class 2 and survey year. 




ST 4.17 | Joinpoint regression results of longitudinal changes in prevalence of Class 3, 











1 2002 2010 0.05 0.2 0.2 0.840 
2 2010 2017 1.06^ 0.2 4.9 < 0.001 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of Class 3 and survey year. 









ST 4.18 | Joinpoint regression results of longitudinal changes in prevalence of Class 4, 











1 2002 2017 -0.32^ 0.1 -4.1 0.001 
Abbreviations: SE = standard error; CI = confidence interval  
aTwo continuous variables were used to perform the joinpoint regression: the weighted 
prevalence of Class 4 and survey year. 







ST 4.19 | Fit latent class models with up to 8 classes to the 11 categorical core substances (n = 7,541), NSDUH  2010 to 2017 
Classes N Parameters 
Log 
Likelihood 
Lo, Mendell, Rubin 
Likelihood Ratio 




1 16985 11 -33602.112   67226.225 67302.434 67267.478  
2 16985 23 -31315.958 1 versus 2 0.1432 62677.917 62837.263 62764.174 0.654 
3 16985 35 -30374.076 2 versus 3 0.1565 60818.152 61060.636 60949.413 0.753 
4 16985 47 -29971.592 3 versus 4 0.4046 60037.184 60362.805 60213.449 0.794 
5 16985 59 -29807.924 4 versus 5 0.619 59733.849 60142.607 59955.118 0.737 
6 16985 71 -29737.842 5 versus 6 0.5635 59617.683 60109.579 59883.956 0.76 
7 16985 83 -29671.762 6 versus 7 0.5964 59509.524 60084.557 59820.801 0.72 
8 16985 95 -29629.711 7 versus 8 0.7003 59449.423 60107.593 59805.703 0.711 
Abbreviations: AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; ssBIC = sample size-adjusted 














Table 4.20 | Overall size and weighted prevalence of the latent polydrug use 
subpopulations among PWUO (n = 7,541), NSDUH 2010 to 2017 
Polydrug latent class n % SE 
95% CI 
LL UL 
1: mainly PPR  3432 54.88 0.42 53.07 56.69 
2: PPR - heavy alcohol - benzo- 
stimulant - marijuana  
3508 37.02 0.20 36.14 37.89 
3: Heroin - marijuana 341 4.22 0.27 3.03 5.40 
4: Combination opioid - polydrug  260 3.88 0.32 2.52 5.25 
Note: n = total number of survey respondents; % = weighted percentage; SE = standard error; 
95% CI = 95% confidence interval; LL = lower limit; UL = upper limit 
 
 
Table 4.21 | Endorsement probabilities for each core substance by latent polydrug class 
(n = 7,541), NSDUH 2010 to 2017 
Substances used in the 
past 30-days 
Polydrug latent classes among PWUO 
1: mainly PPR 
2: PPR - heavy 
alcohol - benzo- 
stimulant - 
marijuana 






PPR 1 1 0.121 0.741 
Heroin 0 0.058 1 0.605 
Heavy alcohol 0.112 0.391 0.09 0.307 
Cigarettes 0.339 0.83 0.87 0.879 
Other tobacco products 0.101 0.395 0.229 0.325 
Tranquilizers/sedatives 0.101 0.341 0.147 0.438 
Stimulants 0.022 0.155 0.05 0.146 
Marijuana 0.149 0.76 0.482 0.667 
Cocaine 0.007 0.133 0.147 1 
Crack 0 0 0 0.858 











SG 4.1a-d | Differences in prevalence and standard errors of reported substance use for 
period 1 (2002-2005) among all opioid use groups for a) alcohol drinking, b) cigarette, 
other tobacco, and marijuana use, c) prescription stimulant and tranquilizer/sedative use, 
and d) illicit substance (cocaine, crack, hallucinogens/inhalants) 
 




































































































































SG 4.2a-d | Differences in prevalence and standard errors of reported substance use for 
period 2 (2006-2009) among all opioid use groups for a) alcohol drinking, b) cigarette, 
other tobacco, and marijuana use, c) prescription stimulant and tranquilizer/sedative use, 
and d) illicit substance (cocaine, crack, hallucinogens/inhalants) 
 




























































































































SG 4.3a-d | Differences in prevalence and standard errors of reported substance use for 
period 3 (2010-2013) among all opioid use groups for a) alcohol drinking, b) cigarette, 
other tobacco, and marijuana use, c) prescription stimulant and tranquilizer/sedative use, 
and d) illicit substance (cocaine, crack, hallucinogens/inhalants) 
 


































































































































SG 4.4a-d | Differences in prevalence and standard errors of reported substance use for 
period 4 (2014-2017) among all opioid use groups for a) alcohol drinking, b) cigarette, 
other tobacco, and marijuana use, c) prescription stimulant and tranquilizer/sedative use, 
and d) illicit substance (cocaine, crack, hallucinogens/inhalants) 
 
































































































































aOR    Adjusted odds ratio 
APC    Annual Percent Change 
ASPE    Assistant Secretary for Planning and Evaluation 
AUD    Alcohol use disorder 
CAPI    Computer assisted personal interview 
CARA    Comprehensive Addiction and Recovery Act 
CBHSQ   Center for Behavioral Health Statistics and Quality 
CDC    Centers for Disease Control and Prevention 
CI    Confidence interval 
CUD    Cannabis use disorder 
DAC    The Drug Abuse Council 
DEA    Drug Enforcement Agency 
DSM    Diagnostic and Statistical Manual of Mental Disorders 
DUD    Any drug use disorder 
ED    Emergency department 
GSL    Good Samaritan Laws 
HCC    Healthcare for Communities survey 
HIV    Human immunodeficiency virus 
HUD    Heroin use disorder 
ICD    International Classification of Diseases 
IMF    Illegally manufactured fentanyl 
LCA    Latent class analysis 




m    Slope 
MAT    Medication-assisted therapy 
MCL    Medical cannabis laws 
MCP    Medical cannabis program 
MMWR   Morbidity and Mortality Weekly Report 
MTF    Monitoring the Future 
NASPER National All Schedules Prescription Electronic Reporting 
Act 
 
NESARC National Epidemiologic Survey on Alcohol and Related 
Conditions 
 
NHIS    National Vital Statistics Survey 
NMUPO   Nonmedical use of prescription opioids 
NMUPS   Nonmedical use of prescription stimulants 
NPS    Novel psychoactive substances 
NSDUH   National Survey of Drug Use and Health 
NVSS    National Vital Statistics System 
ODUD    Other drug use disorder 
OPR    Opioid pain relievers 
OUD    Opioid use disorder 
PDAPP   Prescription Drug Abuse Prevention Plan 
PMDP    Prescription drug monitoring program 
PPR    Prescription pain relievers 
PR    Weighted prevalence; prevalence rate 




PWUO   People who use opioids 
RTI    Research Triangle Institute 
Rx-OUD   Prescription opioid use disorder 
SAMHSA Substance Abuse and Mental Health Services 
Administration 
 
SE    Standard error 
SG    Supplemental Graph 
SID    State Inpatient Databases 
ST    Supplemental Table 
STRIDE   System to Retrieve Information from Drug Evidence 
SUD    Substance use disorder 
U.S.    United States 
USD    United States dollars 
USDHHS   United States Department of Health and Human Services 
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